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General Introduction
The Increasing Burden of Atrial Fibrillation
Atrial fibrillation (AF) is the most common, progressive cardiac arrhythmia and 
is associated with severe complications such as stroke or heart failure. AF develops 
in subjects of all ages and is associated with numerous (non)cardiac diseases.1-3 
At present, AF affects nearly 6 million patients in Europe and 2.3 million in the 
United States. It is forecast that the incidence of AF will reach approximately 5.6 
million Americans in 2050.4 In the Netherlands, the total number of new AF 
patients is approximately 45,085 per year and this number is still rising.5 AF is 
therefore regarded as the epidemic of the 21st century. 
Therapy for Atrial Fibrillation
AF can be treated with anti-arrhythmic drugs or invasive ablative therapy. 
Pharmacological therapy consists of either rhythm or rate control by anti-
arrhythmic drugs combined with (novel) oral anticoagulants to prevent thrombo-
embolic events.4, 6-9 However, anti-arrhythmic drug therapies are associated with 
numerous side effects such as ventricular pro-arrhythmia, and anticoagulants may 
cause (fatal) bleedings, for example intracranial hemorrhages.9 Invasive ablative 
therapy consists of isolation of triggers, mainly located within the pulmonary 
vein region10, or modification of the arrhythmogenic substrate of AF.11 
Unfortunately, present treatment modalities of AF are in most patients only 
moderately effective.11 In addition to this, progression of AF is accompanied by 
a gradual increase in therapy failure and in the end stage cannot be treated even 
with extensive therapy. Failure of AF therapy is mainly caused by insufficient 
knowledge of the mechanism underlying AF in the individual patient.
Post-Operative Atrial Fibrillation
AF after cardiothoracic surgery (CS) is a frequently observed complication with 
reported incidences ranging between 10 and 65%.12-16 Despite improvements 
of the surgical techniques since the first CS in 196017, the frequency of post-
operative AF (PoAF) has not declined. PoAF develops mainly 24 to 72 hours 
after CS and may result in thromboembolic complications (2 to 3-fold increased 
risk of post-operative stroke), hemodynamic deterioration, increased length and 
hence costs of hospitalization.18 Recent studies have demonstrated that PoAF 
is not only associated with increased early but also with late mortality rates.12, 
19 Numerous predictors for PoAF have been identified, including predisposing, 
intra-operative and postoperative factors, which may modify electrical properties 
of atrial tissue (substrate) and in the presence of triggers give rise to AF.13, 20-23 
The exact mechanism underlying PoAF is still unknown and there are also no 
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diagnostic tools available to identify patients at risk of developing PoAF.
Mapping of Atrial Fibrillation
Cardiac mapping may provide insight into the mechanism underlying AF. Cardiac 
mapping is defined as a method by which potentials recorded directly from the 
surface of the heart are spatially depicted as a function of time in an integrated 
manner.24 Numerous cardiac mapping techniques, mainly endocardial, have 
been developed over the years. However, endocardial mapping techniques have 
several technical limitations such as a low spatial resolution and no access to 
possible arrhythmogenic structures such as Bachmann’s Bundle.25 Recent studies 
using intra-operative, high-resolution epicardial mapping studies have identified 
longitudinal dissociation between neighboring atrial bundles and epicardial 
breakthroughs as the key elements of the arrhythmogenic substrate associated 
with longstanding persistent AF.20, 22 However, mapping in these studies was 
performed at only a limited number of atrial sites in small patient groups. 
At present we have no knowledge of the degree and extension of the 
arrhythmogenic substrate underlying AF nor do we know the corresponding, 
most suitable electrical parameters. Hence, a diagnostic tool to recognize the 
arrhythmogenic substrate is crucial.
Epicardial mapping of the entire atrial surface during open-chest surgery provides 
1) the possibility to examine the arrhythmogenic substrate underlying AF in 
the individual patient and 2) knowledge to develop novel diagnostic tools and 
treatment modalities.
Aims
The aims of this thesis are to examine 1) the clinical applicability of a novel, 
intra-operative high-resolution, multi-site epicardial mapping approach covering 
the entire atria as a routine procedure during cardiac surgery, 2) whether there 
are preferential sites of electropathology during sinus rhythm in patients with 
various underlying heart diseases, 3) the relevance of conduction abnormalities 
during sinus rhythm at Bachmann’s Bundle, 4) the role of endo-epicardial 
asynchrony in persistence of AF, 5) characteristics of post-operative atrial ectopy 
and AF, and 6) the relation between electrical parameters assessed with high-
resolution mapping, atrial ectopy and post-operative AF.
Chapter 1
14
Outline of the Thesis
In chapter 2, we discuss the importance of intra-operative, high-resolution 
mapping of the atria to provide insight into the pathophysiology of AF. In 
chapter 3, the role of Bachmann’s Bundle in the pathogeneses of AF is reviewed. 
The study design of our mapping project entitled QUest for the Arrhythmogenic 
Substrate of Atrial fibRillation (QUASAR) is presented in chapter 4. A detailed 
description of the novel intra-operative high-resolution, multi-site epicardial 
mapping approach of the entire atria follows in chapter 5. This approach includes 
quantification of various electrophysiological parameters at a high-resolution 
scale. 
The outcomes of epicardial mapping of Bachmann’s Bundle - a structure which 
can only be reached from the epicardial site - are presented in chapter 6. In 
chapter 7, mapping of the atria is performed in patients with coronary artery 
disease in order to determine whether areas of electropathology are already 
present in electrically non-remodeled atria during sinus rhythm. We identified 
conduction disorders during sinus rhythm and their role in prediction of PoAF. In 
patients with congenital heart disease resulting in right atrial dilatation, mapping 
was performed during sinus rhythm in order to identify electropathology prior 
to surgical correction of the congenital defect. The outcomes are depicted in 
chapter 8. 
Epicardial breakthroughs (‘focal waves’) have been identified as a key element of 
the arrhythmogenic substrate underlying AF. These focal waves are thought to be 
the result of transmural propagation of fibrillation waves and they can only arise 
in the presence of endo-epicardial asynchrony. Direct proof of endo-epicardial 
asynchrony of the atrial wall during AF in humans is presented in chapter 9. 
Knowledge of development of PoAF is essential as it may aid in designing 
(preventive) therapy strategies. Facts and features of PoAF examined by using 
continuous cardiac rhythm recordings during the first five post-operative days 
are described in chapter 10. Characteristics and time courses of PoAF episodes 
and supraventricular beats are examined in the individual patient undergoing 
coronary artery bypass grafting. Supraventricular ectopy triggers AF episodes 
in the general population, but the predictive value of supraventricular ectopy 
for PoAF after coronary artery bypass grafting is yet unknown. Cut-off values 
of supraventricular ectopy for prediction of PoAF are introduced in chapter 
11. Whether intra-operative inducibility of AF is also associated with early or 
late PoAF in patients with various underlying cardiac diseases is investigated in 
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chapter 12. The relation between post-operative cardiac ectopy and late post-
operative atrial tachyarrhythmia in adult patients with congenital heart diseases 
is studied in chapter 13. In chapter 14, the time course of late post-operative 
AF in patients with congenital heart disease is examined. In chapter 15, the 
effects of anti-arrhythmic drug therapy for (supra)ventricular tachycardia during 
pregnancy is discussed. The findings and implications of this thesis are discussed 
in chapter 16.
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Abstract 
Isolation of the pulmonary veins may be an effective treatment modality for 
eliminating atrial fibrillation (AF) episodes but unfortunately not for all patients. When 
ablative therapy fails, it is assumed that AF has progressed from a trigger-driven to 
a substrate-mediated arrhythmia. The effect of RF-ablation on persistent AF can be 
attributed to various mechanisms, including elimination of the trigger, modification 
of the arrhythmogenic substrate, interruption of crucial pathways of conduction, atrial 
debulking, or atrial denervation. This review discusses the possible effects of pulmonary 
vein isolation on the fibrillatory process and the necessity of cardiac mapping in order to 
comprehend the mechanisms of AF in the individual patient and to select the optimal 
treatment modality.
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Atrial fibrillation (AF) is at this moment a major subject of interest for both clinicians 
and scientists. The interest for AF is partly the result of the fact that AF is the most 
common arrhythmia and therefore frequently encountered in daily clinical practice. 
As it is more common in the elderly (5% in subjects >60 years), the incidence of AF 
will only continue to rise due to ageing of the population. Subjects with AF represent a 
spectrum of patients with arrhythmia episodes varying in duration, number, pattern of 
onset, triggers and mode of termination. In addition, the arrhythmia presentation itself 
can also change over time. Despite the variable clinical presentation, AF is characterized 
by an irregular heartbeat, stasis of blood flow in the left atrial appendage which increases 
the vulnerability to thrombo-embolism, and loss of the atrial kick that may compromise 
cardiac hemodynamics. Hence, these severe sequelae of AF require effective treatment 
[1-4].
In 1998, Haïssaguere et al. demonstrated that paroxysms of AF can be triggered by 
ectopic foci mainly located within the pulmonary veins (PV) [5]. Electrical isolation 
of the pulmonary veins  (PVI) has since then been regarded as a potential curative 
therapy and is nowadays indicated as a class Ia treatment modality for patients with 
symptomatic paroxysmal AF in whom antiarrhythmic drug therapy failed [6]. Examples 
of various ablation technologies are demonstrated in Figure 1. Numerous studies have 
provided evidence that PVI can be an effective treatment modality, but unfortunately 
not for all patients [7-9]. Miyazaki et al studied AF recurrences after PVI in 574 patients 
(paroxysmal AF: 452, persistent AF: 122). Twenty-seven months after the first PVI 376 
patients maintained sinus rhythm without the aid of antiarrhythmic drugs (paroxysmal 
AF: 304, persistent AF: 72). The other patients needed multiple (maximum of 4) redo 
procedures. Early recurrences of AF after 6 months revealed that they were mainly due 
to recovered PV conduction, whereas recurrences after 1 year were mainly caused by 
non-pulmonary vein triggers [7]. Kottkamp et al. reported the long-term outcome of 
ablative therapy in 80 patients with paroxysmal AF and 20 patients with persistent AF. 
Seven day Holter recordings were made before ablation, within one hour after ablation 
and 3, 6 and 12 months after ablation. In patients with paroxysmal AF, AF episodes 
decreased over time (74%). In patients with persistent AF and recurrences after ablation, 
the number of AF episodes increased over time but the duration of these AF episodes 
diminished. After a follow-up period of 12 months, only 22% of the patients with 
longstanding persistent AF (LsPAF) were free of AF episodes. From these findings the 
authors suggested that PV trigger elimination did not play a role in abolishing LsPAF 
and that ablation might only have modified the arrhythmogenic substrate [10].
Several studies were conducted to examine whether PVI was actually more effective than 
anti-arrhythmic drug therapy in eliminating AF episodes. The Medical ANtiarrhythmic 
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Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-
AF) trial was the first large randomized multicenter trial, comparing the efficacy of 
PVI versus anti-arrhythmic drug therapy. 294 Patients were enrolled over a period of 3 
years; 148 patients were treated with anti-arrhythmic drug therapy and 146 underwent 
pulmonary vein isolation. In order to assess the AF burden continuous rhythm 
monitoring was performed during 7 days at baseline, and 3, 6, 12, 18 and 24 months 
after initiation of therapy. A significant difference in AF burden was found between the 
PVI and AAD group at 24 months follow-up (9% vs. 18%, respectively; P = 0.007). 
However, the cumulative AF burden during the entire follow-up period revealed no 
significant difference between both groups (13% and 19%, respectively; P = 0.10) [11].
Fig. 1 Pulmonary vein isolation technologies
Isolation of the pulmonary veins using cryothermal energy (panel A) or radiofrequency energy (panel B). Panel A: 
A cryothermal balloon catheter (red arrow) is positioned into the left superior pulmonary vein and circumferential 
ostial ablation results in disappearance of PV potentials (P). Panel B: An endovascular, remote, steerable, radiofre-
quency ablation catheter is positioned in the left superior pulmonary vein. The radiofrequency ablation catheter in a 
steerable sheath is attached to a robotic arm (red arrow), which is controlled from a workstation (W). The workstation 
is equipped with an instinctive motion controller (IMC) which provides tactile feedback. Navigation with the robotic 
arm is facilitated by a three-dimensional electro-anatomical map of the left atrium (LA).
Atrial fibrillation: to map or not to map?
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Effects of the Pulmonary Vein Isolation Procedure
Why and when is PVI a successful procedure for AF? The success of PVI in eliminating 
AF episodes can be attributed to a number of factors like 1) isolation of the trigger(s), 
2) modification of the arrhythmogenic substrate located in the left atrial posterior 
wall, 3) interruption of crucial pathways of conduction, 4) atrial debulking or 5) atrial 
denervation.
It is generally assumed that the arrhythmogenic substrate for AF is located at the left 
atrial posterior wall. In humans, ‘rapid electrical activity’ (organized electrograms 
with relative short cycle lengths) during AF was found at the left atrial posterior wall. 
Recently, Shivkumar et al. tested the feasibility of Focal Impulse and Rotor Modulation 
(FIRM) by a novel method in 12 patients (paroxysmal AF: 1; persistent AF: 11) in a 
multicenter setting [12]. Unipolar AF electrograms were obtained by a 64-pole basket 
catheter (IE 4-8 mm). In these patients, they identified 18 locations of ‘rapid electric 
activity’ in the left atrium and 5 in the right atrium; 21 were labelled as rotors. The 
procedural endpoint was defined as acute AF termination or organization (>10% cycle 
length prolongation) and was conceived in all patients. FIRM demonstrated localized 
AF rotors/focal sources in patients with different AF types and recommend larger studies 
with follow-up and randomization. Consequently, they initiated the Conventional 
ablation for atrial fibrillation with or without Focal Impulse and Rotor Modulation 
(CONFIRM) trial containing 92 patients (paroxysmal AF: 26; persistent AF: 66) 
undergoing 107 consecutive ablation procedures [13]. They allocated patients to FIRM 
following conventional ablation (N = 36; PAF: 7; persistent AF: 29) or conventional 
ablation alone (N = 71). In 97% of the procedures, they observed focal activity (left 
atrium 76%; right atrium 24%). Acute success was achieved in 86% of FIRM versus 
20% of conventional ablation. In addition, patients with FIRM had a higher freedom 
of AF episodes (82.4% vs. 44.9%; p > 0.001) during an averaged follow-up period of 
273 days. Hence, it was claimed that FIRM-guided ablation might be a more efficient 
AF ablation approach for both paroxysmal and persistent AF. 
Alterations in refractoriness may also contribute to PV arrhythmogenicity. Jais et al. 
assessed both the effective and functional refractory period in patients with and without 
a history of AF [14]. In patients with AF, the refractory period in the PV area was 
shorter than in the left atrium. On the contrary, in the control group the refractory 
period in the left atrium was shorter than in the PV area. Comparing the control 
and the AF group, the refractory period in the PV was significantly shorter in the AF 
patients. Hence, the relative shorter refractory period of the PV area seems to contribute 
to its arrhythmogenicity. Haissaguerre et al. observed that AF cycle length within the 
coronary sinus progressively increased during PVI [15]. Based on their observations and 
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data from other studies demonstrating reentry in the PV-left atrial junction region they 
stated that in some patients with AF, the PV-left atrial junction region is a generator of 
venous waves maintaining AF (“Venous Wave Hypothesis”) [16]. 
Disconnection of crucial intra-atrial conduction pathways, e.g. Marshall bundle, located 
at the PV-left atrium junction may also explain why PVI is successful in eliminating AF. 
Marshall bundle is located within the vein of Marshall close to the left superior PV 
and connects the coronary sinus muscle sleeve to the left atrium. Epicardial mapping 
studies in canine atria demonstrated that Marshall bundle may serve as a source of atrial 
ectopy giving rise to AF. Direct connections between the Marshall bundle and the left 
superior PV contributed to focal activity within the left superior PV. When conduction 
between the PV and left atrium was slowed by ablation, focal activation within the 
left superior PV was prevented, despite persistent focal activation originating from 
the Marshall bundle in some dogs. This finding also suggests that the Marshall bundle 
can be regarded as an accessory pathway to the left superior PV and may explain why 
circular lesions fail to isolate the PV. However, evidence from human data supporting 
this hypothesis is lacking [17].
Another hypothesis for the success of the PVI is atrial debulking. “The critical mass 
of fibrillation” hypothesis states that a certain minimal size of atrial tissue is essential 
for initiation and sustenance of AF [18, 19]. Perpetuation of AF is determined by 
the number of simultaneously wandering wavelets [20]. Thus, a larger atrial mass can 
accommodate more wavelets thereby stabilizing AF and reduction of atrial mass may 
therefore be anti-fibrillatory. It is thought that PVI diminishes atrial mass as a significant 
amount of atrial myocardium may be replaced by scar tissue [18, 19]. 
Finally, effectiveness of the PVI can also be explained by atrial denervation. There is 
accumulating evidence that the autonomic nervous system plays a role in the pathogenesis 
of AF. Vagal stimulation increases spatial dispersion in atrial refractoriness, caused by e.g 
local variability in density of vagal nerve endings/muscarine receptors, discrepancies in 
the coupling of muscarin receptors to ion-channel effectors, variation in K+-channel 
density or variations in the distribution of acetylcholinesterase. A higher vagal tone due 
a reduced acetylcholinesterase activity has been indeed been demonstrated in patients 
with AF [21]. Pappone et al. analyzed heart rhythm variability and found a post-
ablation shift of the sympathovagal balance towards parasympathetic predominance. In 
a subsequent study, vagal denervation was performed in 297 patients with paroxysmal 
AF referred for PVI. Vagal sites were defined as sites where vagal reflexes (bradycardia, 
asystole, atrioventricular block, hypotension) occurred during ablation. At such a site, 
ablation was performed until the vagal reflexes were completely abolished. Vagal reflexes 
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were present in 104 patients; ablation sites were located at the cranial left superior PV-
left atrium, the septal right superior PV-left atrium, the postero-inferior left inferior PV- 
left atrium and the postero-inferior right inferior PV-left atrium junction. In patients 
who have had a vagal denervation, late recurrences were less frequent observed though 
there was a higher incidence of early recurrences compared to patients without vagal 
denervation. This finding was explained by destruction of vagal nerve fibers resulting 
in release of acetylcholine causing early recurrences, followed by a stable vagolytic effect 
later after ablation which prevented AF recurrences [22].
So why and when may PVI then NOT be effective in eliminating AF? It is assumed 
that in patients with long-standing persistent atrial fibrillation, AF has progressed from 
a trigger-driven to a substrate mediated arrhythmia. In these patients, persistence of AF 
no longer depends on the presence of a trigger but is maintained by an ‘arrhythmogenic 
substrate’ (‘true fibrillation’). Patients presenting with AF may have underlying structural 
heart diseases affecting atrial architecture and/or electrical function thereby creating a 
substrate capable of perpetuating AF. In addition to this, AF itself may also modify the 
atrial myocardium which in turn stabilizes AF. For example, AF results in shortening of 
the atrial effective refractory period and reversion of the physiological rate adaptation 
(shortening of the atrial refractory period at slower heart rates), facilitating inducibility 
and stability of AF (electrical remodeling) [23]. Longstanding AF in the goat model 
of AF is associated with changes in myocardial structure including dedifferentation, 
increase in cell size, perinuclear accumulation of glycogen, central loss of sarcomeres, 
changes in mitochondrial shape, fragmentation of the sarcoplasmatic reticulum and 
disorganization of fiber orientation were associated with long-standing AF (structural 
remodeling) [24]. Unfortunately, data on histopathological alterations in humans with 
AF are limited [25].
There are numerous electrophysiological, structural and neurohormonal alterations 
creating a vulnerable substrate for AF. As it is likely that electrical and/or structural 
remodeling affects multiple sites of the atria, the arrhythmogenic substrate of AF will 
not only be confined to the PV area. This hypothesis is supported by the outcome 
of the IRAAF study, (the intra-operative radiofrequency ablation of atrial fibrillation) 
[26]. In this study, creation of linear lesions in the left atrium without PVI eliminated 
AF in more than 90% of the patients. Ablation of AF should either destroy the trigger 
mechanism or alter the substrate perpetuating AF. However, a selective ablation approach 
requires knowledge of the mechanisms underlying AF in the individual patient. Cardiac 
mapping may be a suitable tool to acquire knowledge of the arrhythmogenic substrate 
necessary for selection of the optimal ablation strategy. 
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Cardiac Mapping
Cardiac mapping is originally defined as a method by which potentials recorded directly 
from the surface of the heart are spatially depicted as a function of time in an integrated 
manner [27]. The most commonly used cardiac mapping approach is isochronal or 
activation mapping which is aimed at creating a spatial model of the excitation 
sequence. Extracellular potential features are used to detect the local activation time 
of myocardium surrounding the recording electrode. Isochronal mapping during sinus 
rhythm is demonstrated in Figure 2. A template containing 60 unipolar electrodes 
records extracellular potentials from a 1.10 cm2 area of epicardial atrial tissue at the 
right atrial free wall. An example of an unipolar atrial electrogram recorded during 
sinus rhythm, containing a local atrial potential (A) and a far-field ventricular potential 
(V), is shown on top. Each potential in the electrogram has an identical morphology. 
The local activation time is determined by marking the maximum negative slope (red 
lines). This information is used to construct a color coded activation map. The moment 
that the wavefront enters the mapping area is defined as 0 ms. Isochrones are lines 
connecting simultaneously activated recording sites and are drawn at 10 ms intervals. 
Fig. 2 Principles of isochronal mapping
Upper panel: unipolar epicardial atrial electrogram recorded during sinus rhythm. 
Lower panel: unipolar epicardial atrial potentials recorded at every electrode (N = 60) within a mapping area of 1.10 
cm2. Red lines indicate the local activation time at every electrode. A color coded activation map with isochrones (black 
lines) drawn at 10 ms show that the wavefront is propagating from the lower right corner towards the upper left corner. 
A = atrial potential, V = far field ventricular potential.
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The propagation direction of the wavefront is perpendicular to the isochrones and 
indicated by a black arrow. The resulting activation maps shows a wavefront propagating 
from the lower right corner towards the upper left corner within 20 ms.
As demonstrated by this example, the main element in cardiac mapping is thus correct 
interpretation of the morphology of extracellular potentials. Figure 3 shows a collection 
of unipolar, epicardial, AF electrograms recorded from the middle of the right atrial free 
wall during induced AF (upper panel) and long-standing persistent AF (lower panel). 
In both patients, there is a considerable beat-to-beat variability in the morphology of 
the fibrillation potentials that it is more pronounced in the patient with long-standing 
persistent AF. Fibrillation potentials obtained from the latter patient are often prolonged 
Fig. 3 Unipolar electrograms during induced and long-standing persistent atrial fibrillation
Unipolar, epicardial atrial electrograms recorded from the middle of the right atrial free wall recorded during in-
duced AF (upper panel) and long-standing persistent AF (lower panel). Recordings obtained from the patient with 
long-standing persistent AF are more complex, containing fractionated potentials. 
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and contain multiple deflections (so-called fractionated potentials). Mapping of AF is 
particularly challenging as these complex recordings hamper a correct determination of 
the local activation times. The hallmark of AF is a continuous beat-to-beat change in 
pattern of activation (Figure 4) and electrogram morphology. Thus, mapping of AF is 
very complex.
Fig. 4 Activation maps during permanent atrial fibrillation
Eighteen consecutive color-coded activation maps of the right atrium (area 1.10 cm2) obtained from a patient with mi-
tral valve disease. The maps show clear beat-to-beat changes in the pattern of activation. The earliest to latest activated 
areas are colored from red to dark purple. 
QUASAR (QUest for the Arrhythmogenic Substrate of Atrial fibRillation)
In recent studies, Allessie et al. introduced a novel high resolution mapping approach 
(‘wave mapping’) to compare electrophysiological properties of fibrillation waves during 
induced atrial fibrillation in patients with normal atria (physiological AF) and during 
persistent AF in patients with valvular heart disease (pathological AF). This wavemapping 
technique allows visualization of individual fibrillation waves and quantification of the 
fibrillatory process. Epicardial wavemaps of the right atrium free wall, left atrium and 
the PV region were constructed during persistent AF and compared with epicardial 
maps of the right atrial free wall obtained during induced AF. By applying this technique 
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we were able to differentiate physiological from pathological AF and demonstrated 
that electrical dissociation of atrial muscle bundles (Figure 5: left panel) and epicardial 
breakthrough of fibrillation waves (Figure 5: right panel) play a key role in development 
of the substrate of persistent AF [28-29]. 
Fig. 5 Electropathologic substrate of atrial fibrillation: longitudinal dissociation and epicar-
dial breakthrough
Left panel: example of a wavemap of the right atrial free wall of a patient with long-standing persistent AF and mitral 
valve disease. This wavemap was reconstructed using an algorithm separating fibrillation waves having an interelectrode 
conduction time of ≥12ms everywhere along their boundaries. The sequence of appearance of the waves is indicated by 
the rainbow colour scheme. Arrows indicate the main trajectories of the different fibrillation waves. These maps show 
two types of fibrillation wave; peripheral waves, entering the mapping area from outside the electrode array (black 
arrows) and epicardial breakthrough waves, appearing at the epicardial surface inside the mapping area (white arrows). 
Lower left panel: corresponding dissociation map demonstrating boundaries between waves with an inter-wave conduc-
tion velocity ≥ 19 cm/s (gray boxes: collision) or < 19 cm/s (black boxes, conduction block).
Right panel: example of the spatial distribution of epicardial breakthroughs (EB) during 8 seconds of AF at the right 
atrial free wall. Each asterisk indicates a breakthrough site, its size being proportional to the number of EBs occurring 
at that site. EB’s are widely distributed over the entire epicardial surface and occurred virtually everywhere.
Lower right panel: schematic presentation of a pattern of EB as a result of transmural dissociation in conduction. For 
simplicity, transmural dissociation is represented by 2 planes only. In this example, the endocardial layer is activated by 
a single fibrillation wave propagating from left to right. In the middle, this endocardial wave is propagating transmural-
ly through a junction site with the epicardial layer. Assuming a transmural conduction time of 10 ms, the breakthrough 
of the transmurally propagating wave appeared at t=25 ms at the epicardial surface (asterisk). Depending on the spatial 
distribution of electrophysiological properties like strength of depolarization, excitability, electric coupling, and source-
sink relations, the spread of activation from this site of EB may vary [28, 29].
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Hypothetically, multi-site high resolution atrial mapping can be used to localize sources 
generating AF in patients with trigger-driven AF and to identify areas perpetuating AF 
in patients with substrate mediated-AF. Due to the large variety in disorders associated 
with AF, it is feasable to assume that there are inter-individual differences in the 
mechanisms underlying AF and multi-site high resolution mapping of the entire atria 
is therefore mandatory. In an attempt to diagnose the substrate of AF in individual 
patients, we initiated the QUASAR study (QUest for the Arrhythmogenic Substrate of 
Atrial FibRillation) at the Erasmus Medical Center in Rotterdam. In this project, we 
are developing a real-time, high resolution, multi-site epicardial mapping technique of 
the entire atria as a novel diagnostic tool. For this purpose, we are performing epicardial 
mapping studies in a large number of patients undergoing cardiac surgery with a variety 
of underlying structural heart diseases and different types of AF.  This new mapping 
technique (Figure 6) can be used, not only to gain insights into the arrhythmogenic 
substrate of AF, but also to develop novel therapies or to improve existing treatment 
modalities. 
Fig. 6 Quest for the arrhythmogenic substrate of atrial fibrillation
An epicardial, high resolution, multi-site mapping approach is used for identification of the arrhythmogenic substrate 
in patients with AF. High resolution mapping arrays (inter-electrode distances 1-2 mm) are used for epicardial mapping 
of the atria. Unipolar atrial potentials are used for construction of activation, voltage and conduction block maps.
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Introduction
Bachmann’s Bundle (BB), also known as the interatrial bundle, is well-recognized as a 
muscular bundle comprising of parallel aligned myocardial strands connecting the right 
and left atrial walls and is considered to be the main pathway of interatrial conduction1. 
Disruption of the bundle’s structure causes interatrial conduction block (IAB)2 
which is associated with development of various atrial tachyarrhythmias3, 4 and with 
electromechanical dysfunction of the left atrium (LA)5. Technological progress providing 
sophisticated mapping and imaging techniques in the past decade has increased our 
knowledge of specific anatomical structures and their role in development of both atrial 
brady- and tachyarrhythmias. This review outlines the current knowledge of the relation 
between anatomical and electrophysiological properties of Bachmann’s bundle and its 
possible role in initiation and perpetuation of atrial fibrillation. 
Macroscopic Anatomy of Bachmann’s Bundle
In 1963, Thomas N. James described three pathways connecting the sinus node to the 
atrioventricular node termed the anterior, medial and posterior internodal pathways6. 
Whether these conduction pathways were due to the presence of specialized conduction 
tissue or to the anisotropic orientation of the muscle fibers, remains controversial. 
Nevertheless, James described the anterior pathway as leaving the sinus node in anterior 
direction and giving off a secondary branch at the level of the superior vena cava to 
form BB1. BB stretches subepicardially across the interatrial groove (septal raphe). It is 
at the interatrial groove that the BB can be identified as a discrete bundle (Figure 1 and 
2) separated by fatty tissues from the infolded right atrial wall that is the limbus of the 
oval fossa. Notably, the bundle is not surrounded by a fibrous tissue sheath. Instead, the 
bundle is comprised of strands of atrial myocardium that are similarly aligned in parallel 
fashion. Its rightward and leftward extensions bifurcate to pass to either side of the right 
and left atrial appendages7. Although they can be traced to varying extents with blunt 
dissection, both extensions blend into the musculature of the atrial walls. The superior 
arm of the rightward extension arises in the region of the cavoatrial junction close to the 
site of the sinus node and in the vicinity of the sagittal bundle. The inferior arm arises 
in the subepicardium of the right atrial vestibule. Leftward, BB buttressing part of the 
anterior atrial wall with its thickness (Figure 1) is still traceable to where it encircles the 
neck of the left atrial appendage and blends in with the lateral atrial wall. The superior 
part traverses in the infolding of the atrial wall known to arrhythmologists as the left 
lateral ridge, to pass in front of the orifices of the left pulmonary veins8. The inferior 
part descends towards the atrial vestibule to combine with the circumferentially aligned 
myocardial strands in the subepicardium of the inferior wall8. 
In contrast to the thinner distal extensions, BB’s body across the interatrial groove is a 
broader band (Figure 1 and 2), with median measurements of 4 mm in thickness and 9 
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mm in height. It is described as trapezoidal shaped because of its short lower length (3 
mm) and longer upper length (10 mm)9. 
Figure 1
Left hand panel: Heart viewed from the front has the tips of the right and left atrial appendages (RAA and LAA) pulled 
back. Blunt dissection reveals Bachmann’s bundle (BB) crossing the interatrial groove (white arrows). The black arrows 
mark the rightward and leftward extensions. The blue oval marks the anticipated site of the sinus node. 
Right hand panel: Longitudinal cut through the left heart displays BB cut in cross-section (*). Note that it adds consid-
erably to the thickness of the left atrial (LA) wall in this heart. 
LSPV indicates left superior pulmonary vein; RSPV, right superior pulmonary vein; and SVC, superior vena cava.
Figure 2
Longitudinal cut through Bachman’s bundle and the atrial septum in a heart shows the bundle passing epicardial to the 
interatrial groove that is filled with epicardial fat (*), also represented on the diagram. RA=right atrium, IVC indicates 
inferior vena cava; LAA, left atrial (LA) appendage; LSPV, left superior pulmonary vein; RA, right atrium; and SVC, 
superior vena cava.
Microscopic Anatomy of Bachmann’s Bundle
BB myocytes are organized into relatively well-aligned myocardial strands or myofibers10 
in the subepicardium and differ in orientation and direction from those in the underlying 
atrial walls. A perpendicular myofiber orientation has been observed at the junction 
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with the superior caval vein, whereas myofibers are orientated more randomly at the 
level of the interatrial septum9 BB myocytes are surrounded by thin septa formed of 
tightly packed collagen fibrils running uninterrupted over distances of 392 µm (i.e. 
approximately four times the average myocyte length)11. Over larger distances, those 
thin septa form several interconnections. Thick septa are present near the surface of BB, 
where they often encircle groups of myocytes.
Sherf et10 al suggested that BB contained myocytes specialized for rapid conduction. 
These myocytes differed from ordinary atrial myocytes by a relative paucity of organized 
myofilaments and by their lack of a transverse-axial tubular system. Based on electron 
microscopy, 5 different types of myocardial cells in BB were distinguished. Dependent 
on their cytological features these myocardial cells were labeled as myofibril rich, 
myofibril poor, broad transitional cells, slend transitional cells and P cells. Myofibril 
rich cells in BB did not differ from myocytes in other parts of the atrial myocardium. 
Myofibril poor cells are Purkinje-like cells that are not only numerous in BB, but also 
in other interatrial conduction pathways. P cells in BB are very similar to P cells present 
in the SA and AV node10. Slender transitional cells are shorter and narrower than broad 
transitional cells, but both broad and slender transitional cells show similarities with 
myofibril rich and myofibril poor cells. They possess many myofibril-dense zones, and 
also intracellular spaces filled with cytoplasm. However, other investigators were not 
able to find specialized myocytes11. 
Embryology of the Cardiac Conduction System and Bachmann’s Bundle
To determine whether BB belongs to the specialized cardiac conduction system, the 
embryologic origin of BB was studied. The primary heart tube is known as the embryonic 
origin of chamber myocardium12-15. By expressing chamber differentiation genes, the 
primary heart tube myocardium differentiates into chamber myocardium. An in vitro 
test showed that the expression of these genes can be repressed by T-box transcription 
factor Tbx2, preventing the chamber to differentiate and enabling the primary heart 
tube cells to contribute to other parts of the human heart, including cardiac conduction 
tissue12, 16, 17. Given the discussion whether or not BB is part of the cardiac conduction 
system, it is not yet clear if BB is also a derivate of the primary heart tube myocardium.
By using immunological markers, a joint embryonic origin of different parts of the 
human heart can be demonstrated, as Blom et al18. did by using HNK1 and Jongbloed 
et al. did by using CCS-lacZ19. In the study of Blom et al., HNK1 - staining the 
developing atrioventricular conduction system - was detected in the right venous valve 
(corresponding to the posterior pathway as described by James6), the left venous valve 
and in the anterior pathway. This suggests that both the posterior pathway, the left 
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venous valve and possibly BB have a joint embryonic origin. Jongbloed et al. detected 
CCS-lacZ expression (lacZ stains developing and mature conduction system) in BB, 
the sinoatrial node, His bundle and many other CCS- and non-CCS related structures. 
Noteworthy is that all detected lacZ- and HNK1 positive tissues, including BB, are 
known for their relation with arrhythmias18, 19. This supports the hypothesis that 
the occurrence of arrhythmias preferentially arises from areas that are related to the 
developmental pathway of CCS18, 19, and makes the hypothesis of BB belonging to the 
cardiac conduction system attractive.
Vascularisation of the Bachmann’s Bundle
Vascularisation of BB has been studied by using computed tomography imaging in both 
healthy subjects and patients with structural heart disease20. The sinoatrial node artery 
invariably supplied BB. Even in patients in whom BB could not be visualized, small 
branches originating from the sinoatrial node artery could be detected in the anatomical 
area of BB. In 55% of the patients, BB was vascularised by the right sinoatrial node 
artery originating from the right coronary artery, in 40% by the left sinoatrial node 
artery originating from the ramus circumflexus and in 5% by both sinoatrial node 
arteries. Figure 3 shows a coronary angiogram demonstrating vascularisation of BB by 
branches of the sinoatrial node artery originating from the right coronary artery. 
Figure 3
Coronary angiogram of the right coronary artery demonstrating vascularisation of BB by branches of the sinoatrial 
node artery originating from the right coronary artery. 
BBA indicates Bachman’s bundle artery; RCA, right coronary artery; and SAN, sinus node artery.
Electrophysiological Properties of Bachmann’s Bundle
Changes of the normal anatomy of BB, like disruption of the parallel-orientation 
of muscle fibers may predispose to development of atrial tachycardias. Some studies 
have demonstrated preferential conduction corresponding to the internodal pathways. 
Whether this preferential conduction is due to the presence of specialized conduction 
tissue or to the anisotropic orientation of the muscle fibers, is still a matter of debate19.
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In vivo and in vitro canine experiments revealed that during hyperkalemic atrial 
arrest, fibers of the interatrial band remained excitable. Sinus node impulses were still 
able to propagate to the atrioventricular node, suggesting the existence of specialized 
conduction tissue between the sinus node and the atrioventricular node. In addition, 
electrical activity in the interatrial band persisted when both atria were inexcitable, 
indicating the presence of specialized atrial fibers in this region21, 22. Evidence of 
specialized interatrial band fibers was also provided by Hogan et al who demonstrated 
that pacemaker activity of these fibers could be induced by catecholamines.23 In 1963 
Horiba described BB membrane action potentials in mongrel dogs, with an averaged 
action potential duration of 345 ± 40 ms during sinus rhythm compared to atrial and 
ventricular muscle action potential durations varying between 200 to 300 ms24. In 
addition to this, they demonstrated that BB action potentials were characterized by a 
steep upstroke followed by a pointed overshoot and a short plateau phase (Figure 4)24. 
Similar characteristics of BB membrane potentials were found in subsequent studies22, 
23, 25. Wagner and coworkers recorded transmembrane potentials in superficial canine 
BB fibers during an in vitro experiment22. They measured a resting potential up to -95 
mV, a maximum rising velocity of the upstroke of the action potential (dv/dt) up to 630 
volts/sec., an action potential amplitude of 130 mV, a prominent overshoot (up to 40 
mV) and a distinct plateau22. Those transmembrane potentials differed from recordings 
from left atrial muscle fibers that showed a resting potential up to -80 mV, dv/dt up to 
225 volts/sec., action potential amplitude up to 98 mV, and a less prominent overshoot 
(up to 30 mV). No distinct or a very short plateau phase was present. At that time, the 5 
different types of myocytes10 had not been described yet, but Wagner et al. noticed that 
when the measuring micro-electrode was penetrating deeper than 1 to 5 cells into BB, 
ordinary atrial potentials with lesser plateaus and lower upstroke velocities (1.3 m/s in 
crest vs. 0.9 m/s in deeper layers) were obtained. Similar results were found by Childers 
et al, except for a lower maximum upstroke velocity26. In summary, BB fiber action 
potentials show both similarities and differences with action potentials that had been 
obtained from the Purkinje system, which is part of the CCS, and from those that had 
been obtained from atrial myocardium22, 26. Action potentials recorded from BB fibers 
show a distinct overshoot and convex shoulder to the repolarization phase, whereas 
ordinary atrial cells and Purkinje cells have a smaller overshoot (up to 30 mV in atrial 
cells vs. 40 mV in BB myocytes) and a concave or a straight repolarization. 
BB’s plateau resembles the Purkinje prominent phase 2 plateau. Compared to ordinary 
atrial muscle fibers, transmembrane action potentials of BB myocytes are characterized 
by a higher resting membrane potential and higher dV/dtmax 
22, 26. Unlike Purkinje fibers, 
BB’s action potential durations are significantly abbreviated by acetylcholine22.
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In vivo assessments of interatrial conduction velocity in canine hearts demonstrated that 
like Purkinje fibers, BB fibers conduct impulses at a significantly higher velocity (1.7 
m/s) than surrounding myocardium (0.4 m/s)22. Moreover, Wagner et al. discovered 
that the conduction velocity even varied within BB: it consists of myocardial fibers with 
different conduction velocities22. Assessment of conduction velocity of superficial fibers 
demonstrated velocity values up to 1.3 m/s, whereas in the deeper layers conduction 
velocities of only 0.9 m/s were recorded. From these observations the authors concluded 
that impulse spread must occur through multiple relatively independent linear paths, 
without transverse conduction22. However, most remarkable is the presence of a 
supernormal phase of excitability26 which occurred when the coupling interval of 
premature beats was shortened during pacing. A similar phase of supernormal excitability 
has also been observed in Purkinje fibers27. 
In conclusion, we can say that BB share electrophysiological properties of both Purkinje 
and atrial fibers. 
Bachmann’s Bundle Block
Since BB is the preferential pathway of interatrial conduction, structural abnormalities 
of BB may cause interatrial conduction block (IAB). This was demonstrated by Waldo 
et al. who produced surgical lesions in left and right atrial portions of BB in canine 
hearts and studied alterations in the electrocardiograms 2. After creating surgical lesions, 
significant changes in P-wave morphology (both in duration and polarity) were seen 
Figure 4
Differences between an action potential recorded from Bachmann’s bundle and from atrial myocytes. See text for 
detailed description.
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during pacing from different directions. Conduction delays in BB resulted in partial 
IAB, whereas complete block in BB resulted in advanced IAB. Normal atrial conduction 
is reflected on the surface electrocardiogram by P-waves with a duration of < 110 ms. 
Prolonged interatrial conduction, or interatrial block (IAB), is therefore defined as a 
P-wave of longer than 110 ms. Both partial and advanced IAB produce anomalous 
P-waves28. Partial IAB gives rise to wide, usually biphasic waves, because the left and 
right atria are not activated simultaneously. In advanced IAB, impulses traverse the 
right atrium toward the atrioventricular node, after which it continues its pathway in 
superior direction, to end in the left atrium. This results in a biphasic (+/-) P wave in the 
inferior leads. Atrial disruption caused by fibrosis has been suggested as the mechanism 
underlying IAB. Fibrosis was associated with both ischemic heart disease29 and non-
ischemic heart disease including systemic sclerosis29, 30, dilated cardiomyopathy31, 
hypertrophic cardiomyopathy 31, lymphoma32 and increased atrial strain due to valvular 
heart disease33. 
Histological studies demonstrated that right atrial tissue (including BB tissue) of 
patients with IAB shows apparent fibrosis34, 35, though fibrosis of BB alone has not been 
described.
It has also been suggested that increased atrial strain, irrespective of the underlying heart 
disease, causes delayed conduction over BB33.  
Clinical Importance of Bachmann’s bundle in Pathophysiology of Atrial 
Fibrillation
In a general hospital population, the prevalence of IAB in patients with atrial fibrillation 
(AF) is 52% (in contrast to 18% in patients without AF), suggesting a relationship 
between IAB and development of AF3. Vice versa, in a prospective study including 
16 patients with advanced IAB, 15 patients (94%) developed atrial arrhythmias over 
time. In a follow up period of 30-months in which no interventions were committed, 
patients developed either AF (N=7, 44%), atrial flutter (N=4, 25%) or atrial flutter and 
AF (N=4, 25%). Patients were compared with a control group of 22 patients without 
advanced IAB of similar age, gender, clinical findings, degree of heart failure, left atrial 
size by M-mode echocardiography and duration of follow-up. In the control group, 
only 5 patients developed AF and 1 patient developed atrial flutter during follow-up36. 
Patients in both groups had structural heart disease. 
In a larger and more recent prospective study performed on 118 patients that were 
admitted to a general department of a tertiary care general hospital, 29% of 41 patients 
with partial IAB developed AF during a 12-month follow up period. In contrast, in 
patients with sinus rhythm without IAB (N=44), the incidence of AF was only 9%. 
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75% of patients whom developed AF during the follow-up period showed IAB in 
electrocardiographic registrations at baseline 37. Furthermore, Ariyarajah et al. reported 
a patient with advanced interatrial block who developed atrial flutter over time38. Abe 
et al. studied the progression of paroxysmal to persistent AF in 122 patients with 
paroxysmal atrial fibrillation during a follow up period of 26 ± 12 months. At the 
onset of the study, P-wave-triggered signal-averaged ECG was abnormal in 23 patients. 
Ten of them developed persistent AF whereas only 4 patients with a normal P-wave-
triggered signal-averaged ECG had persistent AF39. Hence, all these studies support 
the hypothesis that IAB, presumably occurring in BB, reflects the presence of electro-
pathological alterations throughout the atria that may predispose to the development of 
atrial tachyarrhythmias in humans. 
Role of Bachmann’s Bundle in Initiation and Perpetuation of Atrial Fibrilla-
tion
It is widely accepted that re-entry is an important mechanism in the initiation of atrial 
tachyarrhythmias40, but whether or not BB is involved in this process has not yet been 
elucidated. 
Ogawa et al. demonstrated in canine hearts that premature impulses generated in the 
high left atrium initiated reentry. The premature beat conducted slowly to the right 
atrium and resulted in echo beats in the left atrium. Starting from the circus movement 
concept of Allessie et al.40, 41 the authors suggested that their observations were due 
to longitudinally dissociation in conduction across BB which resulted in reentry. 
Hence, BB may be involved in initiation of paroxysmal supraventricular tachycardias42. 
Epicardial and endocardial mapping during induced AF in a canine sterile pericarditis 
model showed that unstable reentry circuits with very short cycle lengths maintained 
AF. A large number of these unstable reentrant circuits used BB as part of their reentrant 
pathway43. Based on these findings, the authors hypothesized that a lesion in BB would 
prevent induction of stable AF. In a consecutive study, the authors demonstrated the 
effect of catheter ablation of BB on AF in the same model44. AF (defined as a sustained 
episode of AF lasting > 2 minutes) was induced with rapid atrial pacing, after which the 
mid-portion of BB was transected by radiofrequency ablation. AF terminated during 
ablation and afterwards it was not possible anymore to induce sustained episodes of 
AF by rapid pacing. In 2001, Goyal and Spodick speculated on a possible relationship 
between conduction block in BB and induction of atrial tachyarrhythmias5. They 
hypothesized that IAB, being a marker for left atrial dysfunction may predispose for AF.
By using echocardiography, left atrial functional parameters of patients with and 
without interatrial conduction block were compared. The groups were matched for left 
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atrial size. The extent of left atrial dysfunction was larger in patients with interatrial 
conduction block and related to the degree of conduction delay across BB. However, a 
cause-and-effect relationship cannot be extracted from this study and the data should be 
interpreted with caution. 
Role of Bachmann’s Bundle Pacing in Prevention of Atrial Fibrillation
Given the numerous indications that BB plays a role in initiation and perpetuation 
of atrial tachyarrhythmias, it has been tested whether AF could be prevented by BB 
pacing. One of the first studies comparing pacing at various atrial sites to prevent AF 
was performed by Yu et al. in 200045. In this study, P wave duration of 15 patients 
with paroxysmal AF was measured during pacing at six different anatomical sites, 
including right atrial appendage (RAA), BB, right posterior interatrial septum (RPS), 
distal coronary sinus (CSd), RAA plus RPS simultaneously (DSA), and RAA plus 
CSd simultaneously (BiA). The P wave duration was longest during RAA pacing and 
decreased in order from 1) RAA pacing, 2) CSd pacing, 3) pacing involving septal 
components (BB, RPS, or DSA), and 4) BiA pacing. At that time, it had already been 
observed that pacing at the right atrial septum reduced total atrial activation time35. 
Later studies demonstrated that pacing at BB could also shorten atrial activation time45, 
46. BB, CSd, and RPS drive pacing were more effective than DSA or BiA drive pacing in 
reducing P wave duration. Additionally, these investigators did not succeed in initiating 
AF by BB, RPS, or CSd driving pacing when coupled to RAA extrastimulation, whereas 
they did succeed during RAA, BiA and DSA drive pacing. It was therefore concluded 
that BB, RPS and DCS pacing may be successful in preventing AF45. Duytschaever et al. 
provided evidence that the optimal site to prevent atrial reentry is at the middle portion 
of BB 47. 
In 2002, Gozolits et al.46 performed single-site and dual-site pacing after ablative 
therapy of supraventricular tachycardia in 15 patients without structural heart disease, 
that were not using antiarrhythmic drugs. BB pacing resulted in the shortest endocardial 
atrial activation time of all single pacing sites (81±15 msec), and in the shortest P wave 
duration (96 ± 12 msec). Shorter P wave duration during BB pacing was also observed 
by others48-50. Bailin et al.48 compared RAA pacing with pacing from the anterior 
superior interatrial septum (BB region, N=63) in patients with recurrent paroxysmal AF 
who did not use antiarrhythmic drugs. In the BB group, P wave duration was shorter 
than in sinus rhythm (BB: 123 ± 23 ms versus 132 ± 21 ms, P<0.05). One year after 
implantation, patients who received BB pacing were less likely to develop persistent AF 
(25%) compared to those who received RAA pacing (53%). 
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Conclusion
Bachmann’s bundle is the preferential pathway of interatrial conduction due to its electro-
anatomical properties. Structural changes of BB may cause longitudinal dissociation in 
conduction of adjacent muscle fibers thereby facilitating reentry and hence development 
of atrial fibrillation. Data obtained from clinical studies suggest a relationship between 
electro-pathological alterations of BB and the development of AF. However, areas of 
conduction block may not be confined to BB alone. Conduction abnormalities in BB 
may merely reflect more general electro-pathological alterations occurring everywhere 
in the atria. Further studies are still needed to examine the exact role of BB in initiation 
and perpetuation of AF and to determine whether therapy targeting BB may contribute 
in preventing the development of AF.
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Abstract 
The heterogeneous presentation and progression of atrial fibrillation (AF) implicate the 
existence of different pathophysiological processes. Individualized diagnosis and thera-
py of the arrhythmogenic substrate underlying AF may be required to improve treatment 
outcomes. Therefore, this single-center study aims to identify the arrhythmogenic areas 
underlying AF by intra-operative, high-resolution, multi-site epicardial mapping in 600 
patients with different heart diseases. Participants are divided into 12 groups according to 
the underlying heart diseases and presence of prior AF episodes. Mapping is performed 
with a 192-electrode array for 5– 10 s during sinus rhythm and (induced) AF of the 
entire atrial surface. Local activation times are converted into activation and wave maps 
from which various electrophysiological parameters are derived. Postoperative cardiac 
rhythm registrations and a 5-year follow-up will show the incidence of post-operative 
and persistent AF. This project provides the first step in the development of a tool for 
individual AF diagnosis and treatment.
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Introduction
Atrial fibrillation (AF) is characterized by beat-to-beat changes in the pattern of 
activation within the atria, unlike organized arrhythmias such as atrial flutter and atrial 
tachycardia. This chaotic nature poses a challenge with regard to understanding the 
pathophysiology and effective treatment of AF as shown by the frequent recurrences after 
AF therapy [1–4]. Due to the limited knowledge about the mechanisms involved, each 
AF patient is currently approached in the same manner. Based on the symptomatology 
and a clinical assessment the arrhythmia is either accepted or attempts are made to retain 
sinus rhythm with non-selective treatment modalities. However, this approach does not 
take account of the diversity among AF patients. AF occurs, for example, in association 
with mitral valve disease, hypertension, congenital heart disease, or cardiac sur-gery, 
or in young or older patients without any comorbidity (lone AF) [5, 6]. Furthermore, 
AF can have different clinical manifestations including paroxysmal, persistent, or 
longstanding persistent. On the structural level, the degree of fibrotic tissue in AF 
patients demonstrated heterogeneity as well and does not always predict the severity of 
the AF burden [7]. Therefore, it is likely that the pathophysiological mechanisms may 
differ between patients with AF. If these can be unraveled the possibility for targeted 
treatments may arise.
So far, several ablation procedures have been developed aiming to ablate a trigger site for 
initiation of AF or an arrhythmogenic substrate perpetuating AF. The isolation of trig-
gers residing in the pulmonary veins demonstrated to be most successful in patients with 
paroxysmal AF. Nonetheless, recurrences occur frequently especially in patients with 
persistent AF, suggesting an incomplete eradication, reformation, or progression of the 
arrhythmogenic substrate. Other strategies include the ablation of rotors, ganglionated 
plexi, and complex fractionated electrograms [8–10]. However, these therapies have 
similar, limited success rates and there are no guidelines as to which strategy to choose 
for an individual patient.
The present study has been designed to identify the arrhythmogenic substrate in 
individual AF patients with the use of a high-resolution epicardial mapping approach. In 
previous studies, high-resolution epicardial mapping of patients with Wolf-Parkinson-
White syndrome or longstanding persistent AF demonstrated to be a valuable tool in 
discriminating between patients [11, 12]. However, mapping was performed at only 
three locations and in a limited number of patients with a variety of heart disorders. 
In this study, subjects are categorized according to the underlying heart disorder(s) 
and predisposition for developing spontaneous episodes of AF before or after cardiac 
surgery and epicardial mapping will be performed of the entire epicardial surface 
[13, 14]. The electrophysiological properties of the atria will be analyzed aiming to 
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find the arrhythmogenic substrate and to contribute to the current knowledge of the 
pathophysiology of AF.
Methods
Study Population
All patients 18 years and older, with structural or coronary heart disease scheduled for 
elective cardiac surgery will be asked to participate. Patients who have a high-risk of 
complications during surgery or hemodynamic instability by induc-ing AF such as 
Wolff-Parkinson-White syndrome, poor left ventricular function (<40 %), presence 
of assist devices, hemodynamic instability, usage of inotropic agents, and kidney or 
liver failure are excluded from this study. Furthermore, patients with medical histories 
predisposing them for adhesions making epicardial mapping unfeasible or presence of 
an iatrogenically altered atrial electrophysiology such as prior radiation of the chest 
for malignancies, redo-cardiac surgery, paced atrial rhythms, and prior ablative therapy 
in the atria are excluded as well. Each patient, prior to enrolling in the study, will be 
provided with a written explanation of the study procedure together with an assessment 
of risks in participating in the study. Patients will be enrolled after the written informed 
consent form is signed. After enrollment patients are assigned to a group according to 
the underlying heart disease and whether their medical history includes AF. These groups 
con-sist of the following surgical procedures: coronary artery bypass grafting (CABG), 
mitral valve surgery, aortic valve surgery, mitral valve surgery with CABG, aortic valve 
surgery with CABG, and congenital heart surgery. Each of these groups are divided into 
separate groups for patients with and without prior AF episodes. Figure 1 demonstrates 
the inclusion and following procedures for patients participating in the study.
Study Procedure
Epicardial mapping is performed during open heart surgery [13]. Patients will be 
under general anesthesia and vital signs will be monitored continuously throughout 
the procedure. Mapping will be performed before going on extracorporeal circulation, 
during sinus rhythm, and (induced) AF. AF is induced by fixed rate pacing at the right 
atrial appendage with a pulse width of 2 ms delivered by temporary pacemaker wires. 
Pacing bursts will start at a rate of 250 bpm and will be increased with steps of 50 bpm 
each time AF is not induced after 3 attempts. If AF is not induced at a pacing rate of 
400 bpm or loss of capture occurs, attempts will be terminated. As AF is induced it 
may terminate spontaneously, otherwise, if an induced arrhythmia sustains after the 
mapping procedure, electrical cardioversion will be performed immediately afterwards. 
If a patient is in AF at the onset of the mapping procedure, mapping will be performed 
during AF and during sinus rhythm after electrical cardioversion if there is no atrial 
thrombus present on transesophageal echocardiogram.
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Epicardial mapping of the right and left atria will be per-formed using a custom-made 
electrode array (192 electrodes, diameter 0.45 mm, 2-mm interelectrode distance; GS 
Swiss, Küssnacht, Swiss). All electrograms recorded by the electrode are stored on hard 
disk after amplification (gain 1000), filtering (bandwidth 0.5–400 Hz), sampling (1 
KHz) and analogue to digital conversion (16 bits). An indifferent electrode is attached 
to a steal wire fixed in subcutaneous tissue and a reference signal is attached to the 
right atrium. In addition, a ventricular surface electrocardiogram (ECG) is recorded 
simultaneously. Signals will be recorded at 9 right and left atrial sites during sinus 
rhythm for 5 s per site and during (induced) AF for 10 s per site. Mapping is initiated 
at the lower right atrium and is proceeded upwards over the right atrial appendage. 
Thereafter, the left atrium will be mapped starting between the pulmonary veins and 
will continue along the atrioventricular groove from the lower pulmonary veins to the 
left atrial appendage and finally at the roof of the left atrium for Bachmann’s bundle. 
The mapping positions are demonstrated on a 3D model in the online Supplementary 
Video (1). The entire mapping procedure will not prolong the surgical procedure by 
more than 10–15 min [13].
Follow-up and Study Endpoint
The postoperative heart rhythm is continuously monitored until hospital discharge 
and rhythm registrations will be stored in order to determine the incidence of early 
postoperative AF. After discharge, all patients will be scheduled to visit an out-patient 
clinic, two times during the first year and thereafter once a year during the following 
4 years. Clinical history focused on tachyarrhythmias will be taken and a surface ECG 
will be made. If indicated, a 24-h Holter recording will be performed. If patients, for 
any reason, are unable to visit the out-patient clinic, follow-up is done by telephone. In 
the event that documented rhythm disorders have occurred, records will be requested 
from the visited hospital. The main endpoint of the study is reached when persistent AF 
develops.
Data and Statistical Analysis
Local activation times of the recorded atrial signals will be marked, from which color-
coded activation and wave maps will be reconstructed by custom-made software which 
has previously been described in more detail [11]. Data exclusion criteria include 
progressive in- or decrease in AF cycle length (AFCL) between sequential recordings 
(recorded via the reference signal) indicated by an approximately two times in- or decrease 
in AFCL, recordings of other rhythms than sinus rhythm or AF, or ≥50 % of missing 
recording data. Data analysis and the criteria for data inclusion are demonstrated in 
Fig. 2. Electrophysiological parameters that will be derived include conduction velocity, 
incidence of conduction block, number of fibrillation waves, incidence of epicardial 
Chapter 4
56
Fig. 2 
Flow-chart of data evaluation. Atrial fibrillation (AF) data from patients that were reinduced >2 times is excluded. 
Custom-made software detects atrial markings with the presented properties for sinus rhythm (SR) and AF. If ≥50 % of 
a 1 cm2 quadrant is not marked, this quadrant will be excluded from further analysis. Rhythm evaluation is performed 
with use of the activation and wave maps, and the position in SR is evaluated for overlap with a total SR map construc-
ted with use of the reference signal. All data is manually checked, from which the parameters are derived afterwards
Fig. 1 
Flow-chart of patient inclusion and following study procedures. After enrollment, patients are assigned to 1 of 12 
groups for data analysis according to the presence of previous atrial fibrillation (AF) occurrence and the type of surgery 
that will be performed (i.e., underlying heart disease). Subsequently, all patients are mapped during surgery and 
continuously monitored after surgery to detect postoperative AF. During the 5-year follow-up (FU), the additional 
tests consist of an electrocar-diogram (ECG) and Holter monitoring when patients indicate symptoms suspected of AF. 
ICF informed consent form, CABG coronary artery bypass grafting, MV mitral valve surgery, AV aortic valve surgery, 
CHD congenital heart disease
breakthroughs, AFCL, dominant frequency, electrogram voltage (the amplitude of the 
highest deflection in case of fractionation) and fractionation [11, 12]. For analysis, the 
electrodes of the mapping array are assigned to quadrants of 1 cm2. The variables will 
consist of averaged values or the percentage of occurrence/incidence for each quadrant. 
Figure 3 illustrates the construction of an activation map during sinus rhythm, quadrant 
partition, and its conversion into various parameters of all atrial sites. Figure 4 shows 
a wave map during AF and the variables that will be analyzed. Furthermore, rotor 
occurrence and the relation between patterns of activation, fractionation, fibrillation 
intervals, conduction abnormalities, and voltage will be studied and compared be-tween 
the different atrial sites, atrial rhythms, and patient groups. Rotors will be defined as a 
wave of excitation rotating around a phase singularity for one or more cycles [15] and 
analyzed by determining the dominant frequencies at each recording site in order to 
identify high-to-low frequency gradients and determination of the degree of patterns 
of activation. Linear regression analysis and linking of fibrillation waves, indicative of 
repetitive paired Student’s t test will be used to compare various electrophysiological 
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Fig. 2 
Flow-chart of data evaluation. Atrial fibrillation (AF) data from patients that were reinduced >2 times is excluded. 
Custom-made software detects atrial markings with the presented properties for sinus rhythm (SR) and AF. If ≥50 % of 
a 1 cm2 quadrant is not marked, this quadrant will be excluded from further analysis. Rhythm evaluation is performed 
with use of the activation and wave maps, and the position in SR is evaluated for overlap with a total SR map construc-
ted with use of the reference signal. All data is manually checked, from which the parameters are derived afterwards
parameters between different sites and different atrial rhythms. Unpaired Student’s t test 
will be used to compare various electrophysiological parameters between patient groups.
The present study is the first that will explore the value of various parameters in 
discriminating the arrhythmogenic substrate of different patients with AF. We aim for 
a sample of (at least) 50 subjects in each group for the following reasons. First, our 
initiative should be considered as an exploratory study. We want to obtain early results 
in a relative limited number of patients, which will provide a basis for future (in depth) 
investigations. Therefore, we accept that our study will be underpowered to draw defi-
nite conclusions with good precision. Additionally, it is relevant to obtain estimates 
with sufficient precision, also in early, hypothesis generating studies such as ours. In 
the binomial distribution, a probability of an observation of 50 % is achieved with the 
greatest measurement error. Taking that probability as the ‘worst case’, in a dataset of 50 
patients, the 95 % confidence intervals (CIs) around an observation would be ±14 %. In 
the 6*50 = 300 AF patients together, the 95 % CIs would be ±6 %. We consider these 
Fig. 1 
Flow-chart of patient inclusion and following study procedures. After enrollment, patients are assigned to 1 of 12 
groups for data analysis according to the presence of previous atrial fibrillation (AF) occurrence and the type of surgery 
that will be performed (i.e., underlying heart disease). Subsequently, all patients are mapped during surgery and 
continuously monitored after surgery to detect postoperative AF. During the 5-year follow-up (FU), the additional 
tests consist of an electrocar-diogram (ECG) and Holter monitoring when patients indicate symptoms suspected of AF. 
ICF informed consent form, CABG coronary artery bypass grafting, MV mitral valve surgery, AV aortic valve surgery, 
CHD congenital heart disease
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Fig. 4 
Left: wave map during atrial fibrillation at the right atrial free wall. A total of 5 waves activate the recording area in 41 
ms; 3 peripheral waves (black arrows) and 2 initiate at epicardial breakthroughs (white star and white arrows). Black 
lines between electrodes indicate conduction block (<18 cm/s). Isochrones of waves are set at steps of 5 ms after T0. 
Parameters derived from the wavemap include a number of epicardial breakthroughs, waves, and conduction velocity. 
Right: Examples of corresponding electrograms are shown. The parameters that will be derived from electrograms inclu-
de atrial fibrillation cycle length (AFCL), fractionation, and voltage
Fig. 3 
Left: activation map constructed during sinus rhythm. The atrial complexes (A) of all 192 recordings are automati-
cally detected and marked at the steepest deflection. The electrode with the earliest atrial marking is set at time (T) 0. 
Activation times of the other electrodes are in reference to T0. Isochrones are set at 5 ms intervals after T0. The black/ 
white arrow illustrates the direction of conduction. Conduction block (<18 cm/s) is represented by thick black lines. V 
ventricular complex. Right: The mapping surface is divided into quadrants and parameters such as block %, and mean 
voltage are determined for each quadrant of each mapping location (total: 36 quadrants). LA left atrium, PV pulmo-
nary veins, BB Bachmann’s bundle, RA right atrium
precisions acceptable for this exploratory study that will, hopefully, discover parameters 
that may be used in future studies to discriminate between AF patients with different 
underlying heart diseases.
Ethics
The study protocol was approved in February 2010 by the Medical Ethics Committee 
(2010–054) in the Erasmus Medical Center, Rotterdam, The Netherlands.
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Discussion
Study Population and Mapping Sites
Previous epicardial mapping studies for AF were performed in small numbers of patients 
and at only a few atrial sites or with a low resolution [11, 12, 16–19]. The present 
study is the first to perform intra-operative high-resolution epicardial mapping in a large 
number of patients and enables analyses between patients with different heart diseases. 
In addition, all sites of both the right and the left atrium accessible from the epicardial 
side are mapped including Bachmann’s bundle. Bachmann’s bundle might have an 
important role in the pathophysiology of AF [20]. By mapping the entire surface of 
both atria there is an increased chance of finding the arrhythmogenic substrate, which 
might be located in different atrial regions among AF patients.
The Arrhythmogenic Substrate in AF
The heterogeneous nature in which AF presents and the frequently failing AF treatments 
so far, demonstrate the importance for an individualized strategy in the treatment of AF. 
Fig. 4 
Left: wave map during atrial fibrillation at the right atrial free wall. A total of 5 waves activate the recording area in 41 
ms; 3 peripheral waves (black arrows) and 2 initiate at epicardial breakthroughs (white star and white arrows). Black 
lines between electrodes indicate conduction block (<18 cm/s). Isochrones of waves are set at steps of 5 ms after T0. 
Parameters derived from the wavemap include a number of epicardial breakthroughs, waves, and conduction velocity. 
Right: Examples of corresponding electrograms are shown. The parameters that will be derived from electrograms inclu-
de atrial fibrillation cycle length (AFCL), fractionation, and voltage
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The first step is a better understanding of the pathophysiology underlying initiation and 
perpetuation of AF. The focus for initiation of AF often originates in the pulmonary 
veins and Moe et al. described the concept of self-sustaining fibrillatory waves 
responsible for perpetuation of AF [21, 22]. However, recurrences of persistent AF after 
successful isolation of the pulmonary veins cannot be explained by these concepts alone. 
The occurrence of longitudinal dissociation during AF was demonstrated later on and 
showed to be most prominent in persistent AF [11]. Furthermore, focal fibrillation 
waves emerging within the recording area, referred to as epicardial breakthroughs, occur 
much more frequently during persistent AF than during acute AF [12], as well as drivers 
such as rotors and focal sources [23]. These findings suggest that progressive electro-
pathological changes within the atria are associated with persistent AF. Nonetheless, the 
exact pathophysiological changes and locations at which they occur are not yet known. 
The underlying diseases most likely initiate different pathophysiological mechanisms that 
lead to AF. For example, valvular disorders give rise to atrial pressure or volume overload, 
coronary artery disease can cause atrial ischemia and infarction, and congenital heart 
diseases may also include congenital atrial abnormalities. For this reason, the patients 
in this study are divided in separate groups according to the under-lying heart disorders 
and AF occurrence prior to surgery.
Previous studies have investigated the underlying cause responsible for perpetuation of 
AF. Atrial fibrosis has been suggested to be an important element in the pathophysiology 
of AF. There is a significant larger amount of atrial fibrosis seen in patients with AF [7, 
24]. An excessive extracellular matrix leads to uncoupling of cells and may facilitate 
inhomogeneous conduction, reentry, and multiple wavelets. MRI or electro-anatomical 
voltage mapping can be helpful diagnostic tools for the determination of degree of 
fibrosis in AF patients and identification of areas of fibrosis. However, no association 
has been found between the amount of fibrosis and clinical AF characteristics [7, 24]. 
Electrical signal conduction involves processes on a structural, cellular and molecular 
level, and these together determine if conduction is altered and AF occurs. Therefore, 
the arrhythmogenic substrate can probably be more accurately localized by measuring 
electrical potentials and conduction. In the present study, both the recorded extra-
cellular potentials and the spatial domain of the electrograms enables conversion into 
specific electrophysiological parameters that could identify areas with conduction 
abnormalities. If proven successful, this strategy can be developed into a diagnostic 
tool for each individual AF patient. In addition, current ablation strategies aimed at 
identifying and targeting arrhythmogenic areas are not effective in a large proportion of 
patients and might even lead to new arrhythmias [25]. If patients that can benefit could 
be selected beforehand, effectiveness of these treatments might improve.
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Study Limitations
Currently, epicardial mapping can only be performed during open-chest cardiac surgery. 
Therefore, it is not possible to perform epicardial mapping in patients with nondiseased 
hearts. However, with constantly advancing techniques it may become possible in the 
future to perform epicardial mappings during video-assisted thoracoscopic surgery in 
patients without any heart disease. Secondly, although epicardial mapping can reach 
sites endocardial mapping cannot, some sites are not accessible, for example, the atrial 
septum. Therefore, epicardial mapping is not able to analyze conduction in the entire area 
of the atria. In addition, recordings are performed sequentially, as simultaneous high-
resolution mapping of the entire surface is not possible yet with currently available tech-
nical equipment. As time during surgery is limited, mapping is performed immediately 
after AF induction or electrical conversion. Consequently, if a progressive increase, or 
decrease in AFCL occurs during the recordings, this data will have to be excluded [26–
28]. General anesthesia may also increase AFCL [29]. However, the same anesthetic 
protocol is applied in all patients and previous studies have shown that there remain 
differences in AF between patients despite anesthesia [11, 12]. Furthermore, recent 
studies have shown that endo-epicardial dissociation can occur during AF and might 
be associated with persistent AF [30]. This suggests that it is important to investigate 
endocardial and epicardial conduction simultaneously as conduction can be disturbed 
in all three dimensions. Finally, there is a small chance asymptomatic persistent AF 
episodes may be undetected during follow-up. The measured incidence of persistent 
late postoperative AF may therefore underestimate the true incidence of persistent late 
postoperative AF.
Clinical Relevance
This project can provide the tools to discriminate the arrhythmogenic substrate of AF in 
patients with different heart diseases and is potentially the first step towards a patient-
tailored strategy for the treatment of AF.
Project Status
At present, the inclusion for this study is ongoing. We expect the data of this project to 
become available in 2016 or 2017.
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A Novel Intra-Operative, High Resolution 
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Abstract 
Purpose A new technique is demonstrated for extensive high-resolution intra-operative 
atrial mapping that will facilitate the localization of atrial fibrillation (AF) sources and 
identification of the substrate perpetuating AF.
Methods Prior to the start of extra-corporal circulation, a 8×24-electrode array (2-mm 
inter-electrode distance) is placed subsequently on all the right and left epicardial atrial 
sites, including Bachmann’s bundle, for recording of unipolar electrograms during sinus 
rhythm and (induced) AF. AF is induced by high-frequency pacing at the right atrial 
free wall. A pacemaker wire stitched to the right atrium serves as a reference signal. The 
indifferent pole is connected to a steal wire fixed to subcutaneous tissue. Electrograms 
are recorded by a computerized mapping system and, after amplification (gain 1000), 
filtering (bandwidth 0.5–400 Hz), sampling (1 kHz) and analogue to digital conversion 
(16   bits), automatically stored on hard disk. During the mapping procedure, real-time 
visualization secures electrogram quality. Analysis will be performed offline.
Results This technique was performed in 168 patients of 18 years and older, with 
coronary and/or structural heart disease, with or without AF, electively scheduled for 
cardiac surgery and a ventricular ejection fraction above 40 %. The mean duration of 
the entire mapping procedure including preparation time was 9 ± 2 min. Complications 
related to the mapping procedure during or after cardiac surgery were not observed. 
Conclusions We introduce the first epicardial atrial mapping approach with a high 
resolution of ≥1728 recording sites which can be performed in a procedure time of 
only 9±2 mins. This mapping technique can potentially identify areas responsible for 
initiation and persistence of AF and hopefully can individualize both diagnosis and 
therapy of AF.
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Introduction
Atrial fibrillation (AF) can be eliminated by ablation of either the trigger or the substrate 
perpetuating AF. A multi-site, high-resolution mapping approach of the entire atria which 
can, beside localizing sources generating AF in patients with trigger-driven AF, identify 
the substrate responsible for perpetuation of AF would be desirable. Such a mapping 
approach would allow individualization of the diagnosis of AF and subsequently also 
of AF therapy which is at present not available. In this report, we introduce a novel 
high-resolution, multi-site epicardial mapping technique of the entire atria as a routine 
procedure during open chest surgery aiming for identification of the arrhythmogenic 
substrate underlying AF.
Material and Methods
Surgical Technique
Prior to commencement to extra-corporal circulation, after heparinization and arterial 
cannulation, a temporary bipolar epicardial pacemaker wire is stitched to the right atrial 
free wall serving as a temporal reference electrode. The indifferent electrode consists 
of a steal wire fixed to subcutaneous tissue of the thoracic cavity (Fig. 1). Epicardial 
mapping during sinus rhythm and (induced) AF is performed with a custommade 
flexible 192-unipolar electrode mapping array, mounted on a custom-made spatula 
2 Material and methods
2.1 Surgical technique
Prior to commencement to extra-corporal circulation, after
heparinization and arterial cannulation, a temporary bipolar
epicardial pacemaker wire is stitched to the right atrial free
wall serving as a temporal reference electrode. The indifferent
electrode consists of a steal wire fixed to subcutaneous tissue
of the thoracic cavity (Fig. 1). Epicardial mapping during si-
nus rhythm and (induced) AF is performed with a custom-
made flexible 192-unipolar electrode mapping array, mounted
on a custom-made spatula if preferred by the surgeon. The
spatula can be bended to match the atrial curvature (Fig. 2).
If AF is not the presenting rhythm, AF is induced by fixed rate
pacing at the right atrial free wall using a different temporary
bipolar pacing wire. Recordings of real-time epicardial elec-
trograms from Bachmann’s bundle are used to confirm atrial
capture. Fixed rate pacing is started at a rate of 200 beats per
minute (bpm). If an AF induction attempt is not successful
after three burst attempts, the rate is increased by 50 bpm,
up to maximal 400 bpm until AF occurs or atrial refractoriness
is reached. After completion of the mapping procedure, AF is
terminated by electrical cardioversion or sustained until
cardioplegia is conducted, depending on the operators’ pref-
erence. In case of AF as the initial heart rhythm, electrical
cardioversion is performed in order to map sinus rhythm after
completing mapping of AF.
Mapping is sequentially conducted along several imagi-
nary lines between anatomical borders in order to cover the
entire right and left atria (Fig. 3). The mapping array is shifted
along these imaginary lines with a fixed orientation at each
position visually trying to avoid omission of areas at the ex-
pense of possible overlap between successive mapping sites.
Mapping of the right atrium starts at the cavotricuspid isthmus
continuing up to the right atrial appendage, perpendicular to
the caval veins. Bachmann’s bundle is mapped from the roof
of the left atrium towards the superior cavo-atrial junction. For
the left atrium, mapping is performed along the left atrioven-
tricular groove from the lower border of the left inferior
RA
RV
Fig. 1 A pacemaker wire stitched to the right atrial free wall serving as a
temporal reference electrode (top). A steal wire fixed to (sub)cutaneous
tissue serving as the indifferent electrode (bottom). RA right atrium, RV
right ventricle
46 mm
Ø 0.45 mm
2 mm
14 mm
100 ms
Fig. 2 Mapping array containing
192 unipolar electrodes (top left).
Examples of recorded
electrograms at proximal, middle
and distal electrodes of the array
(top right). Mapping array and the
identically shaped steel spatula
(bottom)
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Fig. 1
Top: A pacemaker wire stitched to the right atrial free wall serving as a temporal reference electrode. Bottom: A steal 
wire fixed to (sub)cutaneous tissue serving as the indifferent electrode. RA right atrium, RV right ventricle    
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if preferred by the surgeon. The spatula can be bended to match the atrial curvature 
(Fig. 2). If AF is not the presenting rhythm, AF is induced by fixed rate pacing at the 
right atrial free wall using a different temporary bipolar pacing wire. Recordings of 
real-time epicardial electrograms from Bachmann’s bundle are used to confirm atrial 
capture. Fixed rate pacing is started at a rate of 200 beats per minute (bpm). If an AF 
induction attempt is not successful after three burst attempts, the rate is increased by 50 
bpm, up tomaximal 400 bpm until AF occurs or atrial refractoriness is reached. After 
completion of the mapping procedure, AF is terminated by electrical cardioversion or 
sustained until cardioplegia is conducted, depending on the operators’ preference. In 
case of AF as the initial heart rhythm, electrical cardioversion is performed in order to 
map sinus rhythm after completing mapping of AF. Mapping is sequentially conducted 
along several imaginary lines between anatomical borders in order to cover the entire 
right and left atria (Fig. 3). The mapping array is shifted along these imaginary lines 
with a fixed orientation at each position visually trying to avoid omission of areas at 
the expense of possible overlap between successive mapping sites. Mapping of the right 
atrium starts at the cavotricuspid isthmus continuing up to the right atrial appendage, 
perpendicular to the caval veins. Bachmann’s bundle is mapped from the roof of the 
left atrium towards the superior cavo-atrial junction. For the left atrium, mapping is 
performed along the left atrioventricular groove from the lower border of the left inferior 
2 Material and methods
2.1 Surgical technique
Prior to commencement to extra-corporal circulation, after
heparinization and arterial cannulation, a temporary bipolar
epicardial pacemaker wire is stitched to the right atrial free
wall serving as a temporal reference electrode. The indifferent
electrode consists of a steal wire fixed to subcutaneous tissue
of the thoracic cavity (Fig. 1). Epicardial mapping during si-
nus rhythm and (induced) AF is performed with a custom-
made flexible 192-unipolar electrode mapping array, mounted
on a custom-made spatula if preferred by the surgeon. The
spatula can be bended to match the atrial curvature (Fig. 2).
If AF is not the presenting rhythm, AF is induced by fixed rate
pacing at the right atrial free wall using a different temporary
bipolar pacing wire. Recordings of real-time epicardial elec-
trograms from Bachmann’s bundle are used to confirm atrial
capture. Fixed rate pacing is started at a rate of 200 beats per
minute (bpm). If an AF induction attempt is not successful
after three burst attempts, the rate is increased by 50 bpm,
up to maximal 400 bpm until AF occurs or atrial refractoriness
is reached. After completion of the mapping procedure, AF is
terminated by electrical cardioversion or sustained until
cardioplegia is conducted, depending on the operators’ pr f-
erence. I case of AF as the initial heart hythm, electrical
cardioversion is performed in order to map sinus rhythm after
completing mapping of AF.
Mapping is sequentially conducted along several imagi-
nary lines between anatomical borders in order to cover the
entire right and left atria (Fig. 3). The mapping array is shifted
along these imaginary lines with a fixed orientation at each
position visually trying to avoid omission of areas at the ex-
pense of ssible o erl p between success ve app ng sites.
Mapping of th right atrium starts at the cavotricus id isthmus
continuing up to the right atrial appendage, perpendicular to
the caval veins. Bachmann’s bundle is mapped from the roof
of the left atrium towards the superior cavo-atrial junction. For
the left atrium, mapping is performed along the left atrioven-
tricular groove from the lower border of the left inferior
RA
RV
Fig. 1 A pacemaker wire stitched to the right atrial free wall serving as a
temporal reference electrode (top). A steal wire fixed to (sub)cutaneous
tissue serving as the indifferent electrode (bottom). RA right atrium, RV
right ventricle
46 mm
Ø 0.45 mm
2 mm
14 mm
100 ms
Fig. 2 Mapping array containing
192 unipolar electrodes (top left).
Examples of recorded
electrograms at proximal, middle
and distal electrodes of the array
(top right). Mapping array and the
identically shaped steel spatula
(bottom)
222 J Interv Card Electrophysiol (2015) 44:221–225
Fig. 2
Top left: Mapping array containing 192 unipolar electrodes.  Top right: Examples of recorded electrograms at proximal, 
middle and distal electrodes of the array. Bottom: Mapping array and the identically-shaped steel spatula.
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sinus oblique fold along the border of respectively the right and left pulmonary veins 
down to the atrioventricular groove. Figure 4 shows the positions of the 192-electrode 
array along these mapping lines. The mapping array is held in place through either 
light manual pressure or by means of  the spatula. In case of the posterior area between 
the pulmonary veins, pressure from the weight of the heart and underlying structures 
provides stability for the mapping array. This technique was performed in 168 patients 
of 18 years and older, with coronary and/or structural heart disease, with or without 
AF, electively scheduled for cardiac surgery and a ventricular ejection fraction above 
40 %. The mean duration of the entire mapping procedure including preparation time 
was 9±2 min. Complications related to the mapping procedure during or after cardiac 
surgery were not observed.
Mapping technique
The mapping array consists of an electroless nickel immersion gold (ENIG) plated 
electrode array, mounted on a thin, flexible DuPont™ Pyralux® copper-clad (25-μm 
thickness) polyimide laminate, and coverlay composite (25 μm) film (0.18 mm), 
manufactured by GS Swiss PCB AG, Küssnacht, Switzerland. Sterilization is performed 
by the local sterilization unit before use in the operation room. The sterilized array is 
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Fig. 3
The electrode array placed between de pulmonary veins in the oblique sinus (top) and on the right atrial wall (bottom) 
during recording of epicardial electrograms
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connected to 3-meter-long, shielded flat cables delivered to the surgeon in a sterile sack. 
The flat cables are connected to a battery-driven, custom computerized mapping system 
which is connected to a laptop computer. Custom-made software visualizes real-time 
atrial  electrograms recorded at all 192 electrodes to secure atrial recordings with good 
electrogram quality. Three channels are designated to display the surface ECG, reference 
signal and a calibration signal of 1mV amplitude and 1000ms pulse width. Five seconds 
of sinus rhythm and 10 s of AF are recorded  at every mapping site. All recordings are 
amplified (gain 1000), filtered (bandwidth 0.5–400 Hz),  sampled (1 kHz), analogue 
to digital converted (16 bits) and automatically stored on hard disk as E01-files labelled 
with the atrial rhythm, mapping site and patient identification code. Analysis will be 
performed offline as previously described [1].
Discussion
Previous AF mapping studies during surgery did not cover the entire surface of both 
atria or used low-resolution arrays or recordings of short durations [2, 3]. Our mapping 
approach is the first high-resolution, multi-site mapping approach. It consists of a fixed 
mapping scheme with a 192-electrode mapping array, which results in a minimum 
of 1728 recording sites. The mapping array covers large areas of atrial tissue at each 
position resulting in a short all-over procedure time of 9 min without increasing 
cardiopulmonary bypass time. Unfortunately, high-resolution multi-site mapping is 
not  performed simultaneously as this is technically not yet possible. However, with the 
reference signal from the right atrial free wall, we are able to construct a timeline between 
the different recordings and create an overall conduction map during sinus rhythm. 
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Fig. 4
Mapping scheme demonstrating positions of the 192-electrode array on a 3D model. The left and right atria are 
covered by four positions each; to reach Bachmann’s Bundle, the array is placed within the transverse sinus between the 
aorta and superior vena cava.
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This map can also demonstrate the possible overlap between recording sites. During 
AF, the reference signal obtains information about the changes in AF cycle length in 
order to assess the consistency of the arrhythmia. Previously, the indifferent electrode 
was fixed to the sternum; however, electrogram quality improved when the indifferent 
electrode was fixed to subcutaneous tissue. Mapping studies were only performed in 
patients undergoing elective cardiac surgery for the first time as mapping is technically 
unfeasible with prior cardiac surgery or pericardiocentesis due to pericardial scarring 
limiting access to atrial sites.
An advantage of epicardial mapping is that some potential arrhythmogenic structures 
such as Bachmann’s Bundle can only be reached from the epicardial site and not from 
the endocardium. However, the interatrial septum cannot be mapped using a closed 
beating heart approach and the electrode array does not cover the myocardial sleeves 
within the pulmonary veins. In recent mapping studies of AF [1, 4], we introduced a so-
called wavemapping technique to classify and quantify  electrophysiological properties 
of fibrillation waves. This unique mapping approach makes it possible to study features 
of AF both in the spatial domain, like focal fibrillation waves or areas of conduction 
block, and the temporal domain, like irregularity of fibrillation intervals. As an example, 
intra-atrial variation of various electrophysiological parameters, assessed during 10 s of 
induced AF in a patient with coronary artery disease, is summarized in Fig. 5a. Using 
specific cut-off values, every quadrant was depicted as blue (low), white (intermediate) 
or red (high). The dominant frequency was 6.1 Hz and ranged from 4.5 to 9.2 Hz. 
The number of fibrillation and epicardial focal waves was on average respectively 2.3 
and 2.1/cm2/s, varying between 1.5 to 4.4 /cm2/s and 0.1 to 5.9 /cm2/s. The averaged 
beat-to-beat irregularity was 35.0 ms and the averaged conduction velocity 72.2 cm/s; 
the degree of conduction delay and block during AF varied from 4.1 to 26.9% (on 
average 12.6%). In comparison, electrophysiological parameters quantified during long-
standing persistent AF in patient with mitral valve disease are demonstrated in Fig. 5b. 
The dominant frequency was 6.7 Hz (range, 4.7 to 7.8). Compared to all quadrants in 
the patient with coronary artery disease, the number of fibrillation and epicardial focal 
waves was considerably higher (number of fibrillation waves, 3.5±1.3 /cm2/s (1.1–5.7), 
P<0.001; number of focal waves, 4.3 ± 3.2 /cm2/s (0.1–13.0), P<0.001). The averaged 
beat-to-beat irregularity was comparable (32.9 ms). Conduction velocity was on average 
63 cm/s (P<0.01), and the degree of conduction delay and block varied from 0.4 to 
45.4% (on average 24.8%, P<0.001). Hence, during long-standing persistent AF, the 
number of fibrillation waves and incidence of focal waves was higher and conduction 
abnormalities occurred more frequently; the areas involved are shown in the quadrant 
maps. Therefore, this mapping technique can potentially identify vulnerable areas 
responsible for initiation and persistence of AF by localizing and quantifying the 
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the first high-resolution, multi-site mapping approach. It con-
sists of a fixed mapping scheme with a 192-electrode mapping
array, which results in a minimum of 1728 recording sites. The
mapping array covers large areas of atrial tissue at each posi-
tion resulting in a short all-over procedure time of 9 min with-
out increasing cardiopulmonary bypass time. Unfortunately,
high-resolution multi-site mapping is not performed simulta-
neously as this is technically not yet possible. However, with
the reference signal from the right atrial free wall, we are able
to construct a timeline between the different recordings and
create an overall conduction map during sinus rhythm. This
map can also demonstrate the possible overlap between
recording sites. During AF, the reference signal obtains infor-
mation about the changes in AF cycle length in order to assess
the consistency of the arrhythmia. Previously, the indifferent
electrode was fixed to the sternum; however, electrogram
quality improved when the indifferent electrode was fixed to
subcutaneous tissue. Mapping studies were only performed in
patients undergoing elective cardiac surgery for the first time
as mapping is technically unfeasible with prior cardiac surgery
or pericardiocentesis due to pericardial scarring limiting ac-
cess to atrial sites.
An advantage of epicardial mapping is that some po-
tential arrhythmogenic structures such as Bachmann’s
Dominant Frequency Nr of Waves Nr of Focal Waves
Irregularity Conduction Velocity % Slow Conduction
+ Block
Dominant Frequency Nr of Waves Nr of Focal Waves
Irregularity Conduction Velocity
% Slow Conduction
+ Block
(a)
(b)
Fig. 5 Mapping of induced vs
long-standing persistent AF.
Intra-atrial variation in various
electrophysiological parameters
measured during 10 s of AF,
including dominant frequency
(blue <6 Hz, white 6–7 Hz, red
>7 Hz), number of fibrillation
waves (blue<2 /cm2/s, white
3–4 /cm2/s, red >3 /cm2/s), num-
ber of focal waves (blue <1 /cm2/s,
white 1–4 /cm2/s, red >4 /cm2/s),
irregularity (blue <20 ms, white
20–50 ms, red >50 ms), conduc-
tion velocity (blue ≥70 cm/s, white
51–69 cm/s, red ≤50 cm/s) and
incidence of slow conduction and
block (red >25 %, white 6–25 %,
blue ≤6 %). See text for further
description. aMapping of induced
AF in a patient with coronary
artery disease. bMapping of
long-standing persistent AF in a
patient with mitral valve
insufficiency
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Fig. 5
Mapping of induced vs longstanding persistent AF. Intra-atrial variation in various electrophysiological parameters 
measured during 10s of AF, including dominant frequency (blue:<6HZ, white:6-7Hz, red >7Hz), number of fibril-
lation waves (blue:<2cm2/s, white:3-4cm2/s, red:>3cm2/s), number of focal waves (blue:<1 cm2/s, white:1-4cm2/s, 
red:>4cm2/s), irregularity (blue:<20ms, white:20-50ms, red: >50ms), conduction velocity (blue:≥70cm/s, white:
51-69cm/s, red:≤50cm/s), incidence of slow conduction and block (red:>25%, white:6-25%, blue:≤6%). See text for 
further description. Panel A mapping of induced AF in a patient with coronary artery disease. Panel B Mapping of 
longstanding persistent AF in a patient with mitral valve insufficiency.
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degree of electropathology in the individual patient. Furthermore, by understanding 
the electropathological substrate in AF patients and providing individualized diagnoses, 
high-resolution mapping might be able to direct current AF therapies more efficiently 
or may lead to new insights for treatment strategies which could in turn improve current 
treatment outcomes. 
We would like to thank all the participating cardiothoracic surgeons and operation 
assisting personnel of the Erasmus Medical Center for their dedication in performing 
the mapping procedures.
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Abstract
Background: Bachmann’s bundle (BB) is considered to be the main route of interatrial 
conduction and to play a role in development of atrial fibrillation (AF). The goals of 
this study are to characterize the presence of conduction disorders in BB during sinus 
rhythm and to study their relation with AF.
Methods and Results: High-resolution epicardial mapping (192 unipolar electrodes, 
interelectrode distance: 2 mm) of sinus rhythm was performed in 185 patients during 
coronary artery bypass surgery of whom 13 had a history of paroxysmal AF. Continuous 
rhythm monitoring was used to detect postoperative AF during the first 5 postoperative 
days. In 67% of the patients, BB was activated from right to left; in the remaining 
patients from right and middle (21%), right, central, and left (8%), or central (4%) site. 
Mean effective conduction velocity was 89 cm/s. Conduction block was present in most 
patients (75%; median 1.1%, range 0–12.8) and was higher in patients with paroxysmal 
AF compared with patients without a history of AF (3.2% versus 0.9%; P=0.03). A 
high amount of conduction block (>4%) was associated with de novo postoperative AF 
(P=0.02). Longitudinal lines of conduction block >10 mm were also associated with 
postoperative AF (P=0.04).
Conclusions: BB may be activated through multiple directions, but the predominant 
route of conduction is from right to left. Conduction velocity across BB is around 
90 cm/s. Conduction is blocked in both longitudinal and transverse direction in the 
majority of patients. Conduction disorders, particularly long lines of longitudinal 
conduction block, are more pronounced in patients with AF episodes. 
WHAT IS KNOWN
• Bachmann’s bundle is an anatomical structure be-tween the right and left atrium and is 
 considered to be the main route of inter-atrial conduction with specialized conduction 
 properties.
• Clinical and experimental studies suggested Bachmann’s bundle plays a role in development of 
 atrial fibrillation.
WHAT THE STUDY ADDS
• Bachmann’s bundle is not only activated from the right side during sinus rhythm, but also from its mid portion 
 (septum) and left side. Moreover, the effective conduction velocity was only approximately 90 cm/s.
• Conduction disorders across Bachmann’s bundle was associated with paroxysmal and early-
 postoperative atrial fibrillation, suggesting a possible role in AF risk.
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Introduction
About a century ago, Jean George Bachmann examined conduction across a muscular 
band of parallel, longitudinally orientated muscle fibers running from the right auricle at 
the superior cavoatrial junction over the roof of the left atrium (LA) toward the left atrial 
appendage (LAA). This bundle, which came to be called Bachmann’s bundle (BB)1, is 
considered to be the preferential route of interatrial conduction. Whether this is because 
of the presence of specialized conduction tissue or the parallel-aligned orientation of the 
muscle bundles remains controversial2–8. In vivo measurements of interatrial conduction 
velocity in canine hearts demonstrated that the effective conduction velocity across BB 
is considerably higher compared with other atrial sites5,6,9. Creation of a surgical lesion 
across BB resulted in interatrial conduction block and caused biphasic P waves on the 
surface ECG10. Clinical studies have demonstrated that biphasic P waves pre-dispose 
to development of atrial fibrillation (AF)11–13. It was therefore assumed that conduction 
disorders within BB play a major role in the pathophysiology of AF, although the exact 
mechanism is not understood11,14,15. To date, conduction properties of BB in humans 
have never been investigated in detail. In this study, we therefore performed direct high-
resolution mapping of BB during sinus rhythm (SR) in patients under-going coronary 
artery bypass surgery to examine (1) whether conduction disorders are present at BB, 
(2) the extensiveness of conduction disorders and their impact on LA excitation, and (3) 
differences in characteristics of conduction disorders between patients with and without 
AF episodes.
Methods
This study is part of a prospective observational project, entitled Quest for Arrhythmogenic 
Substrate of Atrial fibRillation (QUASAR), which was approved by the Medical Ethical 
Committee in the Erasmus Medical Center (MEC 2010–054). The QUASAR project 
adheres to the declaration of Helsinki principles, and written informed consent was 
obtained from all patients before the surgical procedure.
Study Population
Epicardial mapping was performed in 185 patients undergoing elective coronary artery 
bypass surgery. Patients with paced atrial rhythm, Wolff–Parkinson–White syndrome, 
renal failure, previous open-chest cardiac surgery, prior ablative therapy, presence of assist 
devices, and prior radiation for chest malignancies were excluded. Patient characteristics 
are summarized in Table. Thirteen patients (aged 70±5 years, 62% male) had paroxysmal 
AF (PAF) since 2 years (range 4 months to 23 years); the remaining 172 patients (aged 
65±9years, 155 (85%) male) had no history of AF. None of the patients had a typical 
biphasic P wave in the inferior leads of the surface ECG. Mapping was performed in 
patients with a mean heart rate of 71±13 beats per minute.
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Epicardial High-Resolution Mapping
Epicardial high-resolution mapping was performed after sternotomy during 
normothermia and before extracorporal circulation. A bipolar pacemaker wire serving 
as a temporal reference electrode was placed at the right atrial free wall and a steal 
wire was attached to subcutaneous tissue in the thorax as an indifferent electrode. BB 
was mapped with electrode arrays containing either 128 or 192 unipolar electrodes 
(interelectrode distances: 2.0 mm) with lengths of, respectively, 32 and 48 mm; the 
width of both arrays was 16 mm.
Mapping of BB was performed by positioning the mapping array within the sinus 
transversus, behind the aorta with its tip against the LAA, as demonstrated in Figure 1. 
In case of the 128-electrode mapping array, the device was pulled backwards over the 
roof of the LA toward the superior cavoatrial junction.
Five seconds of SR was recorded at every mapping site. The recordings included surface 
ECG lead I, the right atrial bipolar reference electrogram, a calibration signal with an 
amplitude of 1 mV, and a duration of 1000 ms. Recordings were made with a custom-
made mapping system with an amplifier (gain 1000), filter (bandwidth 0.5– 400 Hz), 
and an analogue-to-digital data converter (16 bits). All data were sampled at 1 kHz and 
stored on hard disk.
Analysis of the Mapping Data
Signals were analyzed with custom-made software, as previously described in detail.16–19 
Color-coded activation maps of every SR beat were automatically created by marking 
the steepest negative deflection of extracellular potentials. An averaged SR activation 
map was then constructed by time alignment of all individual beats recorded during 5 
seconds of SR, thereby excluding aberrant and atrial premature beats. These averaged 
activation maps were used for analysis of voltages, conduction velocities, conduction 
blocks, and patterns of activation. Voltage maps were constructed by measuring peak-
to-peak amplitudes of unipolar SR potentials.
As demonstrated in the lower panel of Figure 1, the mapping array was divided into 3 
equally sized quadrants (16×16mm) to examine differences in conduction velocity over 
the right, central, and left part of BB. Conduction velocity across BB was measured by 
automatically constructing isochrones at every 5 ms. The main trajectories of propagation 
were created perpendicular to the isochrones.18,20 For the first part, the main trajectory 
was constructed from the initial isochrone at 5 ms back to the onset of the wavefront. If 
the onset of the wavefront consisted of multiple electrodes, the electrode which resulted 
in the most perpendicular trajectory in relation to the isochrone was chosen as start 
of the wavefront. From the first isochrone, the trajectory was constructed between 
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consecutive isochrones, choosing the most perpendicular segment to the next isochrone 
until the last activated electrode was reached. When the last activated site covers more 
than one electrode, again the electrode resulting in the most perpendicular line was 
chosen. Conduction velocity was subsequently calculated by summating the lengths of 
all segments between the isochrones and dividing it by the time difference of the earliest 
and latest activated electrode.
Differences in activation time (local conduction delay) between neighboring electrodes 
were calculated in areas of 2×2 electrodes. The maximum local conduction delay between 
2 adjacent elec-trodes was calculated to determine the incidence of slowing of con-
duction and conduction block. Slowing of conduction was defined as a local conduction 
delay of ≥7 ms corresponding to a conduction velocity <28 cm/s and conduction block 
as a local conduction delay of ≥12 ms corresponding to a conduction velocity <18 cm/s, 
as previously described.17,18 Lengths of all lines of conduction block were measured, 
and they were subdivided into longitudinal or transversal lines of conduction block. 
Longitudinal conduction block was determined as lines of conduction block that 
interrupt wavefronts emerging in longitudinal direction and transverse block vice versa.
To study variation in patterns of activation of BB during SR, entry sites of SR wavefronts 
into BB were labeled as right atrial, central, LA, or combined entry sites. A right atrial 
entry site was defined as a wavefront first entering the mapping array from the right 
side and propagating toward the left side of BB, whereas in case of a LA entry site, 
activation started from the tip of the electrode positioned at the border of the LAA and 
spread toward the right side of BB. A wavefront emerging in the middle of the mapping 
array propagating to either the right and left side was labeled as a central entry site. 
Simultaneously activated areas (conduction velocities >200 cm/s) within BB were also 
labeled as central entry sites.
Postoperative Atrial Fibrillation
Early postoperative AF (PoAF) was defined as sustained AF episodes lasting >30 s. The 
incidence of PoAF was determined using continuous rhythm monitoring up to the first 
5 days after cardiac surgery. The occurrence of PoAF was correlated with the amount of 
conduction block and the length of lines of the conduction block.
Statistical Analysis
Normally distributed continuous variables are presented as mean±SD and skewed 
data as median (minimum−maximum). Categorical data are expressed as numbers and 
percentages. Data were compared using either Student t test, Mann–Whitney U test, 
χ2, or Fisher exact test when appropriate. Correlation between voltage or conduction 
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Table Patient Characteristics
BMI indicates body mass index; LA, left atrium; and LVF, left ventricular function.
velocity and patient characteristics was made by using linear Pearson regression model. 
Adjustments were made for sex, age, body mass index, hypertension, diabetes mellitus, 
hyperlipidemia, peripheral vascular disease, left ventricular function, and LA dilatation. 
Multivariate logistic regression models were used to test the relation between slow 
conduction or conduction block and the same patient characteristics. As a result of the 
small groups with a high amount of slow conduction and conduction block, univariate 
analyses were done to select the determinant of interest. Age, sex, a history of AF, 
hypertension, diabetes mellitus, left ventricular function, and LA dilatation were chosen. 
In addition, the association between conduction block and PoAF was also investigated 
with logistic regression models. Because of the limited number of patients with PoAF, 
univariate analyses were performed to select properties of interest for multivariate 
analysis for the prediction of PoAF with conduction block. Type of conduction block, 
age, sex, hypertension, and LA dilatation were included in the multivariate analysis for 
PoAF. A P value <0.05 was considered as statistically significant.
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Figure 1. 
Mapping of Bachmann’s Bundle (BB). Top, Postmortem human heart from a right lateral superior view. Epicardial 
mapping of Bachmann’s bundle is performed by introducing the mapping array behind the aorta and positioning its tip 
against the border of the left atrial appendage (white arrow). Middle, 192 unipolar elec-trode mapping array (intere-
lectrodes distances of 2 mm) covering an area of 48×16 mm. Bottom, Schematic view of the position of the mapping 
array on BB. The mapping area was subdivided into 3 different quadrants of 16×16 mm and labeled as right, central, 
and left side. AO indicates aorta; LAA, left atrial appendage; RA, right atrium; RAA, right atrial appendage; RSPV, 
right superior pulmo-nary vein; SVC, superior caval vein; and VCS, vena cava superior.
Results
Patterns of Activation
Figure 2 shows color-coded SR activation maps of BB demonstrating the different 
types of patterns of activation observed in our study population. Arrows indicate main 
direction of propagation. In the majority of the patients (N=124, 67%), BB was activated 
by a single wavefront propagating from the right to the left side of BB as demonstrated 
in the upper left map of Figure 2. However, in 53 patients (29%), BB was activated by 
multiple wavefronts entering BB from different sites. In case of multiple different entry 
sites, wavefronts either collided or were separated by areas of conduction block. The 
upper right map of Figure 2 shows wavefronts entering on the right side and central part 
of BB, which was observed in 21% of the patients. Activation of BB from the right, left 
side, and central part of BB occurred in 8% of the patients. A typical example is given 
in the lower left map; wavefronts not only enter BB from the right and the left side, but 
a large wavefront also emerges in the central part of BB (dashed asterisk) and activates 
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a large area more or less simultaneously. In the remaining 8 patients (4%), a wavefront 
entered in the central part of BB and spread subsequently to both the right and left side 
of BB (lower right map). There was no difference in incidences of the various patterns of 
activation between patients without a history of AF and with PAF (P=0.72).
Peak-to-Peak Amplitude of Sinus Rhythm Potentials
Mean voltages of all unipolar SR potentials (N=218±29/ patient) were 3.0±1.4 mV 
and ranged from 0.3 to 7.2 mV. Lower averaged voltages were associated with ageing 
(P<0.001) and female sex (P=0.046); there were no correlations with a history of PAF, 
increased body mass index, hypertension, diabetes mellitus, hyperlipidemia, peripheral 
vascular disease, left ventricular dysfunction, or LA dilatation (P>0.05). Intraindividual 
variation in voltages across BB was 7.4±3.2 mV (minimum, 0.5±0.3 mV; maximum, 
8.0±3.3 mV).
Conduction Velocity
The frequency distribution of the different effective conduction velocities of wavefronts 
propagating from the right to the left side of BB is shown in Figure 3 for the right 
side (left panel), central part (middle panel), and left side (right panel). In all patients, 
the effective conduction velocity did not differ between the right side (90±24 cm/s), 
central part (88±16 cm/s), or left side (89±15 cm/s) of BB (P>0.05); mean effective 
conduction velocity over the entire length of BB was 89±13 cm/s (range 57–128 
cm/s). Lower conduction velocity was associated with lower voltages (P=0.002). Mean 
effective conduction velocity was not dependent on age (P=0.35) and was comparable 
between patients with PAF (97±15 cm/s) and patients without a history of AF (89±13 
cm/s; P=0.09). Areas of slow conduction were observed in the majority of the patients 
(N=172; 93%); the median amount of slow conduction in all patients was 1.8% (0–
9.2) and showed a trend toward a higher amount of slow conduction in patients with 
PAF compared with patients without a history of AF (2.6% [0.9–6.5] versus 1.7% 
[0–9.2]; P=0.07). Furthermore, a high amount of slow conduction (>2% or >4% slow 
conduction) was not associated with a higher age (P=0.16 and P=0.33).
Characteristics of Conduction Block
A frequency histogram of the amount of conduction block at BB is illustrated in the 
upper panel of Figure 4. In all patients, the median prevalence of conduction block 
was 1.1% and the mean prevalence was 1.9%. Areas of conduction block were present 
in the majority of the patients (N=138, 75%); in the remaining 47 patients (25%), 
conduction block did not occur. In patients with conduction block, the amount of 
conduction block varied from 0.2% to 12.8% (median prevalence: 1.8%). Conduction 
block was higher in patients with PAF compared with patients without a history of AF 
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Figure 2. 
Activation patterns at Bachmann’s Bundle. Top, A postmortem human heart with a superior view at Bachmann’s 
bundle. Bottom, Color-coded activation maps illustrating the 4 different patterns of activation observed at Bachmann’s 
bundle. Propagation started either at the right (upper left map; N=124), right and central (upper right map; N=39), 
right, central, and left (lower left map; N=14), or solely from the central part (lower right map; N=8). Isochrones are 
drawn at 5 ms intervals, and arrows indicate the main direction of propagation. See text for detailed explanation. BB 
indicates Bachmann’s Bundle; I, inferior; L, left; LAA, left atrial appendage; LSPV, left superior pulmonary vein; R, 
right; S, superior; and SVC, superior caval vein.
(3.2% [range 0–11.6] versus 0.9% [range 0–12.8]; P=0.03). Representative examples of 
the spatial distribution of areas of conduction block in patients with a variable amount 
of conduction block are depicted in the color-coded activation maps and corresponding 
conduction block maps in the middle panel of Figure 4. As can be seen in these maps, 
lines of conduction block occurred not only in the longitudinal direction, but also in 
the transverse direction of propagation. Electrograms around lines of conduction block 
showed both double potentials and fractionated potentials (Figure 4, lower panel).
In the entire study population, the prevalence of longitudinal and transverse lines of 
conduction block ranged from, respectively, 0% to 12.8% (median: 1.3%) and 0% to 
12.8% (median: 1.0%; P<0.01). Patients with PAF had a higher amount of conduction 
block in both longitudinal (1.1% [0–12.8] versus 4.0% [0–11.7]; P=0.03) and transverse 
direction (1.0% [0–12.8] versus 1.9% [0–12.3]; P=0.03).
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As lines of longitudinal conduction block affect the right to left propagation across 
BB, the maximum lengths of all lines of longitudinal conduction block across BB 
were measured. Figure 5 shows the relative frequency of the maximal lengths of all 
longitudinal lines of conduction block observed in patients without a history of AF (left 
panel) or with PAF (right panel). Patients with PAF had longer lines of longitudinal 
conduction block than patients without a history of AF (median 8 mm versus 2 mm; 
P=0.03).
In most patients without a history of AF (51%), there were no or only small areas (2 
mm) of longitudinal conduction block. Long lines of longitudinal conduction block 
(≥12 mm) were measured in only 12% of the patients (N=20). Although there were 
only 13 patients with PAF, solely 3 patients had no or small areas of conduction block. 
Five patients in this group (38%) had long lines of conduction block (≥12 mm). The 
maximum length of transverse lines of conduction block was also longer in patients with 
PAF than without AF (median 6 mm [range 0–20 mm] versus 2 mm [range 0–20 mm], 
P=0.03).
Figure 3. 
Effective conduction velocity across Bachmann’s bundle. Relative frequency histograms in patients (N=124) with wave 
fronts propagating from right to left demonstrating the effective conduction velocity across Bachmann’s bundle in the 
right side (left), central part (middle), and left side (right).
Impact of Longitudinal Conduction Block on Right to Left Propagation
The effects of longitudinal lines of conduction block on total activation time of BB 
and thus arrival time in the LA were determined for all patients mapped with the 192 
unipolar mapping array with a single wavefront propagating from the right to left side of 
BB (N=52). The initial arrival times of these wavefronts at the LAA in relation to initial 
activation of BB for every patient individually are plotted in the upper panel of Figure 
6. As can be seen, there is no effect of the length of the lines of longitudinal conduction 
block on the time required for right to left activation of BB.
Explanations for this observation are given in the lower panels of Figure 6. The left 
activation map shows a line of conduction block with a length of 12 mm with no 
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Figure 4. 
Conduction block. Top, Frequency histogram 
demonstrating the incidence of conduction 
block across Bachmann’s bundle. Bottom, 
Color-coded activation maps
and conduction block maps with a varying 
amount of conduction block ranging from 
0.3% to 4.7%. Examples of epicardial 
unipolar potentials recorded from areas of 
conduction block are shown outside the 
map. The color-coded circles in front of the 
electrogram correspond to the areas of block 
indicated in the conduction block maps.
effect on the right to left conduction. The wavefront propagated around the line of 
conduction block without any conduction delay and arrived at the LAA side 44ms after 
the first activation of BB. The middle and right activation maps demonstrate that even 
a complete line of conduction block (16 mm) across BB did not affect the arrival time 
at the LAA because in these patients areas behind the lines of conduction block were 
activated by wavefront emerging from other sites, including the left and central part of 
BB. As a result, the activation of the LAA site in these patients occurred only 33 ms and 
22 ms after the first moment of activation of BB.
Early Postoperative Atrial Fibrillation
During the first 5 postoperative days, AF was observed in 56 patients (30%), including 
7 patients (13%) who already had preoperative PAF. The incidence of de novo PoAF 
is plotted for each patient individually without a history of AF in Figure 7 and ranked 
according to the intraoperatively determined prevalence of longitudinal conduction 
block (x axis). There was a large variation in the length of areas of longitudinal conduction 
block in patients who developed PoAF. Although 10 patients (50%) with long lines of 
longitudinal conduction block developed PoAF, patients without or only small areas 
(2 mm) of conduction block in longitudinal direction also frequently developed PoAF 
(N=20; 23%).
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The lower panel in Figure 7 shows the results of univariate and multivariate analyses. 
A higher age was not related with the occurrence of PoAF in patients without a history 
of AF (odds ratio 1.0, 95% confidence interval 1.0–1.1; P=0.31). Although an equal 
amount of conduction block was found in patients with PoAF compared with patients 
without PoAF (P=0.09, not shown in Figure 7), >4% conduction block was associated 
with development of PoAF (odds ratio 3.1, 95% confidence interval 1.2–8.1; P=0.02). 
When analyzing the amount of conduction block for the different orientations sep-
Figure 5. 
Longitudinal conduction block 
in Bachmann’s Bundle. Two pies 
illustrating relative incidence of the 
maximum lengths of lines of 
conduction block across 
Bachmann’s bundle in patients 
without a history of atrial fibrillation
(AF; left) and with paroxysmal AF 
(PAF; right).
Figure 6. 
Impact of longitudinal lines of conduction block. Top, The effect of the maximum length of line of conduction block 
in longi-tudinal direction and the first activation of the left atrial appendage is plotted for all patients (N=124) with a 
single right to left wavefront across Bachmann’s bundle. Bottom, Examples of the effect on the left atrial appendage 
activation time by different maximum lengths of lines of longitudinal conduction block. The left map illustrates a 
broad wavefront curving around the line of conduction block. The middle and right map demonstrate a right to left 
wavefront with a complete line of longitudinal conduction block coexisting with wavefronts entering BB from the 
central part (white or dashed asterisk) and left side.
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arately, there was no difference between the amount of transverse (P=0.06) or longitudinal 
conduction block (P=0.14) and development of PoAF. Also, a higher risk of development 
of PoAF was not associated with >4% conduction block in either longitudinal (P=0.28) 
or transverse direction (P=0.26).
In patients without a history of AF, the length of lines of longitudinal conduction 
block did not differ between patients with and without PoAF (median 4 mm versus 
2 mm; P=0.07). However, patients with PoAF had more often long lines (≥12 mm) of 
longitudinal conduction block (N=11) compared with patients without PoAF (N=9; 
P<0.01). Patients with long lines of longitudinal conduction block had a 3 times higher 
risk (odds ratio 2.9; 95% confidence interval 1.1–8.2; P=0.04) of developing PoAF, 
whereas patients with lines of conduction block of 12 mm or longer in transverse 
direction had the same risk of developing PoAF (odds ratio 2.2; 95% confidence interval 
0.51–9.9; P=0.28).
Figure 7. 
Relation between the amount of longitudinal conduction block and development of early postoperative AF. Top, The 
effect of the amount of longitudinal conduction block on development of early postoperative AF in patients without 
a history of atrial fibrillation (AF; N=172). Bottom, Results of univariate and multivariate logistic regression between 
clinical determinants and development of early post-operative AF. CB indicates conduction block; CI, confidence 
interval; LA, left atrium; and OR, odds ratio.
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Discussion
High-resolution epicardial mapping of BB during SR in patients with coronary artery 
disease showed that BB was activated by multiple wavefronts entering BB not only from 
the right side, but also from the left side and central part in a considerable number of 
patients. The average effective conduction velocity across BB was ≈89 cm/s and did not 
differ between patients with or without AF. Lines of conduction block were found in 
the majority of the patients (74%) and occurred both in longitudinal and transverse 
direction. The effect of these lines of conduction block on excitation of the LA was 
limited. However, a high amount of conduction block and long lines of longitudinal 
conduction block were associated with the presence of PoAF. excitation at the left side 
of BB, depending on the length and degree of conduction delay of the pathway taken. 
Besides that, a wavefront emerging from the left side in BB in the presence of a long line 
of conduction block could also be explained by turning of a wavefront around the end 
of the line of conduction block outside the mapping array. However, as the mapping 
array covers the entire width of BB, this is unlikely.
Preferential, but Not the Only Interatrial Route
Experimental studies demonstrated that crushing of BB led to significant delay in 
excitation of the LA.1 However, in our study population, the presence of long lines of 
longitudinal conduction block did not result in delayed LAA activation because areas 
behind the lines of conduction block were activated by wavefronts emerging from either 
the left side or central part of BB. As demonstrated in previous studies, our observations 
confirm that BB is not the exclusive route of interatrial conduction and that propagation 
of electric waves from the right to the LA occurs along other interatrial pathways when 
conduction across BB is impaired. These other interatrial pathways include the limbus 
of the fossa ovalis, the coronary sinus, and interatrial bundles both superior and inferior 
along BB.21–24 Conduction across BB has to date only indirectly been examined by using 
endocardial and epicardial mapping techniques.25–27 In patients who underwent catheter 
ablation of AF, 3-dimensional electro-anatomic (non)contact mapping techniques were 
used to examine the first LA activation site during SR. The earliest LA activation was 
frequently observed at the antero-superior LA, which was assumed to be the end of BB. 
Activation at this site was either solitary or simultaneously with other interatrial sites, 
which often included the postero-septal wall or the limbus of the fossa ovalis.26,27 Similar 
to these findings, we also observed that in the majority of our patients, a single wavefront 
propagated across BB from the right to the LA, which may initially activate the LA. In 
30% of our patients, BB was activated by wavefronts emerging in the central part of the 
mapping area. Although some studies observed that BB is isolated from the interatrial 
septum, others suggested that muscular connections between BB and the interatrial 
septum are present.8,24,28 It is therefore likely that when right to left conduction along 
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BB is delayed, BB can also be excited by wavefronts conducting faster in other interatrial 
pathways (eg, limbus of fossa ovalis or coronary sinus), propagating upwards in the 
interatrial septum and activating the central area of BB. Interestingly, wavefronts not 
only entered BB on the right side and propagated leftwards, but also entered on the left 
side and propagated rightwards. These left-sided wave-fronts emerged both early and 
late in relation to the onset of activation of the right side of BB. This can be explained 
by the presence of the aforementioned additional bundles parallel to BB, crossing the 
roof of the LA.24 When wave-fronts propagate faster across these parallel bands than BB, 
they can enter BB relatively early on the left side and collide with the right to leftwards 
propagating wavefronts. When conduction across BB is delayed, interatrial conduction 
occurs in other interatrial pathways, resulting in late excitation at the left side of BB, 
depending on the length and degree of conduction delay of the pathway taken. Besides 
that, a wavefront emerging from the left side in BB in the presence of a long line of 
conduction block could also be explained by turning of a wavefront around the end of 
the line of conduction block outside the mapping array. However, as the mapping array 
covers the entire width of BB, this is unlikely.
Bachmann’s Bundle, the Superconductor?
Propagation of wavefronts occurs faster in longitudinal than transverse direction. It 
is therefore assumed that longitudinal parallel orientation of the fibers in BB results 
in higher conduction velocity, thereby making BB a preferential route of interatrial 
conduction. In addition, some studies suggest that the fibers of BB have specific 
characteristics similar to components of the specialized Purkinje fibers, such as a higher 
resting membrane potential, rapid velocity upstroke of the action potential, distinct 
overshoot, and a broader phase 2 plateau.5,6 However, in contrast to the Purkinje cells, 
action potentials in BB abbreviated after application of acetylcholine, which suggests 
BB cardiomyocytes differ from the Purkinje cells of the cardiac conduction system.5 
Altogether, these studies showed that cardiomyocytes of BB have cell characteristics 
similar to both the specialized conduction system and atrial cardiomyocytes.
The effective conduction velocity across BB measured in animal studies was often faster 
at BB than other atrial sites.4,5,9 Goodman et al performed mapping in a Langendorff-
perfused canine heart with a 5-point electrode array.9 They observed a maximum 
conduction velocity of 300 cm/s in BB, which is comparable with conduction velocity in 
specialized Purkinje fibers. However, in our study population, we measured an effective 
conduction velocity of only 89 cm/s in BB, which is comparable with conduction 
velocities at other sites in the atria.29 Previous studies found higher effective conduction 
velocities across BB by measuring velocity between only a few points. Conduction 
velocity in BB could have been overestimated because wavefronts propagating from the 
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right to the LA might fuse with wave fronts entering the central part of BB. This results 
in a large simultaneously activated areas, which could mimic fast propagation of a single 
wavefront between the first and last activated site. In our study population, the effective 
conduction velocity might also have been overestimated because of late merging of 
wave fronts arising from deeper layers. Only single wavefronts propagating from the 
right to left site of BB were chosen to minimize the risk of overestimation. Yet, despite 
the presence of only one single wavefront, a different angle of the wavefront entering 
BB, which is highly anisotropic in nature, can influence conduction velocity. On the 
contrary, areas of simultaneous activation (>200 cm/s) were interpreted as central entry 
sites of wavefronts propagating partially through deeper layers. They were sometimes 
observed after a line of conduction block, whereas they also collided with a right to left 
propagating wavefront without being separated by lines of conduction block. In the 
latter case, the conduction velocity could have been overestimated.
The Role of BB in the Pathophysiology of AF
Waldo et al made surgical lesions in BB of dogs and observed significant changes in the 
P wave morphology and duration.10 Delay in BB led to partial interatrial conduction 
block, whereas complete block of BB caused advanced interatrial conduction block 
which was characterized by biphasic P waves, particularly in the inferior leads on the 
surface ECG. Clinical studies have shown that advanced interatrial conduction block 
increases the risk of developing atrial tachyarrhythmias, including AF.12,13
The role of BB in initiation and perpetuation of AF has been investigated in animal 
studies.14,30,31 In the goat model of Allessie, initiation of AF episodes was preceded by 
atrial extrasystolic beats that were blocked at the middle of BB.14 Subsequently, re-
excitation at the same side of the line of conduction block suggested reentry in BB. 
Mapping during AF of both atria and the interatrial septum in a sterile pericarditis 
canine model revealed multiple unstable reentry circuits involving the interatrial 
septum.30,31 As BB was the most commonly used interatrial pathway for these reentry 
circuits, the investigators suggested that BB is essential for perpetuation of AF.30 In this 
same canine model, complete transection of BB with radiofrequency ablation resulted 
in termination and noninducibility of AF.31
We observed multiple entry sites of BB during SR in patients with and without lines of 
conduction block. A line of conduction block across the entire width of BB did not result 
in delayed LA activation and the specific P wave alterations associated with development 
of AF. These findings differ from the earlier observations of P wave alterations after 
surgical transection of BB. In case of complete surgical transection of BB, other muscular 
connections, that is, interatrial septal path-ways to BB, may also be disrupted.
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According to these earlier studies, BB may play an important role in development of 
AF, although the exact mechanism remains unclear. Although over 20% of the patients 
without or with only a small area of conduction block developed PoAF, a high amount 
of conduction block and long lines of longitudinal conduction block were associated 
with de novo PoAF. These results indicate that the length of lines of conduction block 
facilitate reentry and hence development of AF. Yet, patients without (long) lines of 
conduction block developed both PAF and PoAF as well, suggesting that not only areas 
of conduction block in BB are involved in development of AF. The amount of conduction 
block at BB may merely reflect electric disease which is also present elsewhere in the 
atria. Other atrial sites may contain more extensive areas of conduction block and thus 
play a larger role in the pathophysiology of AF.
Becker microscopically examined BB, terminal crest, and pulmonary vein areas in 20 
postmortem mainly known with coronary artery disease; 10 patients had a history of 
PAF.32 In all patients, fibro-fatty tissue and fibrotic patches were found, which may 
cause conduction disorders as a result of disruption of cell-to-cell connections.29,30 These 
histological changes were more common in patients with PAF, which may explain the 
higher amount of conduction block in patients with PAF in our study population. 
As all examined areas-pulmonary veins, terminal crest, and BB-were more affected in 
patients with PAF, delayed intra-atrial conduction predisposing to development of AF 
is probably the result of extensive conduction block throughout the atria and interatrial 
connec-tions rather than conduction block across BB only. In addition, conduction 
disorder may be further impaired by, for example, atrial extrasystolic beats, which in 
turn initiate AF episodes.
Study Limitations
Mapping of BB is solely performed at the epicardial surface and does not provide any 
information of wavefronts propagating partially in deeper layers or emerging from 
other atrial sites. Hence, only the effective conduction velocity can be assessed. Also, 
the definition of slow conduction and conduction block remains arbitrary, and slow 
conduction cannot definitely be excluded. In the individual patient, the exact proportions 
of BB are unknown, and the mapping array might not always have covered the entire 
BB. However, previous studies demonstrated that the size of BB equals approximately 
the size of the mapping array. Also, our study did not provide any information on 
conduction properties at other atrial sites. Because of the small group of patients with 
a history of AF, comparison between patients with and without a history of AF was 
limited. In line with that, a lack of power might explain the absence of a significant 
relation between slowing of conduction velocity, a higher age, and development of PoAF.
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Conclusions
High-resolution mapping of BB in humans with coronary artery disease during SR 
demonstrated that BB may be the preferential route of interatrial conduction, but can 
be activated from other directions as well. As a consequence, conduction disorders 
exclusively in BB have limited impact on LA excitation. Despite the longitudinal 
orientation of BB fibers, BB is not the superconductor as previously suggested. 
Conduction is blocked in both longitudinal and transverse direction in the majority of 
the patients. Conduction disorders, particularly long lines of longitudinal conduction 
block, are more pronounced in patients with AF episodes.
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Abstract
Aims: Little is known about the value of conduction disorders at the entire atrial 
epicardial surface during sinus rhythm (SR) for intra-operative inducibility of atrial 
fibrillation (AF) or development of early post-operative AF (PoAF). Aims of this study 
are 1) to quantify conduction disorders at the right atrium (RA), Bachmann’s Bundle 
and left atrium during SR and 2) to test the correlation between conduction disorders 
and AF inducibility and development of PoAF.  
Methods: High-resolution intra-operative epicardial SR mapping of the RA, BB and 
LA (128/192 electrodes; inter-electrode distance 2.0mm) was performed in 209 patients 
(175 male, age 66±9.6years) with coronary artery disease. The amount of conduction 
delay (CD) and conduction block (CB) was quantified per 1cm2. 
Results: The total number of recording sites in the entire population was 390,379 
(1,868±285 sites/patient). Prevalence of CD and CB was respectively 1.4(0.2-4.0)% 
and 1.3(0.1-4.3)% and intra-atrial variation was respectively 8.3(1.2-33.4)%/cm2 and 
11.5(0.1-31.5)%/cm2. CD and CB mainly occurred at the superior intercaval region of 
the RA. There was no correlation between CD, CB and AF inducibility (P>0.05) the 
development of early PoAF (P>0.05).
Conclusion: High-resolution mapping of the atrial epicardial surface in patients with 
electrically non-remodeled atria showed not only considerable intra-atrial variation in 
conduction disorders, but also inter-individual differences, despite the similar clinical 
profiles. CD/CB during SR was not correlated with AF inducibility or development 
of PoAF. A predilection site for CD and CB was present at the right atrial superior 
intercaval area. The arrhythmogenicity of this area needs to be further investigated. 
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What’s new?
•	 Conduction disorders during sinus rhythm show considerable both intra-individual 
and interindividual differences in 209 patients with similar clinical profiles.
•	 In all 209 patients, areas with conduction delay or conduction block were present 
during sinus rhythm, although the prevalence was low and the degree of conduction 
disorders was minimal.
•	 Conduction disorders during sinus rhythm are not correlated with either intra-
operative inducibility of atrial fibrillation, or development of early post-operative 
atrial fibrillation.
•	 The superior intercaval area of the right atrium is a predilection site for conduction 
disorders.
•	 Sinus rhythm mapping alone is not a viable approach to detect the arrhythmogenic 
substrate underlying atrial fibrillation.
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Introduction
Previous studies have demonstrated that longitudinal dissociation in conduction and 
epicardial breakthroughs are key elements of the substrate underlying longstanding 
persistent atrial fibrillation (AF) in humans(1, 2). Quantification of the amount of 
conduction block and incidences of epicardial breakthroughs by using a high-resolution 
mapping technique clearly distinguished longstanding persistent AF from acutely 
induced AF(1, 2). Mapping of AF is, however, complex and time-consuming due to 
continuous beat-to-beat changes in electrogram morphology and patterns of activations. 
In addition to this, determination of local activation times is often difficult due to 
fractionation of fibrillation potentials. Identification of the arrhythmogenic substrate 
associated with AF during sinus rhythm (SR), if possible, would therefore be preferable. 
Zaman et al.(3)  recently performed intra-operative mapping studies of the right atrial 
free wall during SR and pacing in a cohort of 34 patients undergoing elective coronary 
artery bypass grafting (CABG), without a history of AF. During SR, bipolar dominant 
frequency electrograms were higher in patients in whom AF was inducible than in non-
inducible patients (96.2 vs. 74.9 Hz)(3). This implies a higher degree of fractionation 
in this subgroup, most likely resulting from local conduction abnormalities. The 
association between conduction disorders during SR and (induced) AF however, has 
yet to be validated in larger patient cohort. Also, the relevance of these conduction 
properties during SR at not only the right atrium (RA), but also left atrium (LA) and 
Bachmann’s Bundle (BB) needs to be evaluated. In addition, the usage of unipolar 
electrograms is preferable, since these are not dependent of electrode orientation and 
direction of wavefront propagation. 
To test the hypothesis that conduction disorders during SR are associated with either 
AF inducibility or development of early post-operative AF (PoAF) we performed intra-
operative, high-resolution epicardial mapping of the entire atria during SR in CABG 
patients without a history of AF. Furthermore, we aim to quantify the extensiveness and 
the spatial distribution of conduction disorders throughout the epicardial surfaces of 
the RA, LA and BB to increase our knowledge on the physiological variation of these 
properties in patients with electrically non-remodeled atria.
Methods
Study Population
The study population consisted of patients without a history of AF undergoing elective 
CABG for coronary artery disease. This study is part of the QUASAR(4) project 
(QUest for Arrhythmogenic Substrate of Atrial fibrillation) and HALT & REVERSE(5) 
project (Hsf1 Activators Lower cardiomyocyte damage; Towards a novel approach to 
REVERSE atrial fibrillation). Both studies are approved by the institutional Medical 
Ethical Committee (MEC 2010-054 and MEC 2014-393) and all patients provided 
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written informed consent. The study was carried out according to the principals of the 
Declaration of Helsinki. Patient characteristics were obtained from electronic patients 
files.
Mapping Procedure
Epicardial mapping was performed prior to commencement to extra-corporal 
circulation(6). A pacemaker wire attached to the terminal crest served as a temporal, 
bipolar reference electrode and a steel wire fixed to the subcutaneous tissue was used as 
an indifferent electrode. The mapping procedure was performed with electrode arrays 
consisting of 128 unipolar electrodes, with a diameter of 0.65mm or 192 unipolar 
electrodes with a diameter of 0.45mm. The inter-electrode distance of both devices is 
2.0mm. Epicardial mapping during SR was conducted following a predefined mapping 
scheme as demonstrated in the upper panel in Figure S1, covering the entire epicardial 
surface of the RA, BB and LA. The electrode array (indicated by red rectangles) is 
shifted along imaginary lines with a fixed orientation at each position trying to avoid 
omission of areas at the expense of possible overlap between adjacent mapping sites. 
Mapping of the RA started at the cavo-tricuspid isthmus and continued perpendicular 
to the caval veins towards the right atrial appendage. BB is mapped from the tip of the 
left atrial appendage across the roof of the LA, behind the aorta towards the superior 
cavo-atrial junction. Mapping of the LA is performed from the lower border of the left 
inferior pulmonary vein (PV) along the left atrioventricular groove towards the left atrial 
appendage. The PV area is mapped from the sinus transversus fold in between the right 
and left PV towards the atrioventricular groove(7). Five seconds of SR were recorded 
from every mapping site, including unipolar epicardial electrograms, a bipolar reference 
electrogram, a surface ECG lead and a calibration signal of 2mV and 1000ms. Data was 
stored on hard disk after amplification (gain 1000), filtering (bandwidth 0.5-400 Hz), 
sampling (1 KHz) and analogue to digital conversion (16 bits).
Mapping Data Analysis
The lower panel of Figure S1 shows color-coded SR activation maps of the right atrial free 
wall. Activation maps were constructed by annotating the steepest negative deflection of 
each extracellular potential, in case of a fractionated electrogram the steepest deflection 
is marked. Premature atrial complexes and aberrant beats were excluded. The averaged 
SR beat was used to quantify electrophysiological properties including prevalence and 
amount of conduction delay (CD) and conduction block (CB). For this purpose, 
differences in local activation times between neighboring electrodes were calculated. CD 
is defined as differences in local activation time of ≥7ms and differences in local ≥11ms 
as CB. Next, the mapping area is subdivided into quadrants of 1x1cm, as demonstrated 
in the upper panel of Figure S1. Quadrants were excluded for analysis when ≥50% of 
the recorded electrograms had a slope threshold ≤80 mV/s and a signal-noise ratio <4. 
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Total percentages of CD and CB were quantified for every 1cm2 in order to analyze the 
spatial distribution and to detect preferential sites for conduction disorders.
Intra-Operative Inducibility of Atrial Fibrillation
AF induction was attempted in every patient. AF was induced by fixed rate atrial 
pacing, starting at a rate of 250 beats per minute with the use of a right atrial temporary 
pacemaker. If AF could not be induced, the pacing rate was gradually increased by 50 
beats per minute up to 400 beats per minute. AF was defined as beat-to-beat changes in 
patterns of activation, AF cycle lengths and electrogram morphologies. 
Early Post-Operative Atrial Fibrillation
Early PoAF was defined as the occurrence of an AF episode with a duration of at least 30 
seconds during the first five days after surgery. PoAF was confirmed by electrocardiogram 
(ECG) or by continuous rhythm monitoring.
Statistical Analysis
All data were tested for normality. Normally distributed data is expressed as mean±standard 
deviation, whereas skewed data is depicted as median (minimum-maximum). Although 
electrophysiological parameters are skewed, the mean is also provided for completeness 
and to enable comparison with other studies. Thus, electrophysiological parameters 
are expressed as mean, median (minimum-maximum). Spearman’s test was used to 
test the correlation between clinical characteristics and non-normally distributed 
electrophysiological parameters. Correction for multiple testing was not applied. 
Results
Study Population
The study population consisted of 209 CABG patients (175 (83.7%) male, age 66±9.6 
years). Baseline characteristics of the study population are summarized in Table S1; 
most patients had a normal left ventricular function (N = 152, 72.7%) without atrial 
dilatation (N = 177, 84.7%). 
Mapping Data
The total number of recording sites in the entire population was 390,379, resulting in 
1,868±285 sites (electrodes) per patient. After exclusion of 249/6957 (3.6%) quadrants, 
a total of 6,708 quadrants (32±4 per patient) were suitable for analysis. Figure 1 shows 
an example of the reconstruction of conduction block maps. The left upper panel 
shows the total activation pattern of the entire RA, BB and LA. Activation started at 
the high RA and spread across BB towards the LA groove. The PV area is activated by 
a wavefront emerging at the lower part of the interatrial septum which fuses with the 
wavefront originating from BB propagating across the LA groove beneath the right 
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lower pulmonary vein. The total activation time of the entire atria is 95ms. The right 
upper panel shows isochronal maps; the arrows indicate main trajectories of the SR 
wavefront. Combined conduction block and delay maps (left lower panel) were derived 
from the isochronal map and depict the spatial distribution of respectively CD (blue 
lines) and CB (red lines); median incidence (P50) in the entire atria respectively 0.4% 
and 0.3%). The right lower panel indicates the amount of CB per 1 cm2. Although 
rarely occurring in this patient, areas of CD or CB are found at various sites within the 
RA, BB and LA. The differences in spatial distribution of CD and CB are illustrated by 
the conduction delay maps (upper panel) and conduction block maps (lower panel) in 
Figure 2. The maps demonstrate not only intra-atrial variation in CD and CB but also 
show remarkable inter-individual differences in these conduction disorders.
Predilection Sites for Conduction Delay
The left panel of Figure 3 shows the median incidence of CD within the entire atria for 
each patient individually ranging from 0.2 to 3.7% (median: 1.4%). Areas of CD were 
present in all patients. The amount of CD was not related to age (ρs = 0.197, P = 0.004), 
left ventricular function (ρs = -0.007, P = 0.917) or left atrial dilatation (ρs = 0.152, P = 
0.028). 
Figure 1 Quantification of atrial conduction abnormalities
Upper left panel: pattern of activation of the entire right atrium, Bachmann’s Bundle and left atrium. Total activation 
time of the entire atria was 95ms. Main directions of wave front propagation are indicated by black arrows. Upper 
right panel: local activation pattern with isochronal maps. Isochrones are drawn at 5ms. Lower left panel: combined 
conduction delay map and conduction block map demonstrating the lengths, orientations and spatial distribution of 
areas of conduction delay (blue lines, median prevalence 0.4%) and conduction block (red lines, median prevalence 
0.3%). Right lower panel: percentage conduction block per predefined quadrant. Blue: 0%, White: >0-<6%, Red: ≥6% 
conduction block/1cm2.
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Figure 2 Intra-individual variation in conduction abnormalities
Typical examples of conduction delay maps (upper panels) and conduction block maps (lower panels), showing 
intra-individual differences in the amount and spatial distribution of conduction disorders. Maps were derived from 
activation maps, as illustrated in Figure S1 and Figure 1.
In the entire study population, areas of CD were found in 2,273 (33.9%) of all 6,708 
quadrants. Intra-atrial variation in CD was 8.3 (1.2-33.4)%/cm2, ranging between a 
minimum of 0.0 (0.0-0.0)%/cm2 and a maximum of 9.7 (1.4-33.8)%/cm2. As in most 
quadrants the median amount of CD was 0%, predilection quadrants for CD could 
not be identified and were therefore also clustered into regions (see online supplement). 
The prevalence and amount of CD within the clustered quadrants are depicted in Table 
1. The right panels of Figure 3 demonstrate the overall prevalence and amount of CD 
per region. CD was observed most frequently at quadrants covering respectively the 
RA superior intercaval region (N = 348 quadrants, 50%) and BB (N = 273 quadrants, 
45%), as depicted in the right upper panel of Figure 3. Not just the prevalence but also 
the amount of CD was highest at BB and RA, when compared with the remainder of 
the atria. Mean amount of CD at quadrants covering BB was 2.1% (median 0.0 (0.0-
19.4)%) and 2.5% (median 1.4 (0.0-22.9)%) at the quadrants covering the RA superior 
intercaval area. 
Predilection Sites for Conduction Block
Areas with CB were observed in all patients. Median amount of CB of the entire atria 
ranged from 0.1% to 4.3% (median 1.3%), as shown in the upper panel of Figure 4. 
Intra-atrial variation in CB was 11.5 (0.1-31.5)%/cm2, ranging between a minimum of 
0.0 (0.0-0.0) %/cm2 and a maximum of 12.6 (1.4-33.8)%/cm2 (see Table S2). There 
was no correlation between the amount of CB and age (ρs = 0.205, P = 0.003), left 
ventricular function (ρs = -0.038, P = 0.597) or left atrial dilatation (ρs = 0.035, P = 0 
.610). However, the amount of CB was correlated with the amount of CD (ρs = 0.506, 
P < 0.001).
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Table 1 Quantification of conduction abnormalities per region
Prevalence CD N(%)
BB 273(45%)
IC4–IC3–CT4–CT3 348(50%)
IC1–IC2–CT1–CT2 242(30%)
RA4–RA3–RM4–RM3 266(37%)
RA1–RA2–RM1–RM2 207(26%)
PV 482(32%)
LA 324(26%)
Degree CD(%) Mean Median Range
BB 2.1 0.0 0.0-19.4
IC4–IC3–CT4–CT3 2.5 1.4 0.0-22.9
IC1–IC2–CT1–CT2 1.5 0.0 0.0-22.9
RA4–RA3–RM4–RM3 1.5 0.0 0.0-16.7
RA1–RA2–RM1–RM2 1.0 0.0 0.0-19.4
PV 1.3 0.0 0.0-27.1
LA 0.9 0.0 0.0-20.3
PrevalenceCB,n(%) N(%)
BB 231(29%)
IC4–IC3–CT4–CT3 362(52%)
IC1–IC2–CT1–CT2 190(24%)
RA4–RA3–RM4–RM3 152(21%)
RA1–RA2–RM1–RM2 82(10%)
PV 288(19%)
LA 142(11%)
Degree CB(%) Mean Median Range
BB 1.6 0.0 0.0-20.8
IC4–IC3–CT4–CT3 4.6 1.4 0.0-33.8
IC1–IC2–CT1–CT2 1.7 0.0 0.0-28.2
RA4–RA3–RM4–RM3 1.0 0.0 0.0-20.8
RA1–RA2–RM1–RM2 0.5 0.0 0.0-15.5
PV 1.1 0.0 0.0-20.6
LA 0.5 0.0 0.0-18.8
Mean, median and range (minimum-maximum) of electrophysiological parameters (prevalence and amount of 
conduction delay and conduction block) per atrial region. Quadrants are clustered as illustrated in Figure 5.
IC = inter caval; CT = crista terminalis; RM = right mid; RA = right atrium; BBL = Bachmann’s Bundle left; BB =
Bachmann’s Bundle; BBR = Bachmann’s Bundle right; LA = left atrium; PVL = left pulmonary vein; PVR = right
pulmonary vein
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The lower panel of Figure 4 shows three examples of the spatial distribution of CB in 
patients with a low, median and high amount of CB. In these patients, lines of CB of 
variable lengths were observed at various sites at the RA, BB, PV area and LA. 
The histogram in the upper panel of Figure 5 shows large differences in the amount of 
CB/cm2 (0-34%). Areas of CB were identified at a total of 1,470 (21.9%) quadrants; 
thus, most quadrants had no areas of CB. In 863 quadrants, the amount of CB was 
between 0-6%. The top ten percentile of all quadrants (N = 606) contained more than 
6% CB, as indicated by red bars. 
Color-coded quadrant maps in the middle panel of Figure 5 demonstrate the amount 
of CB per 1cm2 for the examples used Figure 4. Blue, white and red quadrants indicate 
respectively 0%, 0-6% and ≥6% CB/cm2. These maps show that both the prevalence 
and the spatial distribution of CB vary between patients with similar clinical profiles. 
As depicted in the lower left panel of Figure 5, CB was most frequently observed at 
quadrants covering the superior intercaval area of the RA (52%). Comparable to areas 
of CD, the amount of CB was highest at quadrants within the superior intercaval area 
of the RA (mean 4.6%, median 1.4 (0-33.8)%, lower right panel). 
Correlation between Electrophysiological Properties and AF inducibility
In 8 of 209 patients without AF (4%) AF induction was not attempted due to 
hemodynamical instability or technical errors. AF was inducible in 142 (71%) patients; 
in 29 patients (14%) only a regular atrial tachycardia was induced. Arrhythmias were 
not inducible in 30 patients (15%). Intra-operative inducibility of AF did not correlate 
with amount of CD (ρs = 0.014; P = 0.837) and amount of CB (ρs = 0.121; P = 0.080). 
Quadrants with the lowest voltages (ρs = -.102; P = 0.146) or with the highest amount of 
CD/cm2 (ρs = 0.079; P = 0.257) or CB/cm
2 (ρs = 0.059; P = 0.396) within each patient 
Figure 3 Quantification of conduction delay
Left panel: mean amount of conduction delay at the entire atria. Patients are ranked according to an increment in 
atrial amount of conduction delay. Right upper panel: prevalence of conduction delay per region. Highest prevalence 
is observed at the superior intercaval area. Right lower panel: mean amount of conduction delay per region, showing a 
predilection site at the superior intercaval right atrium.
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Figure 4 Interindividual variation in conduction block
Upper panel: mean amount of conduction block at the entire atria. Patients are ranked according to an increase in 
atrial amount of conduction block. Lower panel: conduction block maps with a variable amount of conduction block 
obtained from three different patients. 
Figure 5 Spatial distribution of conduction block
Upper panel: histogram demonstrating the frequency distribution of the amount of conduction block/1cm2 for all 
quadrants. Blue bar: quadrants without conduction block. White bars: quadrants with >0-6% conduction block. Red 
bars: >6% conduction block per quadrant. Middle panel: color-coded quadrant block map demonstrating the spatial 
distribution of conduction block, using the same patients as in Figure 4. Lower left panel: prevalence of conduction 
block for each atrial region. Lower right panel: mean amount of conduction block per atrial region. A predilection site 
is present at the superior intercaval right atrium.
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did not correlate with AF inducibility. The highest amount of CB/cm2 (ρs = 0.049; P = 
0.488), found at the superior intercaval area of the RA, or presence of CB (χ2 = 1.917; 
P = 0.590) within this area did also not correlate with AF inducibility.
Correlation between Electrophysiological Properties and Post-operative AF
The histogram in Figure 6 indicates the exact proportion of quadrants with 0% CB (blue 
bars), 0-6% CB (white bars) and ≥6% CB for each patient separately. Patients are ranked 
according to an increase in the number of quadrants with ≥6% CB. The incidence of 
early PoAF was 30% (N = 63). The black bars in Figure 6 visualize the development of 
early PoAF for each individual patient. There was no correlation between development 
of PoAF and amount of CD (ρs = 0.032; P = 0.650) or amount of CB (ρs = 0.017; P = 
0.813). Development of early PoAF did not correlate with the highest amount of CD/
cm2 (ρs = 0.036; P = 0.608) or CB/cm
2 (ρs = 0.185; P = 0.007). Incidence (χ
2 = 1.939; P 
= 0.164) or amount (ρs = -0.022; P = 0.753) of CB at the RA superior intercaval region 
did not correlate with development of PoAF. 
Figure 6 Quantification of the degree of conduction block per patient
Histogram showing the percentage of quadrants containing 0% conduction block (blue bars), 0-6% conduction block 
(white bars) or ≥6% conduction block (red bars) for every patient separately. Black bars indicate the presence of early 
post-operative AF.
Discussion
Key Findings
This study quantified conduction disorders per 1 cm2 during SR in a large number 
of patients with coronary artery disease and electrically non-remodeled atria using a 
high-resolution epicardial mapping approach of the entire epicardial surface. Within 
a patient, conduction disorders were scattered throughout the entire RA, BB, PV and 
High-Resolution Sinus Rhythm Mapping
C
ha
pt
er
 7
113
LA, showing considerable regional differences in the prevalence and amount of CD or 
CB. In addition, there was not only an intra-atrial variation, but also an inter-individual 
variation in the electrophysiological parameters for a given atrial site, despite the fact that 
all patients had a similar underlying ischemic heart disease. In all patients, the prevalence 
and amount of conduction disorders was low. Predilection sites for conduction disorders 
are the quadrants covering RA superior intercaval region. Our hypothesis that conduction 
disorders during SR are associated with either AF inducibility or development of early 
post-operative AF (PoAF), could not be confirmed.
Heterogeneity in Conduction
Propagation of electrical waves through atrial myocardium is determined by membrane 
properties, tissue structure and wave front geometry(8). Conduction abnormalities 
play a crucial role in both genesis and perpetuation of atrial arrhythmias. It is generally 
assumed that the major cause of local conduction abnormalities is non-uniform tissue 
anisotropy due to interstitial fibrosis causing slowing of conduction and conduction 
block(9). Although we included patients with electrically non-remodeled atria, 
structural remodeling due to e.g. ageing, obesity, hypertension or ischemia may cause 
local conduction disorders(10). In line with our study, Hansson et al.(11) also found 
a small amount of conduction disorders during SR in 12 patients undergoing CABG 
or surgical transection of an accessory pathway. Epicardial mapping of the right atrial 
free wall using an 56 bipolar electrode array, revealed slowing of conduction (defined as 
propagation velocity 50% of the mean conduction velocity in that direction) in only 3 
patients, at <13% of the total mapping area. 
The amount of conduction disorders in our study population was low and mainly 
confined to the quadrants covering the RA superior intercaval area. Prior studies have 
also demonstrated conduction disorders primarily at the terminal crest region(12). A 
functional conduction delay along the terminal crest, mainly in the transverse direction, 
was observed in patients with typical atrial flutter(13). This can be the result of a lower 
density of intercellular connections in the transverse direction of the terminal crest(14). 
Other explanations for preferential sites of conduction disorders at the RA superior 
intercaval quadrants include disruption of atrial myocardium by (branches of ) the 
sinus node or the sinus node artery(15), pericardial folds near the superior caval vein 
or extensions of (resolved) sinus venosus myocardium(16). In addition, Federov et al. 
demonstrated in an in vitro optical mapping study the presence of an area of conduction 
block in the sinus node region(17).
In contrast to our observations, Lee at al.(18) found epicardial lines of conduction blocks 
at the junction of the right superior pulmonary vein and the LA in 18 patients without 
AF. This discrepancy could be explained by different positions of the electrode arrays as 
their mapping device covered both the myocardial sleeves within the pulmonary vein 
area and the posterior left atrial wall. 
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Intra-operative AF Inducibility 
The group of Zaman et al.(3) demonstrated that bipolar SR electrograms had a higher 
dominant frequency in subjects with AF inducibility than those with non-inducibility 
of AF. In contrast, we did not find a relationship between extensiveness of conduction 
disorders  and intra-operative inducibility of AF. Firstly, intra-operative inducibility 
of AF may be hampered by other factors such as general anesthesia or usage of beta-
blockers prior to surgery as part of the treatment of coronary artery disease. In our 
cohort, usage of anti-arrhythmic drugs was similar in patients with and without AF 
inducibility. Furthermore, we quantified the extensiveness of conduction disorders, 
whereas Zaman evaluated the presence of electrogram fractionation by means of the SR 
dominant frequency.
Development of PoAF
Sakamoto et al.(19) performed intra-operative mapping during SR (60 unipolar 
electrodes, inter-electrode distances 3-5 mm) of the right atrial free wall in 52 patients 
with a variety of structural heart diseases. The presence of non-uniform activation 
patterns (defined as areas of conduction delay, conduction block or fusion of multiple 
wavefronts) was observed in 15 patients (29%) and was associated with PoAF(19). 
However, in our study population, we could not establish a relation between PoAF and 
extensiveness of conduction disorders, even after clustering of the quadrants. Most areas 
of CB consisted of short lines of CB not affecting propagation of the broad SR wave 
fronts. 
PoAF is a multifactorial process and triggers including inflammation, oxidative stress 
and sympathetic activation are omnipresent. However, development of AF requires 
besides a trigger also an arrhythmogenic substrate for its perpetuation(20). This 
paper confirms that it is unlikely that conduction abnormalities contributing to this 
substrate can be identified by SR mapping alone. Conduction disorders associated with 
development of AF may be more pronounced when a trigger activates atrial tissue at 
a high frequencies(18). It needs to be further investigated whether these conduction 
disorders revealed by high-rate pacing are associated with development of PoAF.
Clinical Implications
This study shows that a substantial intra- and inter-individual variation in CD/CB is 
present during SR in patients with ischemic heart disease. CD/CB did not correlate 
with clinical characteristics, AF inducibility or development of PoAF. Therefore, SR 
mapping alone is not a viable approach for identifying patients at risk for PoAF. Areas 
of CD/CB in the present paper most likely represent the physiological variation in 
conduction during SR rather than impaired conduction associated with AF inducibility 
or development of PoAF.
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Conduction disorders are likely to become more pronounced when the atrial tissue is 
activated at a high rate e.g. during pacing maneuvers, atrial extra systolic beats or AF. It 
is generally assumed that these areas with increased heterogeneity in conduction are part 
of the arrhythmogenic substrate. As patients with AF have various underlying cardiac 
diseases, the location and extension of this substrate will most likely be different for each 
individual. Hence, the expected intra- and inter-individual variation in CD/CB during 
AF emphasizes the need for a patient tailored approach in the treatment of substrate 
mediated AF.
Study Limitations
Although the predefined mapping scheme covered the entire epicardial surface of the 
RA, BB and LA, we were not (yet) able to perform simultaneous recordings of all 
mapping sites. Recordings of the interatrial septum could not be obtained with our 
closed beating heart mapping approach. Due to our invasive mapping approach we were 
not able to include healthy control patients. 
Conclusion
High-resolution mapping of the atrial epicardial surface in patients with coronary 
artery disease and electrically non-remodeled atria showed not only considerable intra-
atrial variation in conduction disorders, but also inter-individual differences, despite 
the similar clinical profiles. CD/CB during SR did not correlate with AF inducibility 
or development of PoAF. A predilection site for CD and CB was present at the right 
atrial superior intercaval area. The arrhythmogenicity of this area needs to be further 
investigated. 
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SUPPLEMENTAL MATERIAL
Detailed Methods
Intra-operative Epicardial Mapping Procedure
The epicardial mapping procedure is performed during sinus rhythm, prior to 
commencement to extra-corporal circulation. A floppy electrode array, consisting of 
128 or 192 unipolar electrodes, is attached to a flexible spatula. Electrode diameters 
are 0.65 mm and 0.45 mm respectively, inter-electrode distances are 2 mm. Corner 
electrodes do not record epicardial electrograms; hence 124 or 188 unipolar electrograms 
are recorded. The upper panel of Figure S1 shows the 192 unipolar electrode array. A 
bipolar reference electrode is temporarily attached to the terminal crest. A steel wire, 
fixed to the subcutaneous tissue of the thoracic cavity serves as an indifferent electrode. 
Recordings are obtained from the entire epicardial atrial surface, following a predefined 
mapping scheme. The upper panel of Figure S1 illustrates the positioning of the 
electrode array on the epicardium in a schematic manner. The electrode array is shifted 
along anatomical structures with a fixed orientation at each position trying to avoid 
omission of areas at the expense of possible overlap between adjacent mapping sites. 
This approach covers the entire epicardial surface of both the right atrium (RA), left 
atrium (LA), pulmonary vein area (PV) and Bachmann’s Bundle BB. Mapping of the 
RA started at the cavo-tricuspid isthmus and continued perpendicular to the caval 
veins towards the right atrial appendage. BB is mapped from the tip of the left atrial 
appendage across the roof of the LA, behind the aorta towards the superior cavo-atrial 
junction. Mapping of the LA is performed from the lower border of the left inferior 
pulmonary vein along the left atrioventricular groove towards the left atrial appendage. 
The PV area is mapped from the sinus transversus fold, in between the right and left PV, 
towards the atrioventricular groove. 
Five seconds of SR were recorded from every mapping site, including 124 or 188 
unipolar epicardial electrograms, a bipolar reference electrogram, surface ECG I and a 
calibration signal of 2mV and 1000ms. Data was stored on hard disk after amplification 
(gain 1000), filtering (bandwidth 0.5-400 Hz), sampling (1 KHz) and analogue to 
digital conversion (16 bits). 
Determination of the local activation time
Figure S2 shows an example of electrograms recorded at the superior right atrium from 
one of the study subjects (raw data). As explained by Spach et al1, the maximum negative 
slope of the extracellular potential coincides with the moment of the maximum change 
in transmembrane potential (Vmax, first time derivate, time difference < 50µs)
1. Vmax 
corresponds with moment of maximum increase in sodium current and its conductance2. 
The slope of each deflection is calculated per window of 2 ms. The maximum negative 
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Figure S1 Epicardial mapping procedure
Upper panel: projection of the 192 unipolar electrode array on a schematic posterior view of the atria. Middle panel: 
mapping scheme demonstrating the subdivision of the mapping areas into 1cm2 quadrants. Lower panel: epicardial, 
unipolar sinus rhythm potentials recorded during 5 seconds of sinus rhythm (A = atrial potential, V = farfield ventricu-
lar signal) and corresponding color-coded activation maps. Isochrones are drawn at 5 ms intervals, the arrow indicates 
the main trajectory of the wavefront and thick black lines represent areas of conduction block. See text for detailed 
explanation. IC = inter caval; CT = crista terminalis; RM = right mid; RA = right atrium; BBL = Bachmann’s Bundle 
left; BB = Bachmann’s Bundle; BBR = Bachmann’s Bundle right; LA = left atrium; PVL = left pulmonary vein; PVR = 
right pulmonary vein.
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slope of the potential is marked as the local activation time of the corresponding electrode. 
Figure S3 shows the same selection of unedited electrograms as displayed in Figure S2. 
The steepest negative deflection of each negative atrial electrogram is marked, which in 
turn annotates the local activation time of the corresponding electrode. Premature atrial 
complexes and aberrant beats were excluded from this analysis.
Criteria for conduction delay and conduction block
To study the presence of conduction delay and block, local activation times were 
compared in areas of 2x2 electrodes. The upper panel of Figure S4 illustrates that each 
differences in local activation times were calculated between the index electrode and 
the adjacent electrodes on the right and immediately below in order to avoid double 
counting. With this approach, a total of N = 225 differences in local activation times 
(ΔLAT) were calculated for the 128 electrode array and N = 344 for the 192 electrode 
array. 
The lower panel of Figure S4 shows examples of areas with conduction delay and/or 
conduction block. Conduction delay was defined as a difference in local activation time 
Figure S2 Raw epicardial electrograms
Typical example of a selection of epicardial electrograms, recorded from the superior right atrium. An atrial potential 
(A) and a farfield ventricular signal (V) can be distinguished. 
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Figure S3 Marked epicardial electrograms
The same selection of epicardial electrograms as Figure S2. The steepest deflection of each atrial potential is marked 
with a red line.
of ≥7ms, indicated by a blue line. Differences of ≥11ms were classified as conduction 
block, indicated by a red line. These cut-off values correspond with conduction velocities 
of ≤ 28 cm/s (delay) and ≤ 18 cm/s (block). In literature, the slowest conduction velocity 
during longitudinal propagation was measured around 20 cm/s.3 A somewhat lower 
value of <18 cm/s was chosen in order to be consistent with previous mapping studies 
in which we observed fractionated electrograms and activation from another direction 
at the other site of the line of conduction block.4, 5 
Figure S5 shows the reconstruction of a conduction block map. Magnification of a 
part of a color-coded activation map in the left panel shows the presence of an area 
of conduction block, based on differences in local activation times. Conduction block 
maps, as depicted in the right panel of Figure S5, are reconstructed with this approach. 
The percentage of conduction delay/block per area of interest is calculated as following: 
 
 
3 
 
Figure S5 shows the reconstru ti  of a onduction block map. Mag ification of a part of a 
color-coded activation map in the left panel shows the presence of an area of conduction block, 
based on differences in local activation times. Conduction block maps, as depicted in the right 
panel of Figure S5, are reconstructed with this approach. The percentage of conduction 
delay/block per area of interest is calculated as following:
%CD =  Number of ΔLAT ≥7 ms
Total number of ΔLAT and %CB =  Number of ΔLAT ≥11 msTotal number of ΔLAT
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Figure S4 Identification of conduction delay/block
The presence of conduction disorders is evaluated in areas of 2x2 electrodes. The difference in local activation time is 
calculated between the right and inferior electrodes for each consecutive recording electrode. Conduction delay and 
conduction block are indicated with blue and red lines respectively. LAT = local activation time; CD = conduction 
delay; CB = conduction block.
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Figure S5 Construction of conduction block map
Left panel: color coded activation map, numbers indicate local activation time per electrode. Middle panel: magnifica-
tion of a 2x2 area of the activation map with calculation of the difference in local activation time (ΔLAT) in order to 
identify conduction abnormalities. Right panel: conduction block map based on the activation map in the left panel. 
Amount of conduction block in this area is 12 / 188 = 6.4%. LAT = local activation time; CB = conduction block.
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Table S1 Baseline Characteristics
Baseline Characteristics
No. of patients (N) 209
Age, years 66 ± 9.6
Male gender (%) 175 (83.7)
BSA 1.99 ± 0.3
Hypertension (%) 131 (62.7)
Hypercholesterolemia (%) 91 (43.5)
Diabetes Mellitus (%) 72 (34.4)
Peripheral Vascular Disease (%) 29 (13.9)
Thyroid Disorder (%) 9 (4.3)
Echocardiography
   LVF (%)
   -   Normal function (%) 152 (72.7)
   -   Mild dysfunction (%) 41 (19.6)
   -   Moderate dysfunction (%) 7 (3.3)
   -   Severe dysfunction (%) 1 (0.5)
   LA Size (%)
   -   Dilated LA (>45mm) (%) 32 (15.3)
AF = atrial fibrillation; BSA = body surface area; LVF = left ventricular function; LA = left atrium. 
Table S2 Conduction disorders per 1 cm2
Conduction Delay (%) Conduction Block
Quadrant Mean Median Min Max Mean Median Min Max
IC1 1.1 0.0 0.0 16.7 1.3 0.0 0.0 20.8
IC2 2.2 0.0 0.0 22.9 2.9 0.0 0.0 28.2
IC3 3.0 0.0 0.0 22.9 5.0 2.6 0.0 25.0
IC4 2.7 1.5 0.0 14.7 5.4 3.2 0.0 22.9
CT1 0.8 0.0 0.0 13.9 0.8 0.0 0.0 17.9
CT2 1.8 0.0 0.0 13.0 1.7 0.0 0.0 23.6
CT3 2.2 0.0 0.0 18.1 3.4 0.0 0.0 22.2
CT4 2.1 1.4 0.0 13.9 4.8 0.0 0.0 33.8
RM1 0.7 0.0 0.0 11.6 0.2 0.0 0.0 13.2
RM2 1.3 0.0 0.0 19.4 0.8 0.0 0.0 15.5
RM3 1.3 0.0 0.0 9.9 1.0 0.0 0.0 19.4
RM4 2.0 0.0 0.0 13.4 1.5 0.0 0.0 13.9
RA1 0.8 0.0 0.0 12.5 0.3 0.0 0.0 12.5
RA2 1.0 0.0 0.0 16.7 0.6 0.0 0.0 15.1
RA3 1.3 0.0 0.0 16.7 0.5 0.0 0.0 20.8
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RA4 1.5 0.0 0.0 14.3 1.0 0.0 0.0 13.2
Conduction Delay (%) Conduction Block
Quadrant Mean Median Min Max Mean Median Min Max
BBL1 2.0 0.0 0.0 16.7 1.8 0.0 0.0 18.8
BB0 2.2 0.0 0.0 19.4 1.7 0.0 0.0 18.1
BBR1 2.1 0.0 0.0 18.1 1.9 0.0 0.0 20.8
BBR2 1.9 0.0 0.0 14.7 1.1 0.0 0.0 16.7
Conduction Delay (%) Conduction Block %
Quadrant Mean Median Min Max Mean Median Min Max
LA1 1.3 0.0 0.0 12.5 0.5 0.0 0.0 11.1
LA2 0.7 0.0 0.0 8.8 0.5 0.0 0.0 18.1
LA3 0.9 0.0 0.0 12.5 0.5 0.0 0.0 18.1
LA4 0.7 0.0 0.0 9.7 0.4 0.0 0.0 12.5
LA5 0.9 0.0 0.0 14.6 0.6 0.0 0.0 18.8
LA6 0.9 0.0 0.0 20.3 0.5 0.0 0.0 17.1
LA7 0.8 0.0 0.0 12.3 0.4 0.0 0.0 11.1
LA8 1.5 0.0 0.0 16.2 1.0 0.0 0.0 15.4
PVL1 1.7 0.0 0.0 27.1 1.1 0.0 0.0 18.8
PVL2 1.3 0.0 0.0 15.5 0.7 0.0 0.0 16.7
PVL3 1.1 0.0 0.0 13.9 0.9 0.0 0.0 20.6
PVL4 1.3 0.0 0.0 15.4 1.0 0.0 0.0 19.3
PVR1 1.2 0.0 0.0 12.5 1.0 0.0 0.0 15.3
PVR2 1.0 0.0 0.0 13.9 1.1 0.0 0.0 15.3
PVR3 1.5 0.0 0.0 13.2 1.3 0.0 0.0 15.2
PVR4 1.6 0.0 0.0 13.9 1.5 0.0 0.0 14.5
 
IC = inter caval; CT = crista terminalis; RM = right mid; RA = right atrium; BBL = Bachmann’s Bundle left; BB = 
Bachmann’s Bundle; BBR = Bachmann’s Bundle right; LA = left atrium; PVL = left pulmonary vein; PVR = right 
pulmonary vein 
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Abstract
Background: Congenital heart diseases (CHD) can be associated with right atrial (RA) 
volume overload. The resulting atrial stretch causes intra-atrial conduction abnormalities 
which may be involved in the pathophysiology of atrial fibrillation (AF). We tested the 
hypothesis that heterogeneity in conduction in CHD patients with RA dilatation occurs 
mainly in the RA and that long lines of conduction disorders are associated with AF. 
Methods and Results: Intra-operative, high-resolution (inter-electrode distances 2mm) 
epicardial mapping studies of the RA, Bachmann’s Bundle (BB), left atrioventricular 
groove and pulmonary vein area were performed during SR in 13 CHD patients with 
RA dilatation. Five patients had (pre- or post-operative) AF. Conduction delay (CD) 
and conduction block (CB) were quantified per 1cm2 quadrant. Length of CD/CB 
lines was measured. Data is expressed as mean;median(range). Unipolar signals were 
recorded from 25,197 sites (1,9138±327/patient). Median amount of CD and CB 
was respectively 1.6;1.3(0.9-2.9)% and 1.5;1.3(0.3-3.5)%. CD/CB occurred most 
frequently at quadrants at BB (CD: 50%,CB: 38% ) and RA (CD: 38%,CB: 25%). CB 
lines were longest in patients with AF (P = 0.036), lines ≥16 mm occurred in all patients 
with (pre- or post-operative) AF and were mainly located at RA and BB. 
Conclusions: In patients with CHD and RA dilatation, conduction disorders were not 
solely located at RA but also at BB. Long CB lines (≥16 mm) were mainly observed 
at RA and BB in patients with AF. Hence, it is likely that the length of CB lines is 
associated with the electropathological substrate underlying AF.
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Introduction
Right atrial (RA) volume overload caused by specific congenital heart diseases (CHD) 
is associated with development of atrial tachyarrhythmias (AT) including ectopic atrial 
tachycardia, atrial flutter and atrial fibrillation (AF)1-6. AF occurs irrespective whether 
the CHD is corrected, though repair at a younger age may reduce the risk of late, post-
operative AF2, 6. For example, older age at the moment of atrial deptal defect (ASD) 
closure causes long-term volume overload of the RA7. Subsequently, the increased atrial 
wall stretch will most likely result in atrial dilatation and conduction abnormalities such 
as slowing of conduction or conduction block. 
Several studies reporting on the outcome of ablative therapy in CHD patients indeed 
showed that successful target sites of ablation of AT is in the far majority of the patients 
found in the RA1, 4, 5, 8. Comparison of the degree of atrial remodeling between ASD 
patients without atrial arrhythmia and control patients referred for ablative therapy of 
supraventricular tachycardias showed a trend towards prolongation of the refractory 
period during pacing at the lower lateral RA (222±19ms versus 207±22ms, P=0.03) 
and high RA septal region (239±19ms versus 229±17ms, P=0.04) in the ASD group9. 
In addition, there was a significant increase in conduction delay at the crista terminalis 
region, reflected by double potentials and large time delay between the two components. 
This did not resolve after closure of the septal defect. As these patients did not have a 
history of AF, it is unclear whether the observed conduction disorders play a role in 
the pathophysiology of AF. Electrophysiological parameters were measured at a limited 
number of recording sites in the RA and left atrial sites were not included. Zaman et 
al.10 recently showed in patients with coronary arterty disease, that bipolar dominant 
frequencies of electrograms recorded at the right atrial wall are higher in subjects in whom 
AF could be induced intra-operatively than in non-inducible subjects. This implies that 
areas with conduction disorders, most likely caused by structural abnormalities and 
represented by the fractionated electrograms, are already present during sinus rhythm 
(SR). No studies have sofar quantified the amount of conduction block present in 
the entire right and left atria (LA) and Bachmann’s bundle (BB) of CHD patients. In 
addition, to the amount of conduction block, the length of lines of conduction block 
may determine vulnerability to AF. 
The aims of this study are therefore to test the hypothesis that heterogeneity in 
conduction in CHD patients with RA dilatation occurs mainly in the RA and that long 
lines of conduction block are associated with AF. For this purpose, we performed intra-
operative, high-resolution mapping studies of the entire epicardial surface of the RA, 
BB, and LA during SR, prior to surgical correction of the defect. 
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Methods
Study Population
The study population consisted of 13 adult patients with a CHD causing RA dilatation, 
scheduled for the first surgical correction of the congenital defect. Patients with previous 
cardiothoracic surgery, severely impaired left ventricular function or severe renal failure 
were excluded. This study is part of the QUASAR11 project (QUest for Arrhythmogenic 
Substrate of Atrial FibRillation) which is approved by our institutional Medical Ethical 
Committee (MEC 2010-054). Authors had full access to all the data obtained in the 
study. Written informed consent was obtained from all patients prior to enrollment. 
Patient characteristics were obtained from electronic patient files. 
Intra-Operative Mapping Procedure
Epicardial mapping during SR was performed prior to commencement to extra-corporal 
circulation12. A pacemaker wire attached to the terminal crest served as a temporal, 
bipolar reference electrode and a steal wire fixed to subcutaneous tissue was used as an 
indifferent electrode. The mapping procedure was performed with epicardial electrode 
arrays consisting of either 128 or 192-unipolar electrodes with diameters of respectively 
0.65 or 0.45mm; inter-electrode distances of both devices were 2mm. Mapping was 
conducted following a predefined mapping scheme covering the entire epicardial surface 
of the RA, BB and LA, as demonstrated in the upper panel of Figure 1. Our mapping 
approach has previously been described in detail12. In brief, the RA is mapped from 
the cavotricuspid isthmus, perpendicular to the caval veins, towards the right atrial 
appendage. BB is mapped from the tip of the left atrial appendage towards the superior 
cavo-atrial junction. LA mapping is performed from the lower border of the left inferior 
pulmonary vein, along the left atrioventricular groove (LAVG) towards the left atrial 
appendage. The pulmonary vein area (PVA) is mapped along the borders of the right 
and left PVs from the sinus transversus fold towards the LAVG. 
Five seconds of SR were recorded at every mapping site, including unipolar epicardial 
electrograms, a bipolar reference electrogram, surface ECG lead I and a calibration signal 
of 2mV and 1000ms. Data was stored on hard disk after amplification (gain 1000), 
filtering (bandwidth 0.5-400Hz), sampling (1KHz) and analogue to digital conversion 
(16bits).
Analysis of the Mapping data 
Our mapping approach enables detailed reconstruction of the activation sequence of the 
entire epicardial surface during SR as shown in the lower panel of Figure 1. Mapping 
data were semi-automatically off-line analyzed. Color-coded SR activation maps were 
constructed by annotating the intrinsic deflection of each extracellular atrial potential; 
in case of fractionated electrograms, the steepest deflection was marked. SR activation 
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maps were used to quantify conduction delay (CD) and conduction block (CB) per 
1cm2 quadrants. Comparable to prior mapping studies, areas beneath the mapping 
array were subdivided into quadrants of 1cm2 (black boxes, upper panel of Figure 1); 
Figure 1. Epicardial mapping scheme
Upper left panel: schematic presentation of the RA, BB, PVA and LVAG demonstrating the epicardial mapping 
scheme. Areas covered by the (128 or 192-polar) mapping array were subsequently designated to specific anatomical 
quadrants of 1x1cm2 in order to quantify electrophysiological properties enabling comparison of electrophysiological 
parameters between atrial sites and between patients. The position and orientation of the 192-polar mapping array is 
shown.
Lower panel: Color-coded activation sequence of the epicardial surface during SR.  Arrows indicate the main direction 
of activation.
RA = right atrium (lateral area); RM = right atrium (medial area); CT = crista terminalis; IC = intercaval area; PVR = 
right pulmonary vein area; PVL = left pulmonary vein area; LA = left atrioventricular groove; BBL = Bachmann’s Bund-
le left; BB = Bachmann’s Bundle; BBR = Bachmann’s Bundle right; VCS = vena cava superior; VCI = vena cava inferior
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quadrants were excluded for analysis when >50% of the recorded electrograms had a 
slope threshold <80 mV/s and a signal-noise ratio <4. 
Differences in local activation times of two adjacent electrodes were calculated to 
determine the presence of inter-electrode CD (activation time differences ≥8ms) or 
inter-electrode CB (activation time differences ≥12ms). In addition, the length of every 
line of CD/CB was measured; CD/CB lines were defined as uninterrupted series of 
inter-electrode CD/CB. These mapping parameters have recently been described in 
more detail by De Groot et al.13.
The left panel of Figure 2 shows four typical examples of color-coded activation maps 
with an increasing amount of conduction disorders. Corresponding isochronal maps are 
depicted in the middle panel; lines of CB are indicated with thick black lines and lines 
of CD by crowding of isochrones. Conduction delay/block maps, as presented in the 
right panel, not only demonstrate the location and length of lines of CB (red lines), but 
also of CD (blue lines).  
Statistical Analysis
All data was tested for normality. Normally distributed data is expressed as mean±SD, 
whereas skewed data is depicted as mean; median (minimum-maximum). In case 
of skewed data, the mean value is also provided for completeness and to facilitate 
Figure 2. Reconstruction of conduction block maps
Left panel: color-coded activation maps obtained from the superior RA of four consecutive patients (192-polar map-
ping array). Middle panel: corresponding isochronal maps. Isochrones are drawn at 5 ms; areas of CB are indicated by 
thick black lines. Arrows indicate main direction of activation. Right panel: corresponding delay/block maps showing 
the spatial distribution of lines of CD (blue) and CB (red) within the mapping area. Quantification of CD and CB in 
the mapping area is indicated above the maps.
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comparison with other studies. Lengths of CD/CB lines between patients with and 
without AF are compared using Mann-Whitney U tests.
Results
Clinical baseline characteristics of the study population (N=13, 7 (54%) male, 46±15 
years) are summarized in Table 1. All patients had levocardia, situs solitus and concordant 
atrio-ventricular and ventriculo-arterial connections. Surgical correction was performed 
for ASD (N=3), ventricular septal defect (N=1), partial abnormal pulmonary venous 
return (PAPVR) with ASD (N=5) or PAPVR without ASD (N=1). Patients 10, 11 
and 12 were diagnosed with paroxysmal AF at 9, 12 and 16 months prior to surgery 
respectively; an additional MAZE procedure was performed in these patients. Patients 7 
and 9 developed sustained AF in the early post-operative period (PoAF). A single episode 
of typical atrial flutter was documented in patient 8, several years prior to surgery.
Electrograms were recorded from 452 quadrants at the RA (N=218), BB (N=52), LAVG 
(N=92) and PVA (N=91) resulting in a total of 25,197 atrial recording sites (1,938±327 
sites/patient). On average, 7.3±0.9 beats with a cycle length of 766±116ms were analysed 
at each recording site per five seconds.
Heterogeneity in Conduction
The upper panels of Figure 3 show the median amount of CD (left panel) and CB (right 
panel) of the entire epicardial atrial surface plotted for each patient individually.  Patients 
are ranked according to an increasing amount of CD or CB. The overall amount of CD 
and CB of the entire atria was respectively 1.6;1.3(0.9-2.9)% and 1.5;1.3(0.3-3.5)%. 
These graphs also show a considerable intra-atrial variation in CD (10.2; 9.9(5.6-15.2%/
cm2) and CB (14.7; 12.5(6.7-30.9%/cm2), as indicated by the bars. 
Spatial Distribution of Conduction Disorders
CD and CB occurred in a minority of the quadrants, respectively 163 (36%) and 105 
(23%). Pies in the lower panel of Figure 3 demonstrate incidences of CD/cm2 (blue 
areas) and CB/cm2 (red areas) within the different regions. CD was present at 38% of 
quadrants covering the RA (N=83), 50% of BB (N=26), 29% of LAVG (N=27) and 
30% of PVA (N=27). In 25% of quadrants confined to the RA (N=55), CB was present, 
versus 38% of BB (N=20), 16% of LAVG (N=15) and 22% of PVA (N=20). The 
cumulative frequency histograms in the lower panels of Figure 3 show the distribution 
of CD/cm2 and CB/cm2 at the quadrants covering the RA, BB, LAVG and PVA. 
Figure 4 shows the spatial distribution of CB throughout the atria for every patient 
separately. Patients are ranked according to an increase in the amount of CB; areas of CB 
occurred in all patients at various sites at the RA, BB, LAVG and PVA. As quantified in 
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Table 2, in most patients, the largest amount of CB was observed at BB (N=5; patients 
1, 2, 7, 10 and 12) and at the RA (N=4, patients 4, 6, 11 and 12). In the other patients, 
the highest amount of CB was observed at the LAVG (N=1, patient 9), PVA (N=2, 
patients 5 and 8) or a similar high amount of CB at both the LAVG and RA (N=1, 
patient 3). Within the RA, CB was most often found at the superior regions (quadrants 
IC3/4; CT3/4; RM3/4; RA3/4). 
Length of Lines of Conduction Disorders 
In the entire study population, a total of 392 and 190 lines of respectively CD and 
CB was observed. The upper panel of Figure 5 shows the length of all lines of CD for 
every patient seperately. The length of CD lines was 3.4;2(2-20)mm and did not differ 
between patients without (3.5;2(2-12)mm) and with pre- or postoperative AF (3.4;2(2-
20)mm, P=0.248). The top 5 percentile included 16 CD lines of ≥10mm, which were 
Figure 3. Extensiviness of conduction disorders
Upper left panel: median amount of CD of the entire atria per patient; patients are ranked according to an increase in 
mean CD. Bars indicate the minimum and maximum voltage per cm2, thereby demonstrating intra-atrial variation. 
Upper right panel: median amount of CB of the entire atria per patient; patients are ranked according to an increase in 
mean CB. Bars indicate the minimum and maximum voltage per cm2. Green: patients without a history of AF; orange: 
patients with  PoAF; Red: patients with pre-operative AF.
Lower panel: pies demonstrating relative incidences of quadrants with or without areas of CD(left) or CB(right) per 
region. The numbers indicate the percentage of quadrants in the specific region with CD/CB. Frequency histograms of 
the number of quadrants with CD (left) or CB (right) at the RA, BB, PVA and LVAG.
Chapter 8
138
Table 2. Conduction disorders per atrial region
CONDUCTION DELAY
RA BB LAVG PVA
Patient 
no.
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
1 1.0;0.0(0.0-6.9) 1.1;0.8(0.0-2.8) 0.9;0.0(0.0-6.9) 1.7;0.7(0.0-7.1)
2 1.0;0.0(0.0-8.3) 0.7;0.7(0.0-1.4) 0.2;0.0(0.0-1.4) 0.7;0.0(0.0-2.8)
3 1.9;0.0(0.0-6.9) 3.4;0.7(0.0-12.1) 1.6;0.0(0.0-6.3) 0.0;0.0(0.0;0.0)
4 1.8;0.0(0.0-8.5) 1.8;0.7(0.0-5.6) 0.5;0.0(0.0-1.4) -
5 3.7;1.8(0.0-12.5) 2.5;0.0(0.0-11.8) 3.3;0.7(0.0-13.4) 3.1;0.0(0.0-13.4)
6 0.9;0.0(0.0-5.6) 2.6;0.0(0.0-10.4) 1.1;0.0(0.0-4.2) 1.1;0.0(0.0-5.6)
7 1.9;0.0(0.0-7.7) 0.7;0.0(0.0-2.9) 0.4;0.0(0.0-2.1) 0.3;0.0(0.0-2.1)
8 2.4;0.0(0.0-11.4) 1.4;1.4(1.4-1.4) 1.8;0.7(0.0-7.1) 3.9;4.3(0.0-8.3)
9 2.9;1.4(0.0-9.3) 2.8;0.7(0.0-9.9) 2.5;0.0(0.0-9.9) 0.7;0.0(0.0-5.6)
10 0.9;0.0(0.0-8.8) 1.0;0.7(0.0-2.9) 0.9;0.0(0.0-2.9) 2.1;1.5(0.0-8.3)
11 0.8;0.0(0.0-4.2) 5.7;3.8(0.0-15.2) 0.0;0.0(0.0-0.0) 0.5;0.0(0.0-2.8)
12 2.1;1.4(0.0-6.9) 2.2;0.0(0.0-8.9) 0.0;0.0(0.0-0.0) 0.6;0.0(0.0-2.8)
13 0.2;0.0(0.0-1.4) 1.8;1.4(0.0-4.2) 2.0;0.0(0.0-5.6 0.9;(0.0(0.0-5.6)
All 1.6;0.0(0.0-12.5) 2.2;0.7(0.0-15.2) 1.0;0.0(0.0-9.9) 1.2;0.0(0.0-13.4)
CONDUCTION BLOCK
RA BB LAVG PVA
Pa-
tient-
no.
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
Mean;Medi-
an(min-max)
1 0.3;0.0(0.0-4.2) 5.6;4.9(1.4-11.3) 0.7;0.0(0.0-2.8) 0.7;0.0(0.0-2.8)
2 3.2;0.0(0.0-19.4) 8.3;8.3(6.9-9.7) 1.2;0.0(0.0-6.9) 0.0;0.0(0.0-0.0)
3 1.0;0.0(0.0-6.7) 0.0;0.0(0.0;0.0) 1.0;0.0(0.0-2.8) 0.0;0.0(0.0-0.0)
4 1.0;0.0(0.0-9.9) 0.4;0.0(0.0-1.4) 0.2;0.0(0.0-1.4) -
5 0.9;0.0(0.0-4.3) 1.5;0.0(0.0-5.9) 0.2;0.0(0.0-1.4) 2.6;0.0(0.0-9.0)
6 2.3;0.0(0.0-10.4) 0.0;0.0(0.0-0.0) 1.2;0.0(0.0-9.7) 1.1;0.0(0.0-4.2)
7 1.4;0.0(0.0-11.9) 7.7;0.0(0.0-30.9) 0.0;0.0(0.0-0.0) 0.3;0.0(0.0-2.1)
8 1.7;0.0(0.0-15.7) 0.7;0.7(0.0-1.4) 0.4;0.0(0.0-4.3) 4.0;2.9(0.0-11.4)
9 4.8;0.0(0.0-16.3) 0.0;0.0(0.0-0.0) 6.4;0.0(0.0-18.3) 0.7;0.0(0.0-5.6)
10 0.9;0.0(0.0-10.3) 5.5;4.4(0.0-13.9) 0.0;0.0(0.0-0.0) 1.1;0.0(0.0-4.4)
11 1.7;0.0(0.0-12.5) 1.5;1.6(0.0-3.0) 0.8;0.0(0.0-3.0) 0.7;0.0(0.0-4.2)
12 3.8;0.0(0.0-22.9) 1.0;0.0(0.0-3.8) 2.2;0.0(0.0-13.6) 0.8;0.0(0.0-4.8)
13 0.0;0.0(0.0-0.0) 2.1;0.0(0.0-8.3) 0.0;0.0(0.0-0.0) 0.2;0.0(0.0-1.4)
All 1.7;0.0(0.0-22.9) 2.5;0.0(0.0-30.9) 1.0;0.0(0.0-18.3) 0.9;0.0(0.0-11.4)
Electrophysiological parameters per atrial region for all consecutive patients. RA=rightatrium, BB=Bachmann’sBundle, 
LAVG=left atrioventricular groove, PVA=pulmonary vein area.
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observed in 10 (77%) patients. Amongst them were 3 patients with pre-operative AF, 1 
patient with early PoAF, and 6 patients without AF. Of these ≥10mm CD lines, six were 
located at the superior RA in four patients, whereas five lines were located at BB in five 
patients. The remaining lines were located at LAVG (N=3 lines, 3 patients) and PVA 
(N=3 lines, 3 patients).
The length of all CB lines per patient is depicted in the lower panel of Figure 5. Length 
of CB lines was 7;4(2-40)mm and was longer in patients with pre- or postoperative AF 
(9;4(2-40)mm) than in patients without AF (6;4(2-34)mm, P=0.036). 
CB lines with a length of ≥16mm (N=19) were observed in all patients with AF 
(patients 9, 10 and 11), in both patients with early PoAF (patients 7 and 12) and in 
only one patient without AF (patient 2). The majority of these CB lines was located 
at the RA (N=13 lines), mainly at the area between the caval veins and the terminal 
crest, as demonstrated in Figure 4. CB ≥16 mm was also observed at BB (N=4 lines) 
and the LAVG (N=2 lines) but never at the PVA. In all six patients with long CB lines, 
these lines were observed at the RA in addition to BB (N=3 patients) and LAVG (N=2 
patients). 
Figure 4. Regional differences in conduction block
CB maps demonstrating the spatial distribution of lines of CB (red) within the atria for every patient separately. Maps 
are reconstructed as depicted in Figure 2. Patients are ranked according to an increase in the total amount of CB. Grey 
lines indicate electrically silent tissue. * patient with AF prior to surgery; # patient with PoAF.
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Discussion
Key Findings
This study quantified conduction disorders at the entire atrial epicardial surface during 
SR at a high-resolution scale in adult CHD patients with RA dilatation. Heterogeneity 
in conduction was most pronounced at not only RA but also BB. Long lines of CB 
(≥16mm) at these sites were mainly observed in patients with pre-operative AF or 
early PoAF. However, extensiveness of and regional differences in CD and CB varied 
considerably between patients.
Electrical Remodeling in CHD patients
Left to right shunting in CHD patients as a result of differences in atrial pressure causes 
prolonged right atrial overload which in turn provokes right atrial stretch. There is 
conflicting evidence whether atrial stretch leads to an increase or a decrease in effective 
refractory period14-16. Dispersion of atrial refractoriness is increased by atrial stretch, as 
has previously been described17, 18. These electrical alterations provide a potential pro-
Figure 5. Length of lines of conduction delay and block 
The number and length of all lines of CD (upper panel) or CB (lower panel) for each patient separetly. Green: patients 
without AF; orange: patients with PoAF; red: patients with pre-operative AF.  Sizes of the circles correspond to the 
number of lines of CD/CB. 
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arrhythmogenic substrate. Elvan et al.19 investigated the effect of acute atrial stretch on 
the amount of CB by high resolution mapping of the RA and LA in 9 patients during 
long-standing persistent AF. They demonstrated an increase in amount of CB after 
dilatation at the LA and RA, whereas a decrease in CB was observed after dedilatation19.
Electrical remodeling in uncorrected CHD patients with RA overload has mainly been 
investigated during right atrial endovascular electrophysiological studies. Right atrial 
“electrophysiological abnormalities” in e.g. refractoriness and sinoatrial conduction time 
were identified in approximately 29-35% of children prior to ASD closure20, 21. The 
frequency of these abnormalities increased with age (time of exposure to atrial stretch) of 
uncorrected ASD patients20, 22. Hence, it is likely that prolonged atrial overload induces 
atrial electrical remodeling.
In the present study, the amount of conduction disorders during SR was quantified at 
not only the RA, but also BB and LA. Conduction disorders were found in all patients. 
Although areas of CB were scattered throughout the entire atria, long lines of CB 
occured mainly at the intercaval RA region and at BB in patients with AF and PoAF. 
Morton et al.9 reported a higher number of double potentials, with a greater conduction 
delay between the components, at the terminal crest area during constant pacing in 
patients with an ASD. However, in the present study conduction properties were 
analyzed during SR without pacing manoeuvers. The same was done by Zaman et al. 
in patients with coronary artery disease, although not on a high-resolution scale, using 
bipolar electrograms10. They conclude that the existence of fractionated electrograms 
(high dominant frequency) at the right atrial free wall during SR is associated with the 
substrate underlying AF, but did not study the electrophysiological characteristics of 
the remainder of the atria. The present study identified the superior intercaval RA as a 
predilection site for conduction disorders. However, there was no correlation between 
the presence of CD/CB in this region and pre- or post-operative AF. It is likely that by 
stimulation of  atrial tissue at higher rates, underlying conduction disorders became 
more pronounced, which could explain the discrepancy between the different studies. 
Eijsbouts et al. observed in a rabbit model an increase in length of CB lines as a 
result of atrial stretch23. CB plays an important role in initation and perpetuation of 
AF24, and its length appears of crucial importance in development of atrial reentry 
tachyarrhythmia25. We observed long lines of CB in not only all patients with AF, but 
also in one patient without AF. This patient (number 2) was also the only patient without 
AF but with pulmonary hypertension. Increased right atrial pressure, associated with 
pulmonary hypertension in addition to an ASD, may aggrevate conduction disorders as 
demonstrated previously23. Although PoAF is a multifactorial process and triggers such 
as inflammation, sympathetic activation and oxaditive stress are present, development 
of AF requires existence of an arrhythmogenic substrate26. Hence, since long CB lines 
were observed in all patients with pre- and postoperative AF, and in only one patient 
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without AF, it is most likely associated with the arrhythmogenic substrate underlying 
AF. The association between increased CB length and (Po)AF has also been confirmed in 
a recent study by Teuwen et al.27, who investigated the relevance of conduction disorders 
in BB during sinus rhythm. In a cohort of patients with (N=13) and without (N=172) 
paroxysmal AF undergoing coronary artery bypass grafting, they showed that the length 
of CB lines, in particular in the longitudinal direction, was longer in patients with AF.
Study limitations
Simultaneous recordings of all mapping sites as indicated by the mapping scheme could 
not be performed due to technical limitations. Recordings of the interatrial septum 
could not be obtained with our closed beating heart mapping approach. 
Conclusion
Quantified conduction disorders at a high-resolution scale in adult CHD patients with 
RA dilatation demonstrated that lines of CD/CB are predominantly located at BB and 
RA. Long lines of CB (≥16mm) at these locations were mainly observed in patients with 
pre- or postoperative AF. The extensiveness of and regional differences in CD and CB 
varied considerably between patients. Hence, it is likely that the length of lines of CB, 
rather than just the presence of CB, plays an important role in the development of  AF. 
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Abstract
Background: The presence of focal fibrillation waves during atrial fibrillation (AF) 
can, besides ectopic activity, also be explained by asynchronous activation of the atrial 
endo- and epicardial layer and transmurally propagating fibrillation waves. To provide 
direct proof of endo-epicardial asynchrony, we performed simultaneous high-resolution 
mapping of the right atrial endo- and epicardial wall during AF in humans.
Method and Results: Intraoperative mapping of the endo- and epicardial right atrial 
wall was performed during (induced) AF in 10 patients with AF (paroxysmal: n=3; 
persistent: n=4; and longstanding persistent: n=3) and 4 patients without a history of 
AF. A clamp made of 2 rectangular 8×16 electrode arrays (interelectrode distance 2 mm) 
was inserted into the incision in the right atrial appendage. Recordings of 10 seconds of 
AF were analyzed to determine the incidence of asynchronous endo-epicardial activation 
times (≥15 ms) of opposite electrodes. Asynchronous endo-epicardial activation ranged 
between 0.9 and 55.9% without preference for either side. Focal waves appeared equally 
frequent at endocardium and epicardium (11% versus 13%; P=0.18). Using strict 
criteria for breakthrough (presence of an opposite wave within 4 mm and ≤14 ms before 
the origin of the focal wave), the majority (65%) of all focal fibrillation waves could be 
attributed to endo-epicardial excitation.
Conclusions: We provided the first evidence for asynchronous activation of the endo-
epicardial wall during AF in humans. Endo-epicardial asynchrony may play a major 
role in the pathophysiology of AF and may offer an explanation why in some patients 
therapy fails. 
WHAT IS KNOWN
• Persistent atrial fibrillation is associated with a higher degree of longitudinal 
dissociation in conduction and frequent focal waves
• Ablative therapy for atrial fibrillation still often fails, especially in patients with 
persistent atrial fibrillation
WHAT THE STUDY ADDS
• During human atrial fibrillation considerable asynchrony in activation occurs 
between the endocardial and epicardial wall creating an opportunity for transmural 
conduction of fibrillation waves
• Fibrillation waves that conduct transmurally may create new breakthrough waves in 
the opposite layer
• Fibrillation waves traveling in three dimensions stabilizes the process of atrial 
fibrillation and may explain persistence of atrial fibrillation and unsuccessful ablative therapy
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Introduction
Epicardial high-density mapping in patients with atrial fibrillation (AF) and valvular 
heart disease has demonstrated that a considerable portion of fibrillation waves showed a 
focal spread of activation.1 These focal waves were rarely repetitive and mainly appeared 
as solitary events. They could occur virtually everywhere in the atria, and their coupling 
interval was often longer than the dominant AF cycle length. In addition, unipolar 
electrograms recorded at the origin of focal waves, exhibited small R-waves. Based on 
this indirect evidence, it was postulated that fibrillation waves with a focal pattern of 
activation could result from endo-epicardial breakthrough.1  Because endo-epicardial 
breakthroughs can only occur in the presence of electric asynchrony between the 
endo- and epicardial layer, we hypothesized that the substrate of AF consists of layers 
of dissociated fibrillation waves that constantly feed each other.1 To demonstrate that 
endo-epicardial asynchrony (EEA) exists during AF, we performed simultaneous high-
resolution, mapping of the endo- and epicardial wall of the right atrium in patients with 
or without a history of AF undergoing cardiac surgery for coronary artery disease and 
valvular heart disease.
Methods
Study Population
The study sample consisted of 14 patients (10 men; 67±8.3 years) without a history of 
AF (n=4) and with a history of AF (n=10). Surgical procedures that were performed 
included cardiac coronary bypass surgery (n=9), mitral valve surgery (n=7), aortic valve 
replacement (n=2), and tricuspid valve surgery (n=4). Three patients had paroxysmal AF, 
4 persistent AF, and 3 had persistent AF lasting longer than a year. Atrial enlargement 
was present in 5 patients. Clinical characteristics of the study population are provided in 
Table 1. The mapping protocol was approved by the institutional ethical
committee (MEC2010-054), and written informed consent was obtained from all 
patients before the surgical procedure. This study adhered to the declaration of Helsinki 
principles.
Intraoperative Mapping Procedure
The mapping study was performed immediately after sternotomy. After heparinization 
and arterial cannulation, a temporary bipolar epicardial pacemaker wire was stitched 
to the right atrial free wall and served as a temporal reference electrode. The indifferent 
electrode consisted of a steal wire fixed to subcutaneous tissue of the thoracic cavity.
If patients were in sinus rhythm at the onset of the mapping procedure, AF was induced by 
fixed rate pacing at the right atrial free wall using an additional temporary bipolar pacing 
wire. The induction protocol started at a rate of 200 beats per minute. If induction was 
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not successful after 3 burst attempts, the rate was increased by 50 beats per minute, up 
to maximal 400 beats per minute until AF occurred or atrial refractoriness was reached.
Before commencement to extracorporal circulation, a high-resolution endo-epicardial 
mapping clamp was introduced through the right atrial incision for the venous cannula 
and closed with a pursestring suture. The mapping device was positioned toward 
the crista terminalis and consisted of 2 identical rectangular electrode arrays of 8×16 
electrodes (interelectrode distance 2 mm) positioned opposite to each other (Figure 
1). The electrode arrays (GS Swiss PCB AG, Küssnacht, Switzerland) consist of an 
electroless nickel immersion gold–plated electrode array, mounted on a thin, flexible 
DuPont Pyralux copper-clad (25 μm thickness) polyimide laminate, and coverlay 
composite (25 μm) film (0.18 mm). As the space constant of the atrial myocardium 
is ≈2 mm, the effective spatial resolution of 2.0 mm makes it unlikely that narrow 
fibrillation wavefronts will not be detected.2
All recordings were amplified (gain 1000), filtered (bandwidth 0.5–400 Hz), sampled (1 
kHz), and analogue to digital converted (12 bits). A calibration signal of 2mV amplitude 
and 1000 ms pulse width was stored simultaneously with atrial electrograms on hard disk 
using a computerized mapping system. After completion of the mapping procedure, AF 
was terminated by electric cardioversion or sustained until cardioplegia was conducted, 
depending on the operators’ preference. Ten seconds of AF were recorded from every 
patient.
Mapping Data
Series of endo- and epicardial wavemaps of 10 seconds AF were reconstructed from 
the 2 sets of 128 unipolar fibrillation electrograms, using custom-made software that 
has been previously described in detail.1,3 For every electrode, local activation times 
were determined by marking the steepest negative deflection of the unipolar fibrillation 
electrograms. In case of a fractionated potential, the steepest negative deflection was 
chosen. At every electrode at either the endo- or epicardial layer, differences in endo-
epicardial activation times were determined by measuring the smallest time delay within 
the opposite square base of 3×3 electrodes (Figure 2).
The total amount of EEA during the entire recording period was expressed as the 
percentage of transmural differences of ≥15 ms for all endo- and epicardial recording 
sites. The combined asynchrony map (Figure 2, lower right panel) shows the longest 
time delay for every endo-epicardial electrode couple.
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Wavemapping was used to identify the individual fibrillation waves. The starting point 
of the first fibrillation waves was the earliest activated site within the mapping area. Next, 
the entire mapping area was scanned in steps of 1 ms. For all electrodes activated during 
every step, the shortest time difference with the 8 neighboring electrodes was calculated. 
When the time difference was ≤12 ms (17 ms for oblique distances), the electrode site 
was added to the territory of the surrounding wave. In case of a time difference of >12 
ms, the electrode was annotated as the starting point of a new wave. In the wavemap, 
fibrillation waves are color-coded according to their moment of entrance in the mapping 
area, and the colors demarcate the area activated by that specific fibrillation wave.4
Wavemaps also identify focal waves at either the endo- or the epicardial surface. 
Focal fibrillation waves had to meet previously defined criteria. The breakthrough 
site of the focal fibrillation wave had to be located at least 2 electrodes away from the 
border of the mapping array and at least 1 reliable activation time should be available 
between the breakthrough site and the border of the mapping area. The morphology 
of the electrograms in the breakthrough region should not be distorted by large QRS 
complexes or artifacts. If this is the case, the wave is excluded from the analysis. The focal 
wave should at least cover 4 electrodes. The origin of a focal wave had to be activated 
earlier than all surrounding electrodes. If electrodes adjacent to the origin were activated 
simultaneously, all electrodes surrounding this area should also be activated later. Shift 
Figure 1. 
Endo-epicardial mapping device and technique. The mapping device consists of 2 rectangular 8×16 electrode arrays 
with an interelectrode distance (IED) of 2 mm fixed to spatulas and positioned precisely opposite to each other. 
During epi-endocardial mapping the endocardial leg is inserted in the right atrium (RA) through the incision of the 
venous cannula and closed with a purse-string suture. The array is positioned toward the crista terminalis (CT). VCS/
VCI indicates vena cava superior/ inferior.
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Table 1. Clinical Characteristics
ID no. Age, y Sex History of AF Cardiac Surgery LVF Atrial Dimension
1 65 M No AF CABG Good Normal
2 56 M Persistent MVP+TVP Good Normal
3 82 M No AF CABG Good Normal
4 53 M Persistent CABG Poor RA enlargement
5 66 M Persistent MVP+AVR Moderate LA+RA enlargement
6 80 M Paroxysmal CABG+MVP Good Normal
7 63 F No AF CABG Good Normal
8 67 M No AF CABG Good Normal
9 75 F LSPAF MVP+TVP Good LA+RA enlargement
10 59 M Persistent CABG Moderate Normal
11 64 F LSPAF MVP+TVP Good LA enlargement
12 64 M Paroxysmal CABG+AVR Good Normal
13 70 F LSPAF MVP+TVP Good LA+RA enlargement
14 71 M Paroxysmal CABG+MVP Moderate Normal
AF indicates atrial fibrillation; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; F, female; LA, 
left atrial; LSPAF, longstanding persistent atrial fibrillation; LVF, left ventricular function; M, male; MVP mitral valve 
plasty; RA, right atrial; and TVP, tricuspid valve plasty.
of the local activation time to a maximum of 3 ms earlier or later at the earliest activated 
electrode(s) should not result in disappearance of the focal wave. If a breakthrough site 
emerged along the border of another fibrillation wave, the time delay between that wave 
and the origin of the breakthrough had to be at least 40 ms.1 All these criteria were 
checked manually by 2 independent investigators. A more detailed description of the 
mapping criteria with examples is provided in the Data Supplement.
To assess whether focal fibrillation waves could originate from endo-epicardial 
breakthrough, in each case, the opposite layer was examined for the presence of a 
fibrillation wave that could have served as a source for the focal wave. The presence 
of an opposite wavefront, within 4-mm distance and <15 ms before the origin of the 
focal wave, was considered to reflect transmural conduction based on normal atrial 
conduction properties. In this case, the focal wave could from a theoretically point of 
view be attributed to endo-epicardial breakthrough.
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Statistical Analysis
The Wilcoxon signed-rank test was performed to assess the occurrence of EEA and focal 
waves between the epi- and the endocardium.
Results
Endo-Epicardial Asynchrony
In the entire study population, the average percentage of miss-ing data caused by poor 
contact of the mapping array was 7.8±4.9%. The amount of conduction block was similar 
in the epicardial and endocardial plane with incidences of, respectively, 10.8±5.1% and 
10.8±4.6%. Simultaneous epi- and endo-cardial wavemaps of a single AF cycle recorded 
in a patient with longstanding persistent AF demonstrating EEA are shown in Figure 
3. In this example, marked differences in activation patterns of the endo- and epicardial 
wall existed; almost all fibrillation waves at the endo- and epicardial surface appeared at 
different times and propagated in different directions.
Figure 2. 
Construction of activation, wave, and asynchrony maps. Activation times determined at each individual electrode of 
endo-cardial and epicardial arrays are depicted in color-coded activation maps starting at the time of first activation. 
Wavemaps are automatically constructed, which demonstrate the number and sequence of appearance of different wa-
ves activating the mapping area and also illustrate the origin of focal waves beginning within the mapping area (white 
star). Isochrones are set with intervals of 5 ms and indicate the main trajectory of each wave (black/white arrows). 
Thick black lines indicate conduction block ( >12 ms). The asynchrony map of either the endo- or epicardial layer 
consists of the endo-epicardial activation times (AT) defined by the smallest interval of the opposite 9 activation times; 
the total asynchrony map shows the longest time delay assessed at every coupled recording site.
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In this same patient, the spatio-temporal variation in EEA during 10 seconds of AF is 
demonstrated in Figure 4. The degree of EEA varied considerably at different locations 
and at different times. No clear predominance of either the endocardial or the epicardial 
layer was observed. Examples of unipolar electrogram pairs around the plots illustrate 
the high spatio-temporal variation in EEA.
As demonstrated in Figure 5, the total degree of EEA in our study population varied 
widely between 0.9% and 55.9%, and there was no clear difference between endo-
epicardial and epi-endocardial asynchrony (7.8±7.7% and 7.2±7.2%, respectively).
Figure 3. 
Endo-epicardial asynchrony (EEA) in a patient with longstanding persistent atrial fibrillation (AF). The maps represent 
a single AF cycle of 190 ms. Left and right, Simultaneous wave-maps of the subepicardium and subendocardium of a 
part of the free wall of the right atrium (3.0×1.4 cm). The colors indicate the sequence of appearance of the different 
fibrillation waves (rainbow scheme followed by a grayscale). The arrows indicate the main trajectories of the waves. 
The subepicardium of the right atrium was activated by 7 narrow fibrillation waves, enter-ing the mapping area from 
various directions. The endocardium was activated by 9 waves, 3 of them arising as focal waves in the middle of the 
mapping area (white stars). The local endo-epicardial time-differences are plotted in the central map. As a result of the 
different activation patterns at the endo- and epicardial surface, major differences in endo-epicardial activation times 
existed (up to >50 ms). There was considerable spatial dispersion in EEA, with differences in endo- and epicardial acti-
vation times ranging from 0 to >50 ms. The 3 electrogram pairs at the bot-tom clearly show the marked differences in 
endo- and epicardial activation times. Sometimes the epicardium was activated earlier (left), sometimes the endocardi-
um (middle and right).
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Figure 4. 
Spatial and temporal variation in endo-epicardial asynchrony during longstanding persistent atrial fibrillation (AF) 
Endo-epicardial asynchrony (EEA) plots of 10 s of AF, recorded at 3 different locations of the right atrial free wall in a 
patient with AF. The dashed horizontal lines demarcate the band of endo-epicardial synchrony; data points >±50ms are 
clipped. At different sites the degree of EEA (delay ≥15 ms) varied from 5% (top), 31% (middle), and 50% (bottom). 
In addition to spatial dispersion, EEA also showed a strong temporal variation. As can be seen from the middle and 
lower plots, differences in endoepicardial activation time seemed to occur randomly, without a clear predominance 
of either the subendo-cardial or subepicardial layer. Examples of pairs of unipolar endo- and epicardial electrograms 
demonstrating the spatial temporal variation are given around the plots.
Chapter 9
156
Figure 5. 
Endo-epicardial asynchrony (EEA) levels and focal waves. A, Graph demonstrating the total amount of EEA plotted for 
every patient separately; patients are ranked according to the degree of EEA. Type of atrial fibrillation (AF; none, pa-
roxysmal AF [PAF], persistent [PsAF], and longstanding persistent [LSPAF]) is illustrated by the different colors. B and 
C, Dot plots and medians of (B) the incidence of asynchrony where endocardium vs epicardium is activated earlier in 
respect to the other and (C) the percentage of focal waves (of total number of waves) recorded at the endocardium and 
epicardium. For both parameters, there was no difference between the endocardial and the epicardial layers (P=0.51 
and P=0.18).
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Figure 6. 
Three examples of endo-epicardial breakthroughs in a patient with longstanding persistent atrial fibrillation (AF). A, 
A focal wave appeared at the epicardial surface at t=24 (white star). As can be seen from the associated endocardial 
wavemap, just a couple of milliseconds before an endocardial fibrillation wave (red) had passed that site at t=16 ms. 
A transmural conduction time of only 8 ms was taken as supportive evidence that the focal wave could be caused by 
endo-epicardial breakthrough. B, An example of a focal wave arising at the endocardium at t=46. Again a fibrillation 
wave in the opposed layer (green) had passed that site just 5 ms before (at t=41). C, Two breakthroughs occurred at 
about the same time, one at the endocardium at t=66 and another at the epicardium at t=73 ms. In both cases, in the 
opposite layer a fibrillation wave passing the site of origin of the focal waves a few milliseconds earlier at, respectively, 
t=64 and t=69, indicating that the focal waves could result from endo-epicardial breakthrough.
Focal Fibrillation Waves
In total, 1199 focal fibrillation waves were observed: 579 arising at the subendocardium 
and 620 at the subepicardium. The equal distribution of focal fibrillation waves between 
both sides is shown in Figure 5C. Applying the previously stated strict criteria for endo-
epicardial breakthrough, 784 of all 1199 focal waves (65%) could be attributed to result 
from endo-epicardial excitation presuming that normal conduction occurs between 
endo-epicardium (66% of the endocardial and 65% of the epicardial focal waves; Table 
2). Examples of pairs of endo-epicardial wavemaps showing focal fibrillation waves 
originating from endo-epicardial breakthrough of fibrillation waves from the opposite 
layer are given in Figure 6.
Discussion
Despite the relatively small number of patients, our data clearly show that a significant 
degree of EEA is present in the right atrium in patients with AF. Simultaneous endo-
epicardial mapping of isolated canine atria, both during sinus rhythm and atrial 
pacing, only showed small differences in activation times (<1 ms). However, during 
atrial tachyarrhythmias, activation of the endo- and epicardial layers has been shown 
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Table 2. Endo-Epicardial Asynchrony and Focal Waves
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to become more asynchronous (≤25 ms), particularly in the thicker parts of the atria.5,6 
In isolated fibrillating sheep atria, breakthrough sites seemed to be related to subendo-
cardial muscle structures, the 3-dimensional structure of the atria determining the 
appearance of focal waves during AF.7 The concept that endo-epicardial dissociation 
might play an important role in the maintenance of AF stems from experimental studies 
in the goat model of persistent AF.8–10 These studies showed that the endo- and epicardial 
layers of the atrial wall became progressively dissociated during the first 6 months of AF. 
After that time, fibrillation waves in the endo-and epicardial layers often propagated at 
different speed and in different directions, and endo-epicardial breakthroughs became 
more abundant.8,9
In this study, the incidence of EEA tended to be higher in patients with AF although 
we did not observe a clear rela-tion between duration of AF and degree of EEA. This 
can be explained by the fact that we did not map the left atrium and that if EEA of the 
left atrial wall also exists, it may play a more important role in the pathophysiology of 
AF. Also, our study population contained a small number of patients with a variety of 
cardiac diseases.
We provided additional data that most focal fibrillation waves could be explained by 
endo-epicardial excitation. Lee et al11 also frequently observed focal fibrillation waves 
without any sustained focal activity in 18 patients with persistent AF. In contrast, low-
density mapping studies using a 64-pole basket catheter, have suggested that AF is 
maintained by a limited number of rapid stable sources (rotors and/or ectopic foci).12,13 
Body surface mapping during AF elucidated the presence of nonsustained reentries and 
focal breakthroughs in certain domains of the atria.14 Recently, we have discussed the 
discrepancies in the interpretation of high- and low-resolution mapping of AF in detail 
in a crosstalk articles.15,16
The present study supports the concept that during AF, the endo- and epicardial layers 
of the atrial wall can be asynchronously activated.1,16 The presence of dissociated layers 
of fibrillation waves will highly stabilize the fibrillatory process because as soon as 
fibrillation waves die out, they can be replaced by breakthroughs from the opposite side.
In such a substrate, each layer will serve as a multisite generator for the other layer. 
During 10 seconds of AF, >20 to 30 focal waves appeared at each side of the atrial 
wall, in an area of only 2.6 cm.1 Extrapolating this number to the entire atrial surface, 
the total number of focal breakthrough waves can be estimated to exceed 10.000 per 
minute. However, we like to emphasize that the presence of EEA, of course, does not 
disprove that also reentry and focal activity may contribute to the maintenance of AF. 
In different stages of the development of a substrate of AF, the contribution of different 
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mechanisms for perpetuation of AF may vary. We fully acknowledge the large body 
of evidence that reentrant and focal mechanisms are operative during AF.17–20 In fact, 
not all focal fibrillation waves in our patients could be attributed to endo-epicardial 
breakthrough, and sometimes 2 focal waves appeared simultaneously at the endo- and 
epicardial surface. Equally, our data do not rule out the possibility that some of the 
endoepicardial breakthroughs formed a part of a transmural reentrant circuit. However, 
we venture to suggest that progressive, AF-induced, structural atrial remodeling gradually 
transforms the atrial wall into multiple layers of narrow dissociated wavelets. With time, 
more and more focal breakthroughs will be generated, which progressively stabilizes the 
fibrillatory process. At the end, the main source of fibrillation waves is formed by an 
abundant number of focal breakthroughs, occurring virtually everywhere in the atria. 
This is in agreement with the recent finding of Haissaguerre et al14 that the number of 
driver regions increased with the duration of AF, until after 6 months almost the entire 
atrial wall acted as a driver (6 of all 7 regions). It also explains why the termination rate 
of AF by driver ablation sharply declined after 6 months of AF.14
Limitations
Our study population is presently limited to 14 patients and a larger number of patients 
is obviously required for a meaningful statistical analysis and to study the relation 
between persistence of AF and the degree of electric asynchrony. Expanding the study 
population will also allow for statements about a possible correlation between EEA and 
breakthroughs. Moreover, the effective spatial resolution of the recordings is dependent 
on the number of electrodes with good tissue contact. Another limitation is, that to date, 
only a limited part of the atria has been accessible for endo-epicardial mapping (4.2 cm2 
of the right atrium). To get a full understanding of the role of EEA in the development 
of the substrate of AF, endo-epicardial mapping of the left atrium is needed as well. 
However, the left atrium is not standardly opened during cardiac surgery, only during 
selected procedures. In addition, opening the left atrium before cardiopulmonary bypass 
is associated with a considerable increase in the risk for air embolism, which may cause 
brain injury. Therefore, we decided that it was not ethically responsible to perform 
endo-epicardial mapping of the left atrium for this pilot study.
Clinical Implications
Knowledge of the substrate and various mechanisms of perpetuation of human AF is of 
great importance to understand the natural history of AF. At different stages, the substrate 
of AF may require different treatment modalities. At an early stage, pulmonary vein 
isolation alone might be sufficient, whereas in a later stage, also compartmentalization 
of the atria will be necessary to restore sinus rhythm. Furthermore, when the endoand 
epicardial layers of the atria have become electrically dissociated, even extensive ablative 
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therapies may be ineffective and palliative therapy would be a better option. Knowledge 
of the vulnerable parameter(s) for perpetuation of AF, and the ability to diagnose the 
stage of development of the substrate of AF, is essential for an individualized and staged 
therapy of AF.
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SUPPLEMENTAL MATERIAL
Mapping Criteria
Step I. Subtraction of ventricular complexes
Before determination of the local activation time, ventricular complexes were eliminated 
from the unipolar electrograms using a subtracting technique as previously described in 
detail by Hoekstra et al.1 In short, for each fibrillation electrogram an individual template 
of the ventricular far field was obtained by averaging all time windows of ±70ms around 
the R-waves detected from surface ECG lead I. Subtraction of these individual QRS 
templates from the fibrillation electrograms reduces the ventricular far field potentials 
and results in a more or less ‘clean’ unipolar atrial fibrillation electrograms.
Step II. Determination of the local activation time
Examples of electrograms recorded from both the endo- and epicardium and endo-
epicardial (a)synchrony are demonstrated in Figures 1 and 2.
Local activation times were determined by detecting the maximum downslope of the 
unipolar fibrillation potential, as this coincides with the moment of maximum rate of 
rise of the transmembrane potential (time differences less than 50 μs).2 In turn, the 
maximum rate of rise of the transmembrane potential corresponds with the maximum 
increase in sodium current and its conductance.3 The height of the negative slope is 
measured during a 2 ms period. From the moment of the maximum downslope, time 
windows both backward and forward in time are scanned to detect the moment of 
respectively the positive and negative peak of the fibrillation potential. The duration of a 
non-fractionated potential is then defined as the time difference between the moment of 
its negative and positive peak. In case of a fractionated potential, the deflection with the 
steepest down slope was chosen; its duration is defined as the time between the preceding 
positive and following negative deflection.4 The duration of a fibrillation potential had 
to be ≤35ms. The negative slope and amplitude of the unipolar fibrillation potentials 
depend on numerous variables.5,6 Hence, cut-off values applied also vary, depending on 
the signal-to-noise ratios of the recordings and lower limits were set at 0.05 V/sec and 
0.2 mV.5,6,7,8 All fibrillation potentials with slopes <0.05V/sec, amplitudes < 0.2mV and 
durations >35 ms are thus regarded as either far field or poor contact potentials.
After detection of the local activation time, a blanking period of 40 ms was applied 
in both directions. Though we do not know exactly what the refractory period during 
AF is, it is estimated to be approximately 50±13ms.9 Hence, comparable to previous 
studies, by choosing a blanking period of 40ms we avoid overestimation of the number 
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of fibrillation waves by marking fibrillation potentials, which are most likely double 
potentials with interspike intervals between >0 and ≤40ms caused by areas of conduction 
block.10,11
Step III. WaveMapping
A wavemapping approach was used to identify individual fibrillation waves. This 
wavemapping technique has also been described in prior studies.2,3,12,13 The starting point 
of the first fibrillation waves was the earliest activated site within the mapping area. Next, 
the entire mapping area was scanned in steps of 1ms. For all electrodes activated during 
every step, the shortest time difference with the 8 neighboring electrodes was calculated. 
When the time difference was ≤12ms (17ms for oblique distances), the electrode site 
was added to the territory of the surrounding wave. In case of a time difference >12 
ms, the electrode was annotated as the starting point of a new wave. In the wavemap, 
fibrillation waves are color-coded according to their moment of entrance in the mapping 
area and the colors demarcate the area activated by that specific fibrillation wave. The 
cut-off value of >12ms used for separating individual fibrillation waves corresponds for 
2 mm inter-electrode distances with an effective conduction velocity of 17 cm/s, which 
is equivalent to the continuous conduction velocities reported for atrial myocardium 
of intact hearts.14 For separation of the fibrillation waves the requirement of a lower 
limit CV must be fulfilled along the whole boundary of the wave which off course does 
not exclude the possibility of slow conduction within parts of the fibrillation waves. 
Choosing a different cut-off value will lead to a lower or higher number of fibrillation 
waves. However, this change is very gradual and has no major effects on the measured 
differences in the number of focal waves. Only at extreme cut-off values our analysis will 
become useless because it either no longer separates the different fibrillation waves, or 
results in a very high degree of spatial fractionation, resembling a mosaic-like pattern of 
numerous small waves that only propagate over very short distances. Based on the origin 
of the fibrillation wave, three different types of fibrillation waves were distinguished 
1) peripheral waves, entering the mapping area from outside the electrode array, 2) 
epicardial breakthrough, appearing at the epicardial surface inside the mapping area, and 
3) discontinuous conduction waves; defined as fibrillation waves starting with a delay of 
13 to 40ms from the boundary of another wave. If a fibrillation wave originates along 
the border of another fibrillation wave it could theoretically be the result of very slow 
conduction. In order to avoid overestimation of the number of focal waves, we classified 
these waves as discontinuous fibrillation waves. Applications of this wavemapping 
technology have been described previously.
Focal fibrillation waves had to meet several criteria. The breakthrough site of the focal 
fibrillation wave had to be located at least 2 electrodes away from the border of the 
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mapping array and at least 1 reliable activation time should be available between the 
breakthrough site and the border of the mapping area in order to exclude propagation 
from the border of the mapping array. An example is given in Figure 3. The relation 
between the percentage of endocardial or epicardial focal fibrillation waves and the 
distance from the origin of the focal wave to the border of the mapping array is shown in 
Table 1. Next, it is manually checked whether the morphology of fibrillation potentials 
in the breakthrough region is distorted by large QRS complexes or artifacts due to e.g. 
movements of the electrodes in order to avoid false positive focal waves; examples are 
shown in Figure 4.
In case of a fractionated electrogram, marking of one of the other deflections should 
not result in disappearance of the focal fibrillation wave (Figure 5). In order to include 
only focal waves which have a more or less considerable impact on endo-epicardial 
asynchrony, we choose cut-off value of 4 electrodes. Table 2 shows how many focal 
waves will disappear when a cut-off value of 5 or 6 electrodes would have been chosen. 
The origin of a focal wave had to be activated earlier than all surrounding electrodes. 
If electrodes adjacent to the origin were activated simultaneously, all electrodes 
surrounding this area should also be activated later. Shift of the local activation time to 
a maximum of 3ms earlier or later at the earliest activated electrode(s) should not result 
in disappearance of the focal wave. Typical examples of focal waves resulting from these 
criteria are provided in Figure 6.
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Row distance to border Endocardial focal waves Epicardial focal waves
2 25% 25%
3 37% 36%
4 38% 39%
Figure 1. 
The total set of endo- and epicardial electrograms of two patients.
The position of the electrode numbers in the arrays is illustrated below. The green colored segments in the electrogram 
tracings indicate the ventricular far field complexes. The superimposed black traces are the signals after application of 
the ventricular far field subtracting technique as described above. The yellow bands in the marked electrogram figures 
depict the time window in which the electrodes are activated in that AF beat.
Epicardium Endocardium
Table 2. Size of the focal waves. 
 Endocardial focal waves Epicardial focal waves 
4 electrodes 5.0% 5.6% 
5 electrodes 4.5% 5.2% 
6 electrodes 3.8% 4.6% 
 
 
 
Tables
Table 1. Location of the origin of focal fibrillation waves.
Table 2. Size of the focal waves.
Figures
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Patient 5 – Epicardial Electrograms
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Patient 5 – Endocardial Electrograms
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Magnified Epicardial Electrograms
Magnified Endocardial Electrograms
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Patient 5 – Marked Epicardial Electrograms
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Patient 5 – Marked Endocardial Electrograms
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Patient 14 – Epicardial Electrograms
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Patient 14 – Endocardial Electrograms
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Patient 14 – Magnified Epicardial Electrograms
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Patient 14 – Magnified Endocardial Electrograms
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Patient 14 – Marked Epicardial Electrograms
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Patient 14 – Marked Endocardial Electrograms
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Figure  2. 
Examples  of  two  opposite  electrogram  recordings  showing  synchronous  and asynchronous activation.
Figure  3. 
Focal wave originating near the border of the mapping array.
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Figure  4. 
Distortion of the morphology of an atrial fibrillation potential by a far field QRS complex.
Figure  5. 
Fractionated potential next to the origin of a ‘focal’ wave.
Figure  6. 
Wavemaps demonstrating typical examples of focal fibrillation waves.
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Abstract
Introduction: Knowledge of the mechanism underlying post-operative atrial fibrillation 
(PoAF) is essential for development of preventive measures. The incidence and 
characteristics of both PoAF and supraventricular premature beats triggering PoAF, their 
interrelationship and alterations over time have never been examined. The goal of this 
study is therefore to examine the correlation between the incidence and characteristics 
of supraventricular premature beats (SVPBs) and PoAF episodes in patients undergoing 
CABG in the first five post-operative days.
Methods: PoAF episodes (N=327) and SVPBs (N=141,873) were characterized in 29 
patients (63±9 years; 22 (76%) male) undergoing coronary artery bypass grafting and 
compared with a control group of patients without PoAF by using continuous cardiac 
rhythm monitoring during the first 5 days after surgery.
Results: Most patients (N=18, 62%) had multiple PoAF episodes; the median number 
of PoAF episodes per patient was 3 and varied between 1 and 139. The majority of PoAF 
episodes developed on the second and third post-operative day (55%). The averaged 
median duration of PoAF episodes per patient was 469±1085min. Patients with PoAF 
had a higher SVPBs burden compared to subjects without PoAF (0.9% versus 0.2%, P 
< 0.001). SVPBs initiating PoAF had 
shorter coupling intervals than SVPBs which did not initiate PoAF episodes (58% versus 
64% (P < 0.001) and were preceded by heart rate acceleration.
Conclusion: PoAF episodes are mainly repetitive though transient in nature. There was 
a considerable inter-individual variation in both AF and SVPB characteristics, despite 
a similar underlying clinical profile. The SVPB burden is higher in patients with PoAF 
and the mode of onset is characterized by short coupled SVPBs. Determination of 
individual post-operative dysrhythmia profiles enables identification of patients at risk 
for developing PoAF.
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Introduction
Post-operative atrial fibrillation (PoAF) is a common complication after coronary artery 
bypass surgery (CABG), which is associated with prolonged hospitalization, increased 
morbidity (e.g. stroke) and even mortality.1-4 Supraventricular ectopy (SVE) is a well-
known trigger of atrial fibrillation (AF), mainly originating from the pulmonary vein 
region.5 Recent studies have demonstrated that frequent supraventricular premature 
beats (SVPBs, ≥100 SVPBs/day) identified by 24-hour Holter monitoring are predictors 
of de novo AF in the general population.6-8 This trigger burden is higher in patients 
with paroxysmal AF (PAF) compared to subjects without AF. SVPBs initiating PAF 
have shorter coupling intervals as they occur closer to the refractory period and thus are 
more likely to induce AF.9 Triggering of AF by SVPBs in the early post-operative phase 
has been described after CABG yet description of characteristics of PoAF episodes are 
scarce. Steinberg et al.10 demonstrated that the P-wave duration determined with signal-
averaged electrocardiograms is an independent predictor of PoAF. They also examined 
the occurrence of PoAF episodes in the individual patient by using continuous rhythm 
monitorings and found that 25% of the 130 patients had on the second or third post-
operative AF episodes with a mean duration of 2.3±2.4 days.10 In 64 patients undergoing 
CABG, the relation between heart rhythm variability and onset of PoAF lasting more 
than one hour was examined.11  In this patient group, onset of AF was preceded by loss 
of vagal tone and a moderate increase in sympathetic tone. At present, there is no data 
available on characteristics of PoAF in patients undergoing CABG without a history 
of AF prior to cardiac surgery and the interrelationship with SVE. Also, alterations of 
PoAF over time in the individual patient are not known. Knowledge of development of 
PoAF is essential as it may aid in designing (preventive) therapy strategies. 
The goal of this study is therefore to examine 1) the correlation between the incidence 
of SVPBs and PoAF, 2) characteristics of PoAF episodes, 3) characteristics of SVPBs 
triggering PoAF in patients without a history of AF undergoing CABG in the first five 
post-operative days by continuous cardiac rhythm monitoring.
Methods
Study Population
The study population was derived from a cohort of 105 consecutive patients with 
coronary artery disease without a history of documented AF undergoing elective 
CABG and were subdivided into a PoAF group and a control group. The PoAF group 
consisted of 29 patients with de novo PoAF whereas the control group consisted of 29 
age-matched subjects without PoAF. Clinical data were obtained from electronic patient 
files. This observational study is part of the RotterdAm RhythM MOnitoring PRoject 
and is approved by the medical ethical committee (AMOR, MEC 2012-481). Written 
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informed consent was not required, as our local medical ethical committee decided that 
the Medical Research Involving Human Subjects Act does not apply for this project.
Post-Operative Continuous Cardiac Rhythm Registrations 
Post-operative cardiac rhythms were recorded by bedside monitors (Draeger InfinityTM) 
during the first five days after CABG. Data were stored on hard disk in compressed-files, 
collected using a custom-made program (TapeRec), with sampling rate of 200 samples 
per second. These cardiac rhythm recordings were analysed in multichannel Holter 
scanning software (SynescopeTM, Sorin Group©) which imports only International 
Society for Holter and Noninvasive Electrocardiology (ISHNE) files (a standard Holter 
output file format). All registrations were therefore converted into this format.12 Finally, 
the output of the analysed cardiac rhythm registrations were exported from SynescopeTM 
as ASCII files and imported into Excel 2010.
Characterization of PoAF
PoAF was defined as a series of supraventricular beats with irregular R-R intervals in the 
absence of distinct P-waves, sustaining for ≥30 seconds. The duration of every single AF 
episode was quantified manually and used to determine the PoAF burden per patient, 
which was defined as the sum of the durations of all AF episodes divided by the total 
recording time per individual patient. The SVPB burden was determined by calculating 
the ratio of the sum of all SVPBs divided by the total number of QRS complexes; 
SVPBs initiating PoAF were excluded from this analysis. Of every SVPB initiating an 
AF episode, the prematurity index (PI) was calculated by dividing the coupling interval 
of the SVPB by the average cycle length of the two preceding beats. The SVPBs PI 
initiating PoAF were compared with all other not initiating SVPBs PI in the patients 
with PoAF.
Statistical Analyses
All data are tested for normality. Continuous normally distributed variables are depicted 
as mean±SD (range) and skewed variables as median (interquartile range). In the PoAF 
group, the PI of SVPBs initiating PoAF were compared with the PI of SVPBs not 
initiating PoAF by the Wilcoxon signed rank test for dependent variables. Independent 
Student’s T-tests were used to compare the SVPB burden in patients with and without 
PoAF. The chi-square test was used to determine on which postoperative day the longest 
PoAF episodes occurred. A P-value of <0.05 was considered statistically significant. 
Analyses were performed in IBM SPSS Statistics version 21.
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Results
Study Population
Baseline characteristics of both the PoAF group (N = 29, 63±9 years; 22 (76%) male) 
and control group (N = 29, 68±9 years; 24 (83%) male) are depicted in Table 1. Clinical 
characteristics between the PoAF group and control group only differed in the incidence 
of mildly impaired left ventricular function (N = 8 (28%) versus N = 2 (7%); P = 0.037) 
and the number of affected coronary arteries. Patients in the PoAF group had more 
often three-vessel coronary artery disease combined with severe stenosis of the left main 
artery than patients in the control group (N = 4 (14%) versus N = 0 (0%); P = 0.038).
Table 1 Patient CharacteristicsTable 1 Patient Characteristics 
 No PoAF (N = 29) PoAF (N = 29) P-Value 
Age (years) 68±9 63±9 0.069 
Male gender, N (%) 24 (83) 22 (76) 0.517 
BSA (mean ± SD) 
BMI (kg/m2; mean ± SD) 
2.0±0.2 (1.6 – 2.4) 
28±3 (20 – 36) 
2.0±0.2 (1.7 – 2.8) 
28±4 (21 – 36) 
0.887 
0.896 
Risk Factors, N (%) 
- Hypertension 
- Diabetes Mellitus 
- Hyperlipidaemia 
- Peripheral arterial disease 
- Thyroid disorders 
 
18 (62) 
11 (38) 
14 (48) 
4 (14) 
1 (3) 
 
17 (59) 
8 (28) 
15 (52) 
4 (14) 
3 (10) 
 
0.788 
0.401 
0.793 
- 
0.300 
Preoperative Drug, N (%) 
- Anti-arrhythmic drugs 
  - Class II 
  - Class III 
- Anti-platelets 
- Anti-coagulants 
- ACE-inhibitors/AG-II 
- Statins 
 
24 (83) 
24 (83) 
1 (3) 
28 (96) 
2 (7) 
20 (69) 
24 (83) 
 
25 (86) 
25 (86) 
0 
26 (90) 
2 (7) 
20 (69) 
23 (79) 
 
0.717 
0.717 
- 
0.300 
- 
- 
0.738 
Left Ventricular Function, N (%) 
- Normal (EF >55%) 
- Mild impairment (EF 46-55%) 
- Moderate impairment (EF 36-45%) 
- Severe impairment (EF<35%) 
 
24 (83) 
2 (7) 
2 (7) 
1 (3) 
 
20 (69) 
8 (28) 
1 (3) 
0 
 
0.220 
0.037** 
0.553 
- 
Left atrial dilatation*, N (%) 7 (24) 5 (17) 0.517 
Coronary Angiography, N (%) 
1-vessel disease 
2- vessel disease 
3- vessel disease 
Left main + 1-vessel disease 
Left main + 2-vessel disease 
Left main + 3-vessel disease 
 
1 (3) 
6 (20) 
17 (59) 
1 (3) 
4 (14) 
0 
 
1 (3) 
4 (14) 
17 (59) 
0 
3 (10) 
4 (14) 
 
- 
0.487 
- 
- 
0.687 
- 
BMI = Body Mass Index; PoAF = postoperative atrial fibrillation; EF = ejection fraction; *left atrial 
dilatation >45mm 
**Significant at level P < 0.05. 
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Characteristics of Post-Operative Atrial Fibrillation
In 29 patients, 327 episodes of PoAF were identified. All PoAF characteristics for every 
patient separately are summarized in Table 2. The relative frequency histogram of the 
duration of all 327 PoAF episodes is shown in Figure 1. The median duration of the PoAF 
episodes was 3.0 (1.3 – 12.2) minutes. The majority of the PoAF episodes terminated 
within 5 minutes (N = 204, 63%). Twenty-five percent (N = 83) lasted between five and 
60 minutes. Thirty-six (11%) PoAF episodes had a duration of more than one hour but 
shorter than 24 hours; only four PoAF episodes lasted longer than one day (1%). 
 
Number of PoAF Episodes
The median number of PoAF episodes was 3 (1 – 5) per patient in the entire study 
population and varied from 1 to 139. The upper panel of Figure 2 illustrates the number 
of PoAF episodes in each individual patient. In the lower panel, patients are ranked by 
median duration of PoAF episodes; the median PoAF duration was 18 (3 – 72) minutes. 
Duration of PoAF episodes
The lower panel of Figure 2 shows the median duration of all PoAF episodes for each 
individual patient. As can be seen in Figure 2 and Table 2, there is not only a considerable 
inter-individual variation in the duration of PoAF episodes, but there is also a large 
intra-individual variation. 
The median PoAF episode duration of all patients ranged from 0.6 to 4865 minutes 
with an averaged median of 469±1085 minutes. There is no correlation between the 
number of AF episodes and its duration (ρs = 0.24; P = 0.21). 
Figure 1
Relative frequency distribution of the duration of every PoAF episode; the majority of the PoAF episodes lasted less 
than 5 minutes.
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Table 2. PoAF Characteristics of every PatientTable 2. PoAF Characteristics of very Patient 
Patient No. Episode(s) 
per patient (N) 
Duration (minutes), median 
(IQR) 
Burden (%), mean±SD 
20 1 0.6 0.008 
16 1 0.7 0,0 
13 4 1 (0.9 – 597) 0,0 
15 1 18 0,3 
3 1 90 0,3 
7 1 240 0,4 
21 2 10 (6 – 14) 0,4 
18 14 2.5 (1.6 – 5) 0,7 
1 3 16 (11 – 21) 0,9 
28 1 583 0,9 
6 1 716 1,1 
22 2 35 (18 – 51) 1,1 
27 1 1064 1,8 
25 4 10 (5 – 29) 2,0 
10 3 2 (1 – 268) 2,1 
19 4 381 (60 – 700) 2,3 
12 18 4 (2 – 13) 2,8 
29 3 393 (280 – 1123) 3,1 
24 1 3552 5,1 
17 46 2 (1 – 4) 6,2 
23 1 4865 7,1 
5 5 64 (18 – 439) 7,3 
2 139 2 (1 – 4) 9,4 
26 6 202 (51 – 334) 12,6 
8 3 168 (145 – 295) 13,6 
9 1 582 13,7 
11 12 48 (26 – 74) 15,3 
14 45 4 (1 – 16) 17,0 
4 3 548 (312 – 570) 20,1 
29 3 (IQR: 1 – 5) 469 ± 1085 
(range: 0.6 – 4865)* 
5 ± 6 
(range: 0.01 – 20.1%) 
*averaged median 
PoAF burden
The PoAF burden for each patient separately is illustrated in Figure 3; patients are ranked 
by an increase in PoAF burden. The average PoAF burden in the entire study group was 
5% and ranged from 0.01 to 20.1%. 
Figure 4 illustrates the time course of PoAF episodes during the first 5 post-operative 
days for every patient separately. Each dot represents a single PoAF episode and its size 
corresponds to the duration of the episode, as depicted in the legend. PoAF episodes 
lasting >60 minutes occur mainly on the second, third and the first hours of the fourth 
post-operative day as demonstrated in Table 3 (P < 0.001). Thereafter, PoAF episodes 
either disappear or diminish in duration. Also, the long-lasting episodes were not 
preceded by multiple short lasting episodes. 
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Characteristics of Supraventricular Premature Beats
The upper panel of Figure 5 illustrates the distribution of the SVPB burden in the PoAF 
group and control group. In the PoAF group, a total of 15,997,928 beats contained 
113,123 SVPBs, resulting in a SVPB burden of 0.71%. The SVPB burden per patient 
varied from 0.02% to 6.73% with a mean of 0.94±1.46%. In the control group, 28,750 
SVPBs of 17,451,028 beats resulted in a SVPB burden of 0.16%. The averaged SVPB 
burden per patient was 0.24±0.46 and ranged from 0 – 2.16%. Thus, patients with a 
higher number of SVPBs in the post-operative period are more prone to develop PoAF 
(P < 0.001). The averaged median number of SVPBs/hour in patients with PoAF was 
15±32 compared to 3±6 SVPBs/hour in the control group (P = 0.55).  
Within the PoAF group, the PI of SVPBs initiating PoAF were compared with the PI of 
SVPBs that did not initiate PoAF. The lower panel of Figure 5 illustrates the distribution 
of PI of 105,123 SVPBs which did not initiate PoAF and 319 SVPBs which did initiate 
PoAF. The median PI of all SVPBs initiating PoAF was 58 (48 – 64) % and ranged from 
Figure 2 Number of PoAF episodes for each individual patient, shown for patients with a PoAF duration ≤60 (left 
panel) or >60 minutes (right panel) separately. Patients are ranked by the median PoAF duration. See text for detailed 
explanation.
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15% to 105%, whereas the median PI of SVPBs which did not initiate AF was 64 (58 – 
69) % and ranged from 30% to 75%. Hence, the coupling interval of SVPBs initiating 
PoAF was significantly shorter (P < 0.001). However, as illustrated in the lower panel of 
Figure 5, there is large overlap between the SVPBs PI not initiating and initiating PoAF. 
The heart rate prior to every PoAF episodes was measured and showed a significant 
acceleration of the heart rate prior to the onset of PoAF episodes which were initiated 
by a SVPB PI ≤58% compared to PoAF episodes initiated by an SVPB with a PI >58%; 
cycle length 769ms (78 bpm) versus 675ms (89 bpm), P < 0.001 (Figure 6).
Clinical profile
In patients with PoAF antiarrhythmic drugs were administered (Class II: N = 25; Class 
III N = 6; digoxin: N = 9). Additional electrical cardioversion resulting in sinus rhythm 
was performed in 6 patients. In the patients without PoAF,  a beta-blocker was started on 
the second post-operative day in 23 patients and in 1 patient  a class III antiarrhythmic 
drug was resumed. In all patients, ACE-inhibitors and statins were resumed during the 
first postoperative day.
The postoperative period of the PoAF patients was complicated by rethoracotomy 
due to bleeding complications (N = 5), percutaneous coronary intervention 
(N = 2), pneumonia (N = 2) or pneumothorax (N = 1). In the control group, the 
Figure 3 Relative frequency distribution of the PoAF burden for every individual patient; patients
are ranked by the PoAF burden, varying between 0.01 and 20.1%.
Chapter 10
194
Table 3. Duration of postoperative atrial fibrillation
Figure 4 Timing and duration of all PoAF episodes during the first five post-operative days after CABG for every 
individual patient. A dot depicts a single PoAF episode and its size corresponds with the duration of that PoAF episode, 
as illustrated in the legend.
Table 3. Duration of postoperative atrial fibrillation 
 Postoperative day (no.)  
Category (min) 1 2 3 4 5 Total 
0 – 5  4 (2.0) 19 (9.3) 82 (40.2) 9 (4.4) 90 (44.1) 204 
5 – 10 0 4 (12.5) 12 (37.5) 5 (15.6) 11 (34.4) 32 
10 – 15  0 3 (15.8) 8 (42.1) 1 (5.3) 7 (36.8) 19 
15 – 20 0 4 (28.6) 8 (57.1) 2 (14.3) 0 14 
20 – 25 0 1 (16.7) 3 (50) 1 (16.7) 1 (16.7) 6 
25 – 30  0 1 (50.0) 0 1 (50.0) 0 2 
30 – 35 0 0 0 2 (100) 0 2 
35 – 40  0 1 (50.0) 1 (50.0) 0 0 2 
40 – 45  0 1 (33.3) 0 2 (66.7) 0 3 
45 – 50  0 0 0 0 0 0 
50 – 55  0 0 0 1 (100) 0 1 
55 – 60  0 1 (50.0) 1 (50.0) 0 0 2 
>60* 0 13 (32.5) 17 (42.5) 8 (20.0) 2 (5.0) 40 
Data are expressed as N (%). 
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postoperative period was complicated by pneumothorax (N = 1), rethoracotomy 
due to bleeding (N=1) and myocardial infarction without percutaneous intervention 
options (N = 1, P = 0.03). Patients with PoAF were hospitalized one day longer 
than the control group (6.1 versus 5.3, P = 0.045). There was no difference 
between mortality rates between PoAF (N = 2) and control group (N = 1, P = 0.55) 
Figure 5 Upper panel: relative frequency distribution of the SVPB burden in patients with and without PoAF. The 
SVPB burden in patients with PoAF (0.9%) is higher compared to patients without PoAF (0.2%; P < 0.001).
Lower panel: the relative frequency distribution of the SVPBs PI initiating and not initiating PoAF in patients with 
PoAF. SVPBs initiating PoAF have shorter median PI (58%) compared to SVPBs PI (64%) not initiating PoAF (P < 
0.001). PI = prematurity index, PoAF = post-operative atrial fibrillation, SVPB = supraventricular premature beat
Discussion
Key findings 
The present study demonstrated that most PoAF episodes were generally short-lasting 
and transient. PoAF episodes sustaining for more than 60 minutes occurred mainly 
on the second and third day after CABG. Despite similarities in clinical profiles and 
surgical procedures in our study population, there was not only a large variation in the 
number of PoAF episodes, but also in their duration. The SVPB burden in patients with 
PoAF was significantly higher compared to the SVPB burden in patients without PoAF. 
SVPBs initiating PoAF had a shorter PI compared to those that did not initiate PoAF.
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Clinical Relevance of De novo Post-operative AF
De novo early post-operative AF (EPoAF) is an important complication after CABG 
and is related with increased morbidity (e.g. stroke) and subsequently prolonged 
hospitalization and mortality.1-4, 13 Development of EPoAF is associated with a variety of 
clinical parameters 2, 4, 13, 14 (e.g. age, underlying heart disease) and intra-operative factors 
(e.g. duration of cardioplegic arrest, post-operative inflammation) that may modify 
Figure 6 Heart rate prior to PoAF episodes This graph demonstrates the relation between SVPB PI initiating PoAF 
and the heart rate prior to the onset every PoAF episode.
electrical properties of atrial tissue which make the atria more prone for development 
of AF. Previous studies have also demonstrated that de novo onset EPoAF after CABG 
predicts development of late post-operative AF (LPoAF), which in turn is associated with 
recurrent hospitalization, increased cardiovascular events and mortality.1, 15 Thus, even if 
EPoAF episodes are transient and short-lasting, patients with EPoAF should be closely 
monitored in the late post-operative period. However, as our cohort only contained 29 
patients with EPoAF, further studies are required in larger study populations to establish 
the relation between early and late PoAF. 
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In our study population, the averaged median duration of PoAF episodes was 469 
minutes, ranging from 0.6 to 4865 minutes but most PoAF episodes (62.4%) had a 
duration less than 5 minutes. In a cohort of patients with PAF without a history of prior 
cardiac surgery,  40% of paroxysmal AF episodes sustained between 30 seconds and 5 
minutes and only 7% lasted more than one hour.16  Hence, PoAF episodes observed in 
our study were not only transient, but they also had a shorter duration than AF episodes 
in non-surgical patients with PAF. 
The Relation between Supraventricular Premature Beats and PoAF
It is generally accepted that triggers, such as SVPB, can initiate AF. Several studies already 
demonstrated a relation between the incidence of SVPBs and onset of paroxysmal AF.16-
20 Brooks et al. demonstrated that the frequency of SVPBs in patients without AF (1 
(0 – 1) SVPB/hour) is lower than patients with paroxysmal (2 (1 – 22) SVPB/hour; P 
= 0.004) or persistent AF (3 (1 – 6) SVPB/hour; P = 0.04)20, which is comparable with 
our findings.
Data reporting on the relation between SVPBs and PoAF are scarce. SVPBs ≥10 in the 
24 hour prior to CABG was associated with PoAF.21 Another study demonstrated in 
patients undergoing off-pump CABG, that >47 SVPBs in the 24 hour prior to CABG 
was an independent predictor of PoAF.22 Studies regarding the relation between the 
incidence of SVPBs in the postoperative period and PoAF are scarce. Steinberg and 
colleagues10, demonstrated that the mean duration of de novo PoAF episodes in patients 
who had undergone CABG was 2.3±2.4 days, compared to a median duration of 18 
minutes in our study population. They included only PoAF episodes longer than 30 
minutes. Another study, investigating PoAF only included episodes lasting for at least 
one hour.11 We included all episodes lasting for at least 30 seconds in accordance with 
the guidelines13 and observed that most of the AF episodes were shorter than 1 hour (N 
= 295 versus N = 32). Thus, the shorter median duration of PoAF episodes found in 
our study is therefore a better reflection of the true duration of PoAF episodes.Similar 
to observations in the general population, the burden of SVPBs in patients with PoAF 
is higher compared to the SVPB burden in patients without PoAF. Hence, our findings 
emphasize the importance of SVPBs in initiation of PoAF. 
Initiation of Post-Operative Atrial Fibrillation
Endovascular programmed electrical stimulation in the right atrium demonstrated 
that atrial extra stimuli closer to the refractory period are more prone to induce AF.23 
Likewise, prior studies in the general population have shown that SVPBs initiating AF 
have shorter PIs than SVPBs not initiating AF.18, 24-26 
In 1965, Killip and Gault26 examined atrial endocardial electrograms and observed 
that SVPBs with a PI of 48% triggered early relapses of AF after elective electrical 
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cardioversion of AF. In patients with a history of myocardial infarction, coupling 
intervals of SVPBs inducing AF were shorter compared to coupling intervals of SVPBs 
not inducing AF (300±0.026ms versus 371±0.44ms; P < 0.001), but the prematurity 
index was not examined.24 In patients with lone paroxysmal AF, the mean PI of SVPBs 
initiating AF was 43% compared to 48% of SVPBs not initiating AF.25 
Sofar, only one study examined the SVPB PI at onset of PoAF in 14 patients after CABG 
by using recordings from temporary bipolar cardiac pacing wires.9 They concluded that 
SVPBs initiating PoAF originated from various atrial sites and were more premature 
compared to SVPBs not initiating AF (right atrium SVPBs PI: PI 66%; left atrium 
SVPBs PI: 64%). Jideus et al. demonstrated that the majority of PoAF episodes after 
CABG were initiated by SVPB.27 Likewise, we observed that all PoAF episodes started 
with a SVPB; SVPBs initiating PoAF had shorter PIs compared to SVPBs that did not 
initiate AF. In our study, SVPBs initiating PoAF are less premature (PI ≤58%) than any 
of the aforementioned studies, suggesting that patients with de novo PoAF after CABG 
are more vulnerable to develop AF in the presence of less shorter coupled SVPBs in 
comparison with patients with spontaneous AF persisting between 3 weeks and 1 year. 
Our data suggests that patients with a higher SVPB burden, especially SVPBs with 
a PI of ≤58% are more likely to induce PoAF. Yamane et al. demonstrated that after 
endovascular isolation of the pulmonary veins in patients with PAF, there was a decrease 
in the number of SVPBs and a prolongation of the SVPB coupling interval. Recurrences 
of AF were associate with higher incidences of SVPBs. Hence, SVPBS play an important 
role in the pathophysiology of PoAF and may they may be a target for preventive 
therapies.
The autonomic nervous system plays a role in the pathophysiology of AF.28 In this study, 
we did not assess heart rate variability, but we did examine heart rate acceleration prior 
to onset of PoAF.  Dimmer et al. showed an increase in the heart rate prior to PoAF 
onset in patients after CABG. In our study, we observed an acceleration of the heart 
rate prior to PoAF onset in patients with a SVPB PI lower than the median SVPB 
PI (58%) compared to SVPBs PI ≥58%. This suggests that both triggered activity 
(short coupled SVPBs) and increased sympathetic nervous system activity contribute 
to development of PoAF. In patients with a similar clinical profile, we observed a large 
variation in the characteristics of both post-operative SVPBs and PoAF. These large 
inter-individual variations can be explained by differences in the origin of SVE, SVPB 
coupling intervals and the extensiveness of the pre-existing arrhythmogenic substrate. 
Although the underlying heart disease in our study population is similar, it is likely that 
there are regional differences in the degree of structural remodeling due to e.g. aging or 
various comorbidities such as hypertension or diabetes. As at present we cannot “repair” 
the arrhythmogenic substrate, targeting SVPBs may remain the most effective treatment 
modality to prevent PoAF.13 
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Conclusion
PoAF in patients with coronary artery disease is characterized by a large inter-individual 
variation in the number of episodes and their duration. In addition, these characteristics 
varied over time. The SVPB burden in patients who developed PoAF was higher and 
SVPBs initiating PoAF had shorter coupling intervals. As PoAF is multi-factorial in 
nature, the large inter-individual variation in both trigger and substrate of PoAF as 
observed in our study population indicates the need for patient tailored therapy of PoAF.
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Abstract
Background: Early new-onset postoperative atrial fibrillation(PoAF) occurs frequently 
after coronary artery bypass grafting(CABG). In the general population, frequent 
supraventricular premature beats(SVPB) are associated with atrial fibrillation(AF). 
Whether SVPBs also play a role in development of PoAF is unknown. This study 
examines the frequency and burden of postoperative supraventricular ectopy (SVPBs, 
SV-couplets/runs) in patients with coronary artery disease and their relation with PoAF.  
Methods: In 105 patients (83male;66±9years) supraventricular ectopy and PoAF after 
CABG were identified and characterized using continuous rhythm monitoring during 
the first five postoperative days.
Results: SVPBs(N=173,251),  SV-couplets(N=11,799) and SV-runs(N=4,026) were 
identified. PoAF occurred in 28%(N=29) of the patients. Frequency and burden of 
all supraventricular ectopy were higher in patients with PoAF compared to patients 
without PoAF(P<0.001). PoAF was predicted by SVPBs ≥57/hour(OR 8.0) or ≥1196/
day(OR 7.0), SV-run ≥5/day(OR 6.6) and SV-run burden ≥0.2%(OR 11.7) corrected 
for clinical parameters.
Conclusion: Supraventricular ectopy occurred in the majority of patients after CABG 
whereas PoAF was detected in 28% of them. Independent risk-factors for development 
of AF after CABG were the frequency of SVPBs and the frequency and burden of SV-
runs. Hence, these parameters could be used to identify patients at risk for developing 
PoAF allowing preventive measures to be taken.
Supraventricular Ectopy Predicting PoAF
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Introduction
Coronary artery bypass graft surgery (CABG) is recommended in patients with multi-
vessel coronary artery disease.[1] The postoperative period can be complicated by 
dysrhythmias, particularly by new-onset postoperative atrial fibrillation (PoAF) in the first 
five days after surgery, mainly on the second postoperative day.[2] Severe complications 
like stroke (2-37%), heart failure (13-27%) and mortality (2.6-16%) are associated with 
early PoAF, resulting in prolonged hospitalization and increased health care costs.[2-
8] Despite improvements of surgical skills, anaesthesia and cardiopulmonary bypass 
techniques over time, the incidence of early PoAF remains unaltered 15-40%.[2, 3] 
Previous studies suggested that development of PoAF is an interplay between patients 
characteristics(e.g. advanced age, hypertension, diabetes), intraoperative (e.g. atrial 
ischemia, surgical atrial injury) and postoperative factors (e.g. hypotension), in addition 
to inflammation, oxidative stress, the presence of triggers and an arrhythmogenic 
substrate.[2, 5, 7] However, the exact mechanism underlying PoAF is still unknown. 
Paroxysms of AF are assumed to be trigger-driven atrial tachyarrhythmias; previous 
studies showed that supraventricular premature beats (SVPBs), originating from e.g. 
the pulmonary veins serve as triggers for AF.[9-14] In the general population, a high 
frequency of SVPBs (≥30/hour, >100/day) is associated with development of AF.[9, 
10, 14] A high frequency of SVPBs was also found in patients presenting with a stroke.
[11] Hence, the frequency of SVPBs may be used to predict development of AF.[9-11] 
Frost et al. demonstrated an increase in supraventricular ectopy in the 24 hours prior to 
development of PoAF or atrial flutter.
Up to date, there is no information on the relation between characteristics of 
supraventricular ectopic beats, including SVPBs, supraventricular couplets (SV-couplets) 
and – runs (SV-runs) and development of PoAF in patients with coronary artery disease.
The goal of this study is therefore to examine characteristics of SVEBs and their 
interrelationship in the development of PoAF in patients after CABG. 
Material and Methods
Study population
The study population consists of 105 patients undergoing CABG without previous 
reported AF. This observational study is a part of the Rotterdam Rhythm Monitoring 
Project (AMOR), which was approved by the institutional medical ethical committee 
(MEC 2012-481). Written informed consent was not required. Patients data were 
obtained from electronic patient’s files. 
Postoperative continuous rhythm registrations 
Postoperative rhythm registrations obtained from bedside Infinity® monitors (Draeger, 
Lubeck, Germany) were stored on hard disk as compromised compoz-files (cpz) using 
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a custom-made program (Taperec, Rotterdam, the Netherlands) with a sampling rate 
of 200Hz [15]. All recordings were analysed in multichannel Holter scanning software 
SynescopeTM (Sorin Group, Ela Medical, Clamart, France). In order to analyse continuous 
rhythm registrations in SynescopeTM, all recordings were converted into International 
Society for Holter and Noninvasive Electrocardiology (ISHNE)-files, a standard Holter 
output file format [16]. Conversion was performed by another custom-made program 
with preservation of characteristics of the original data. Only ISHNE-files containing 
24-hours data were compatible with SynescopeTM. ISHNE-files containing data of more 
than 24-hours were therefore split into smaller files each containing rhythm registrations 
for a maximum period of 24-hours. After finalizing analysis of rhythm registrations 
data were exported from SynescopeTM as ASCII-files and imported into Excel 2010 for 
further analysis. 
Classification and characterization of supraventricular dysrhythmia
Rhythm registrations were semi-automatically analysed in SynescopeTM by using 
standardized algorithms and manually verified by a cardiologist. First, two ECG-leads 
were selected from lead I, II and III as the other leads were composites. In exceptional 
cases of poor quality of the registrations, only one ECG lead was selected. After selection 
of two ECG-leads, QRS-complexes were automatically classified and grouped into 
multiple templates(including normal, supraventricular and ventricular beats). The upper 
left panel of Figure 1 illustrates examples of 3 templates of a normal, supraventricular and 
ventricular ectopic beat and a part of the event list that is automatically generated after 
manual correction of all templates.
As demonstrated in the lower panel of Figure 1, SVEBs were classified as SVPB, SV-
couplet, SV-run (in the middle panel) or PoAF. A SVPB was defined as a beat with 
cycle length ≤25% of the average cycle length of the two preceding beats (the so-called 
prematurity index (PI)) and a QRS-duration <120ms; those with a cycle length <70% 
were excluded as they were the result of artefacts in registrations most likely caused by 
patient movements. SV-couplets consisted of two consecutive premature supraventricular 
beats, whereas SV-runs contained minimal three consecutive premature supraventricular 
beats with a maximal duration of 29seconds. Early PoAF was defined as series of irregular 
supraventricular beats lasting ≥30seconds occurring in the first five days after CABG
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For every postoperative day the total number of SVPBs, SV-couplets and SV-runs per hour 
was determined. The burden of SVPBs was expressed as the sum of all SVPBs divided by 
the total number of QRS-complexes. The burden of SV-couplets and SV-runs was defined 
as the sum of the durations of all SV-couplets or SV-runs divided by the entire registration 
duration. Likewise, the AF-burden was expressed as the ratio of the sum of the duration of 
all AF-episodes and the duration of the entire registration period. 
Statistical analysis
Continuous normally distributed variables were expressed as mean±SD. Skewed data 
(confirmed by Shapiro-Wilk-test) are described as median (interquartile range). The 
unpaired, two tailed Student’s T-test was used to calculate differences between continuous 
variables. The Mann-Whitney-U-test was applied for categorical variables. A P-value of 
<0.05 was considered statistically significant.  The top 10th- and 25th-percentile of both 
frequency and burden of SVEBs were assessed to identify patients with a higher risk of 
PoAF.[9, 10, 14] The risk for PoAF was determined using univariate and multivariate 
binary logistic regression. Univariate analyses were computed with dependent factor 
Figure 1. Analysis of continuous rhythm registrations. Supraventricular dysrhythmia were classified as SVPBs, 
SV-couplets/runs and PoAF. Definition and characterization are illustrated in the middle and lower panel. See text for 
further details. N=normal, S=supraventricular, SVPB=supraventricular premature beat, V=ventricular.
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Table 1 Patient Characteristics
Table 1 Patient Characteristics 
 No PoAF N = 76 PoAF N = 29 P-Value 
Age (years), mean±SD 
Male, N (%) 
BSA, mean±SD 
Hypertension, N (%) 
Diabetes Mellitus, N (%) 
Hyperlipidaemia, N (%) 
Thyroid disorders, N (%) 
65±9 
61 (73) 
2.0±0.2 
52 (75) 
30 (79) 
38 (73) 
4 (57) 
67±9 
22 (27) 
2.0±0.2 
17 (25) 
8 (21) 
14 (27) 
3 (43) 
0.41 
0.62 
0.86 
0.34 
0.26 
0.87 
0.35 
Coronary Artery Disease N (%) 
1-VD 
2-VD 
3-VD 
LM + 1-VD 
LM + 2-VD 
LM + 3-VD 
 
5 (83) 
13 (77) 
43 (73) 
3 (75) 
8 (73) 
4 (50) 
 
1 (17) 
4 (24) 
16 (27) 
1 (25) 
3 (27) 
4 (50) 
 
0.54 
0.68 
0.90 
0.91 
0.98 
0.14 
Left ventricular function, N (%) 
Normal function 
Mild dysfunction 
Moderate dysfunction 
Severe dysfunction 
 
64 (76) 
8 (53) 
3 (60) 
1 (100) 
 
20 (24) 
7 (47) 
2 (40) 
0 
 
0.08 
0.08 
0.53 
0.54 
Left atrium dilatation  (>45mm) 14 (74) 5 (26) 0.89 
Anti-arrhythmic drugs, N (%) 
Class II 
Class III 
66 (73) 
66 (73) 
1 (100) 
25 (27) 
25 (27) 
0 
0.93 
- 
- 
N (%), mean±SD. BSA = body surface area, LM = left main, VD = vessel disease 
 
PoAF and both the frequency and burden of SVPBs, SV-couplets and SV-runs as fixed 
factors. Correlations between the frequencies (per hour and day separately) and burden 
of SVEBs were determined. Correlation between variables was considered significant if 
Pearsons correlation coefficient was >0.70. Variables with a significant correlation were 
not included together within a multivariate analysis model.
Results
Study Population
Patients (N=105, 83 male; 66±9 years), without previously reported AF, who underwent 
an elective CABG at the Department of Cardiothoracic Surgery of the Erasmus Medical 
Centre were enrolled. Preoperative characteristics are summarized in Table 1. Coronary 
artery disease was classified as 1-vessel disease (VD; N=6; 6%), 2-VD (N=17; 16%), 
3-VD (N=59; 56%), left main (LM) with 1-VD (N4; 4%), LM with 2-VD (N=11; 
10%) and LM with 3-VD (N=8; 8%). Left ventricle function was impaired in 21 (20%) 
patients.
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SVEBs
Duration of rhythm registrations were on average 86±25 hours containing 42,583,653 
beats. SVBPs (N=173,251) were observed in all patients. The median incidence of SVPBs 
per patient was 333(62–1,185). The upper panel of Figure 2 shows the relative frequency 
distribution of the number of SVPB/hour. In all patients, SVPBs (N=21,740) with a 
frequency of <30/hour occurred in 90.9% of the recording time. SVPBs (N=151,511) 
with a frequency of ≥30/hour occurred in 9.1% of the time and were observed in 62 
patients. The burden of SVPBs did not differ between the five postoperative days as 
illustrated in the lower panel of Figure 2 (0.31%, 0.32%, 0.47%, 0.43% and 0.55%; 
P=0.78). SV-couplets (N=11,799) were observed in the majority of the patients (90%) 
with an averaged median of 0.23±2(0–16) SV-couplets/hour(averaged median duration 
434±89(280–735)ms). The upper right panel of Figure 3 shows that the burden of SV-
couplets was low and similar for every postoperative day (P=0.64). 
SV-runs(N=4,026) occurred in 85(81%) patients in 8.5% of the recorded hours with 
an averaged median of 0.04±0(0–4) SV-runs/hour. The averaged median of the total 
duration of SV-runs was 2.8±1.9(1–14)s. The lower right panel of Figure 3 shows that the 
SV-run burden is low and was comparable for the various postoperative days (P=0.76).
Hence, SVEBs occur in almost every patient but there is a large inter-individual variety 
in both frequency and burden. In addition, characteristics of these dysrhythmias did not 
differ between the five postoperative days. 
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Early New-Onset PoAF and the interrelationship with SVEBs
PoAF occurred in 29 patients. The initial PoAF-episodes manifested mainly on the 
second and third postoperative day (82.8%) in an equal number of patients (N=12), 
corresponding with the highest PoAF-burden on day three of 5.6%.
Table 2 demonstrates that both the frequency and burden of SVEBs were higher in 
patients with PoAF (p>0.05). Hence, patients with a higher frequency and burden of 
SVEBs will more likely develop PoAF. However, as there was a large overlap in frequency 
and burden of SVEBs between patients with and without PoAF, the top 10th and 25th-
percentiles of our values were calculated to determine their predictive value for PoAF 
(according methods described in the literature) using uni- and multivariate analyses 
(Table 3). SV-couplets and SV-runs/hour and per day were not included in the same 
Figure 2
Frequency and Burden of Supraventricular Premature Beats. 
Upper panel: relative frequency distribution of the SVPBs frequency per hour. Lower panel: the burden of SVPBs of 
each patient for every postoperative day separately; the number of patients with ≥1 SVPBs is shown on top.
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model of multivariate analysis as they revealed a strong correlation, respectively ρ=0.82 
and ρ=0.85. Independent risk factors of the 10th percentile are SVPB ≥57/h (OR 8.0, 
95% CI 1.4 – 45.8; P = 0.02) and ≥1196/day (OR 7.0, 95% CI 1.2 – 42.6; P = 0.04), 
SV-run ≥0.6/h (OR 6.6, 95% CI 1.2 – 35.8; P = 0.03) and ≥14/day (OR 6.6, 95% 
CI 1.2 – 36.2; P = 0.03) and SV-run burden ≥0.6‰ (OR 8.6, 95% CI 1.5 – 48.4; P 
= 0.02) corrected for male gender, body surface area, hypertension, diabetes mellitus, 
hypercholesterolemia, left atrial dilatation, SVPB PI ≤59% and SV-couplet or SV-run 
per hour/day or burden. In the top 25th percentile independent predictor of PoAF are 
SV-run 0.2/h (OR 4.7, 95% CI 1.4 – 15.6; P = 0.01), ≥5/day (OR 6.6, 95% CI 1.9 – 
22.6; P = 0.003) and burden ≥0.2‰ (OR 11.7, 95% CI 3.3 – 41.2; P < 0.001). 
Parameters with a frequency of <1/hour or day are not suitable in the clinical setting. 
Therefore, proper risk-factors for prediction of PoAF in the daily clinical practice are 
SVPBs ≥57/hour and ≥1196/day, SV-run ≥5/dayand SV-run burden ≥0.2%.
Figure 3
Frequency and burden of SV-couplets and SV-runs. 
Relative frequency distribution of the number of SV-couplets (upper panel) and SV-runs (lower panel) per hour and 
burden. The number of patients with SV-couplets or runs on every day is shown on top.
Chapter 11
212
Discussion
The main findings of this study is that SVEBs occur in almost all patients in the early 
postoperative period after CABG, although the burden of these dysrhythmias is low. 
Patients with PoAF experienced significantly more SVEBs compared to patients without 
PoAF. Using continuous rhythm registrations, we identified several independent 
parameters which could be used to recognise patients at risk for PoAF. 
Table 2 Frequency and burden of SVEBs in patients with and without PoAF
Table 2 Frequency and burden of SVEBs in patients with and without PoAF 
 No PoAF (N=76) PoAF (N=29) P-valuea 
SVPB/hour 
SVPB/day 
SVPB Burden (%) 
SVPB PI (%) 
2.1 (0.6–9.3) 
47.5 (13.1–183.6) 
0.04 (0.02–0.2) 
64 (58–69) 
10.9 (3.6–63.3) 
237.6 (82.0–1467.6) 
0.21 (0.08–1.43) 
63 (57–69) 
<0.001 
<0.001 
0.02 
<0.001 
SV-Couplet/hour 
SV-Couplet/day 
SV-Couplet Burden (‰) 
0.06 (0.02–0.25) 
1.5 (0.4–5.1) 
0.008 (0.002–0.028) 
0.48 (0.13–3.13) 
10.2 (3.0–72.6) 
0.060 (0.018–0.421) 
<0.001 
<0.001 
<0.001 
SV-Run/hour 
SV-Run/day 
SV-Run Burden (‰) 
0.038 (0.007–0.127) 
0.71 (0.15–2.00) 
0.03 (0.01–0.09) 
0.245 (0.125–0.613) 
4.8 (2.0–14.3) 
0.24 (0.11–0.70) 
<0.001 
<0.001 
<0.001 
PI=prematurity index, PoAF=postoperative atrial fibrillation, SVEBs=supraventricular ectopic 
beats, SVPB=supraventricular premature beat, SV=supraventricular. aGroup differences were tested 
with the Mann-Whitney-U-test. 
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Table 3 Multivariate analyses: Risk of PoAF using specific thresholds 
 Variable OR 95% CI P-value 
T
o
p
 1
0
th
-
p
e
rc
e
n
ti
le
 SVPB ≥57H 
SVPB ≥1196D 
SVR ≥0.6H 
SVR ≥14D 
SVR burden ≥0.6‰ 
8.0 
7.0 
6.6 
6.6 
8.6 
1.4 – 45.8 
1. 2 – 42.6 
1.2 – 35.8 
1.2 – 36.2 
1.5 – 48.4 
0.02 
0.04 
0.03 
0.03 
0.02 
T
o
p
 2
5
th
-
p
e
rc
e
n
ti
le
 
SVR ≥0.2H 
SVR ≥5D 
SVR burden ≥0.2‰ 
4.7 
6.6 
11.7 
1.4 – 15.6 
1.9 – 22.6 
3.3 – 41.2 
0.01 
0.003 
<0.001 
CI=confidence interval, D=per day, H=per hour, OR=odds ratio, SVC=supraventricular 
couplet, SVPB=supraventricular premature beat, SVR=supraventricular run 
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SVEBs
Haïssaguere et al.[13] discovered that SVPBs mainly originating from the pulmonary 
vein area may initiate paroxysms of AF. To our knowledge, 3 prior studies have 
determined incidences of SVBPs in a healthy population and found that the novo AF 
could be predicted by different incidences of SVPBs including ≥30/hour[9], >100/
day[10] or >102/day.[14] In addition, ≥1 SV-run/day and SV-runs containing ≥20 
SVPBs also predicted de novo AF [9]. Frost et al.[17] related the incidence of SVPBs 
and SV-runs assessed during a 24 hours continuous rhythm registrations prior to CABG 
in 102 patients with PoAF/atrial flutter, demonstrated that ≥10 pre-operative SVPBs/
hour predicts PoAF/atrial flutter (N=29(28%)) (OR 3.03; 95 CI 1.05–8.77). Another 
study demonstrated an increased number of SVPBs in the 24 hour prior to PoAF in 
the first 96 hours after CABG compared to patients without PoAF.[18] In our study, 
we investigated whether SVEBs occurring in the direct period after CABG could also 
predict development of PoAF. As there is no reference data available, we evaluated the 
top 10th- and 25th-percentile of the SVEBs frequency and burden as cut-off values for 
prediction of PoAF. The resulting thresholds determined in our population appeared to 
be considerably higher than thresholds determined in a healthy population. Conen et 
al.[19] studied the incidence of SVPBs in the general population of approximately the 
same age as our study population; the median frequency of SVPB was 1.4/hour which 
is lower than the incidence of SVPBs in the post-operative period(6±19 SVPB/hour) of 
our population. Hence, SVPBs occur more frequently after CABG. The higher incidence 
of SVPBs (ectopic activity) after CABG might be explained by atrial stretch caused by 
e.g. pressure/volume overload which in turn increases catecholamine concentrations and 
promoting triggered activity and enhanced automaticity.[20, 21] As the frequency of 
SVEBs is dependent on the heart rate, the burden of SVEBs may be a more accurate 
parameter for prediction of PoAF. To our knowledge, burdens of SVEBs have never been 
investigated in healthy subjects and references values are therefore not available. 
There is also no data on the frequency and burden of SV-couplets after CABG. Despite 
the fact that both the frequency and burden of SV-couplets were low in our study 
population, they were higher in patients with PoAF compared to patients without PoAF. 
However, due to the large overlap in SV-couplets characteristics between these 2 groups 
it is likely that both parameters are not useful in daily clinical practice to identify patients 
at risk for PoAF. In a healthy population, AF could be predicted by SV-runs containing 
≥20 SVBPs[9]. Frost et al.[17] showed that ≥1 SV-run 24-hours prior to CABG is a 
risk-factor for developing PoAF (OR 3.02; 90%CI 1.11–8.22); the frequency or burden 
of SV-runs were not examined. Bedside monitors usually only display the frequency and 
duration of SV-runs which allows determination of the SV-run burden. The number of 
SVPBs in a SV-run are not displayed and we therefore did not include this parameter 
in our study. 
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Early, New-Onset PoAF
Since the first CABG in 1960[22], AF has been described as a frequently occurring 
postoperative complication.[2, 4] Despite improvements in surgical techniques and 
postoperative care, the incidence of PoAF remains unaltered approximately 30% and 
is still accompanied by increased morbidity and mortality rates.[3, 5, 8] The presence 
of both a trigger and substrate (electrophysiological alterations, e.g. dispersion of 
refractoriness or inhomogeneity in conduction[23-25]) are mandatory to develop AF. 
In the presence of a trigger such as SVEBs AF can be initiated if a substrate is present. 
Several pre- (e.g. hypertension, diabetes mellitus[4, 5, 7]), peri- (e.g. atrial cannulation 
required for extracorporeal circulation, duration of cardioplegic arrest[5, 7]) and 
postoperative risk-factors have been described which may contribute to development 
of PoAF. The most important preoperative risk-factor of PoAF is advanced age.[3, 7] 
Associated with aging there is an increased dissociation between atrial bundles resulting 
in a decrease of intercellular connections giving rise to conduction abnormalities which 
in turn favours development of PoAF.[26] Pre-existent structural alterations of the 
atria, e.g. cytoplasmatic vacuolization, interstitial fibrosis, and nuclear derangement 
of myocytes, observed in atrial tissues obtained during cardiac surgery increased the 
risk of PoAF.[27] Inflammation is mainly increased on the second and third day 
after CABG which concurrences with the peak incidence of PoAF; administration of 
postoperative anti-inflammatory drugs reduces the incidence of PoAF.[28] Hypokalemia 
and hypomagnesemia can also provoke PoAF by increasing in phase-3 depolarization, 
enhanced automaticity and decreasing conduction velocity.[29] Oxidative stress may 
also facilitate PoAF by shortening of atrial effective refractoriness and affecting atrial 
conduction due to e.g. progressive fibrosis.[30] Increased atrial stretch by volume and 
pressure overload shortens atrial refractoriness thereby also provoking PoAF.[7, 29] In 
addition, it has been shown that connexin-40 is reduced in patients with PoAF thereby 
serving as a substrate of AF.[31] Atrial refractoriness may be influenced by the autonomic 
nervous system (e.g. shortening of the atrial effective refractory period).[5, 7] Hence, 
PoAF is caused by an interplay of multiple patients, perioperative and postoperative 
characteristics, but the exact mechanism underlying PoAF is still unknown. 
Conclusion
Continuous rhythm recordings obtained from patients with coronary artery disease 
without preoperative AF during the first five days after CABG demonstrated that SVEBs 
occurred in most patients. PoAF however, developed in 28%. Independent risk-factors 
for development of AF after CABG are SVPB ≥57/hour or ≥1196/day, SV-run ≥5/day 
and SV-run burden ≥0.2‰. Hence, these parameters can be used to identify patients 
at risk for developing PoAF and allows preventive measures to be taken. Future studies 
should be aimed at evaluating the prospective value of these parameters. 
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Is Intra-Operative Inducibility of Atrial Fibrillation 
a Novel Predictor of Post-Operative Atrial Fibrillation?
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Abstract
Background: Post-operative atrial fibrillation (PoAF) occurs frequently after cardiac 
surgery (CS). Interrelationships between intra-operative inducibility of AF, (de novo) 
early PoAF (EPoAF) and late PoAF (LPoAF) are unknown. Aims of this study are to 
examine 1) the predictive value of intra-operative inducibility of AF for (de novo) 
EPoAF and LPoAF, and 2) the progression of both de novo and recurrent PoAF.
Methods and Results: Patients (N=496, 67±11 years) scheduled for CS were included; 
125 had AF and 80 of them underwent a surgical pulmonary vein isolation (sPVI). AF 
was intra-operatively induced and post-operative rhythms were continuously recorded 
during the first five days. After hospital discharge, patients visited the outpatient clinic 
every year.
Sustained AF was inducible in most patients (no AF: 54%, history of AF: 72%).
LPoAF occurred in respectively <1%, 29% and 14%. Inducibility of AF/AFL did not 
correlate with EPoAF or LPoAF (χ2>0.05). Patients with EPoAF had a 17-times higher 
risk of developing LPoAF (95% CI 4 – 74; P<0.001). LPoAF progressed in 56% patients. 
Conclusion: Intra-operative AF inducibility does not predict EPoAF or LPoAF; EPoAF 
is an independent predictor of LPoAF. LPoAF occurred infrequently and was mainly AF 
recurrences. Progression of LPoAF occurred frequently (56%) and is most likely due to 
progressive atrial remodeling.
 EPoAF LPoAF 
De novo EPoAF 37% <1% 
Recurrent EPoAF 
 no-sPVI 
 sPVI 
 
84% 
44% 
 
29% 
14% 
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Introduction 
Over the past decades, cardiac surgery (CS) for cardiovascular diseases has become an 
established treatment modality in many hospitals. Despite improved surgical techniques 
and healthcare over the years, atrial fibrillation (AF) is still frequently observed after CS.1-4 
Reported incidences of early post-operative AF (EPoAF) range from 10% to 65%. EPoAF 
is associated with severe complications (e.g. stroke, death) and subsequently prolonged 
hospitalization.3, 5, 6  A previous study suggested that intra-operative inducibility of AF 
could be a predictor of the occurrence of EPoAF.7 A previous study demonstrated that 
AF cannot be induced in every patient; in 86 patients with no history of AF undergoing 
endovascular ablation of SVT, AF was inducible in only 26%.8
Recent studies have demonstrated that de novo EPoAF, particularly in patients 
undergoing coronary artery bypass grafting (CABG), increases the risk of late post-
operative AF (LPoAF).6, 9, 10 In patients with a history of AF prior to CS, there is no 
data on the interrelationship between the occurrence of EPoAF and progressiveness of 
LPoAF. In case of endovascular ablative therapy of AF, early AF recurrences predict late 
post-procedural AF.11 However, the predictive value of recurrent EPoAF for development 
of LPoAF in patients with AF undergoing a surgical pulmonary vein isolation (sPVI) is 
unknown. 
The aims of this study are therefore to examine 1) the predictive value of intra-operative 
inducibility of AF for both (de novo) EPoAF and LPoAF, and 2) progressiveness of both 
de novo and recurrent PoAF.
Methods 
Study Population
The study population consisted of 496 adult patients, scheduled for elective CS, 
including CABG, valvular heart surgery (VHS), a combination of VHS and CABG or 
correction of a congenital heart defect (CHD). sPVI was performed in a selection of 
patients who had a history of AF.
Patients with a severe impaired left ventricular function, mechanical or inotropic support, 
an atrial pacing device, previous ablation of atrial arrhythmias or severe renal failure 
were not eligible for inclusion. This study is a part of the QUest for Arrhythmogenic 
Substrate of Atrial fibRillation (QUASAR) project,12, 13 which is approved by the local 
medical ethical committee (MEC 2010-054). All patients provided written informed 
consent prior to inclusion. Prior to surgery, patients were stratified into two separate 
groups: patients with and without a history of AF. Clinical characteristics were obtained 
from electronic patients’ files.
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Intra-operative Induction of AF by Electrical Stimulation
In the QUASAR project, high-resolution epicardial mapping was performed during 
(induced) AF. AF induction was attempted in every patient prior to commencement to 
extra-corporal circulation by fixed rate pacing at the right atrial appendage, with a pulse 
width of 2 ms delivered by a temporary pacemaker wire at an output of 10 mA. Pacing 
started at a rate of 200 bpm and if AF was not induced after 3 attempts, the rate was 
increased by steps of 50 bpm. If AF was not induced at a pacing rate of 400 bpm or loss 
of capture occurred, attempts were terminated and AF was considered non-inducible.13 
AF attempts were categorized as 1) non-inducibility, or inducibility of 2) non-sustained 
AF (nsAF; duration <30sec), 3) non-sustained atrial flutter (nsAFL), 4) sustained AF 
(susAF) and 5) sustained AFL (susAFL). Figure 1 illustrates typical examples of intra-
operative induction of nsAFL and susAF.
Figure 1 Example of intra-operative induction of AFL (upper panel) and AF (lower panel).
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Early Post-operative Atrial Fibrillation
Post-operative cardiac rhythms were continuously recorded during the first five days 
from bedside Infinity® monitors (Draeger, Lubeck, Germany) and stored on hard disk 
as compoz-files (sampling rate of 200Hz).14 The stored cardiac rhythm registrations 
were converted into International Society for Holter and Noninvasive Electrocardiology 
(ISHNE)-files, a standard Holter output file format15, by a custom made program with 
preservation of characteristics of the original data. After conversion, cardiac rhythm 
registrations were semi-automatically analysed in SynescopeTM by using standardized 
algorithms and manually verified by a cardiologist. PoAF is defined as de novo, when 
a patient did not have a history of AF prior to CS. EPoAF was defined as irregular 
R-R intervals in the absence of distinct P-waves, with a duration of at least 30 seconds 
occurring within one month after the surgical procedure. After disconnection from 
continuous cardiac rhythm monitoring, EPoAF was diagnosed by ECGs only. 
Late Post-operative Atrial Fibrillation
After discharge from the hospital, patients visited the outpatient clinic at one month, 
six months and yearly after CS for a maximum of five years. During these visits, LPoAF 
was detected on ECGs or 24-hour Holter recordings. The different types of AF were 
classified according to the ESC AF guidelines.16 
Statistical Analyses
All data was tested for normality. Continuous normally distributed data is expressed 
as mean±SD (min-max) and skewed data as median (interquartile range). Student’s 
T-tests were used to compare normally distributed continuous clinical parameters. 
Non-normally distributed clinical parameters were compared by non-parametric tests 
including Mann-Whitney-U-test. Fisher Exact or χ2-tests were applied for categorical 
variables. The relation between EPoAF, LPoAF and AF induction was examined by uni- 
and multivariate binary logistic regression analyses. Variables with a P-value ≤0.10 at 
univariate analyses or those that were considered clinical relevant were included in the 
multivariate models. A P-value of <0.05 was considered statistically significant. Analyses 
were performed in IBM SPSS Statistics version 21.
Results 
Study Population
The study population consisted of 496 patients (age 67±11 (18 – 85) years, 373 (75%) 
male). Baseline characteristics are summarized in Table 1. The majority of patients 
(N=273, 55%) underwent a CABG, whereas isolated VHS or VHS combined with 
CABG was performed in respectively 122 (25%) and 82 (16%) patients. The remaining 
19 (4%) patients underwent correction of a CHD. 
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A history of AF was present in 125 (25%) patients (paroxysmal AF: N=54, 43%; 
persistent AF: N=47, 38%; long-standing persistent AF: N=21, 17%; permanent AF: 
N=3, 2%). These patients underwent either a CABG (N=27, 22%), VHS (N=64, 51%), 
VHS/CABG (N=26, 21%) or correction of CHD (N=8, 6%). None of the patients had 
a history of AFL. The median follow-up period was 12 (12 – 48) months; a total of 12 
patients were lost to follow-up. LPoAF occurred in 25 patients (5%).
Table 1 Baseline Characteristics
Table 1 Baseline Characteristics 
 No AF AF P-value 
Population, N (%) 371 (75) 125 (25)  
Group, N (%) 
- CABG 
- VHS 
- VHS/CABG 
- CHD 
 
246 (66) 
58 (16) 
56 (15) 
11 (3) 
 
27 (22) 
64 (51) 
26 (21) 
8 (6) 
<0.001 
<0.001 
<0.001 
0.137 
0.084 
Age, (years) 65±11 71±9 <0.001 
Male gender, N (%) 289 (78) 84 (67) 0.017 
Hypertension, N (%) 206 (56) 70 (56) 0.926 
Diabetes, N (%) 102 (27) 27 (22) 0.194 
Hyperlipidemia, N (%) 136 (37) 26 (21) 0.001 
BMI (kg/m2), mean  SD 27.8  4.2 27.7  4.5 0.204 
Anti-arrhythmic drugs**, N (%) 
- Class I 
- Class II 
- Class III 
- Class IV 
271 (73) 
2 (1) 
254 (68) 
5 (1) 
13 (4) 
96 (77) 
0 (0) 
75 (60) 
22 (18) 
4 (3) 
0.408 
1.0 
0.083 
<0.001 
1.0 
Left Ventricular Function, N (%) 
- Normal 
- Mild impairment 
- Moderate impairment 
- Severe impairment 
 
282 (76.0) 
68 (18.3) 
20 (5.4) 
1 (0.3) 
 
82 (66) 
28 (22) 
14 (11) 
1 (1) 
0.059 
0.023 
0.319 
0.026 
0.441 
Left atrial dilatation*, N (%) 66 (18) 66 (53) <0.001 
AF type prior to CS, N (%) 
- Paroxysmal AF 
- Persistent AF 
- Long-standing Persistent AF 
- Permanent AF 
 
 
54 (43) 
47 (38) 
21 (17) 
3 (2) 
 
AF = atrial fibrillation; BMI = Body Mass Index; CABG = coronary artery bypass grafting; CHD = 
congenital heart disease; CS = cardiac surgery; VHS = valvular heart surgery; SD = standard deviation, *left 
atrial dilatation >45mm, **Anti-arrhythmic drugs were categorized in both class II and III, therefore the sum 
of all classes is not 100%. 
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Relation between Intra-Operative Inducibility of AF and De Novo PoAF
De novo EPoAF developed in 139 (37%) of the 371 patients without a history of AF; 
in 17 of them, AF was only reported in electronic patients’ files, yet documentations of 
rhythm registrations were not stored. In 7 patients without a history of AF, AF was not 
induced due to technical issues (EPoAF: N=5) and AF developed spontaneously prior 
to induction in another seven patients (EPoAF: N=2). 
The upper panel of Figure 2 shows the outcome of programmed electrical stimulation 
in the remaining 357 patients with (black bars) or without (white bars) de novo EPoAF. 
AF was not inducible in 79 (22%) patients; 28 (21%) of them developed EPoAF. 
Programmed electrical stimulation in the other patients resulted in either nsAF (N=34, 
9.5%), nsAFL (N=28, 7.8%), susAF (N= 193, 54%) or susAFL (N=23, 2.3%); de novo 
EPoAF developed in respectively 15, 9, 71 and 9 of them.
The lower panel of Figure 2 illustrates incidences of AF from the early to the late post-
operative period in all 139 patients with de novo PoAF.
Figure 2. Upper panel: results of intra-operative inducibility of AF in 357 patients without a history of AF (white bars: 
no EPoAF, black bars: EPoAF). Lower panel: de novo EPoAF developed in 139 (34%) patients (CABG: N = 86, 62%,
HVS: N = 20, 14%, HVS/CABG: N = 32, 23% and CHD: N = 1, 9%). AF at discharge was present in 14 patients; 
only one patient with de novo EPoAF developed LPoAF. AF = atrial fibrillation, AFL = atrial flutter, NS = non-sustain-
ed, Sus = sustained, CABG = coronary artery bypass grafting, VHS = valvular heart surgery, CHD = congenital
heart disease, EPoAF = early post-operative AF, LPoAF=late, post-operative AF.
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EPoAF occurred from the first until the eleventh postoperative day (day 1: N=1, 1%, 
day 2: N=11, 8%, day 3: N=58, 42%, day 4: N=43, 31%, day 5: N=16, 12%, day 
6: N=6, 4%, day 7: N=3, 2% and day 11: N=1, 1%. Treatment of de novo EPoAF 
consisted of anti-arrhythmic drug therapy (N=141; class II: N=87; class III: N=54; 
digoxin: N=29) or a combination of electrical cardioversion and anti-arrhythmic drug 
therapy (N=21). At hospital discharge, AF was present in 14 (10%) patients (CABG: 
N=6, 43%, VHS: N=5, 36% and VHS/CABG: N=3, 21%; P=0.123); only one patient 
had an AF recurrence in the late post-operative period. 
Relation between Intra-Operative Inducibility of AF and Recurrent AF
Of the 125 patients with a history of AF, 80 (64%) patients underwent a sPVI. 
The upper panel of Figure 3 shows the type of AF prior to CS, AF inducibility and 
recurrent EPoAF and LPoAF during follow-up in the other 45 patients (CABG (N=12, 
27%), VHS (N=21, 47%), VHS/CABG (N=9, 20%), correction of CHD (N=3, 6%) 
with AF who did not undergo a sPVI. These patients had either paroxysmal (N=21, 
47%), persistent (N=15, 33%), long-standing persistent (N=6, 13%) or permanent AF 
(N=3, 7%) prior to CS. Recurrent EPoAF developed in 38 (84%) patients.
Intra-operative induction of AF was not performed in 27 patients due to presence of 
spontaneous AF during CS (N=26, 21%) or technical issues (N=1). Induction in the 
remaining 18 patients resulted in either nsAF (N=2, EPOAF: N=1, 6%), susAF (N=11, 
EPoAF: N=8, 44%) or susAFL (N=1, EPoAF: N=1, 6%). AF was non-inducible in four 
(22%) patients (EPoAF: N=3, 17%). 
The first episode of recurrent EPoAF occurred most frequently on the first (N=13, 34%) 
and third post-operative day (N=10, 26%) compared to the second (N=4, 11%), fourth 
(N=7, 18%), fifth (N=2, 5%), sixth (N=1, 3%) and seventh post-operative day (N=1, 
3%; P=0.015). Anti-arrhythmic drug therapy was administered in 22 patients (class II: 
N=11; class III N=9; digoxin N=8). Of the patients with recurrent EPoAF, 24 (63%) 
patients had AF at the moment of discharge. LPoAF developed in 13 (34%) patients 
who also had EPoAF (CABG: N=3, 23%, VHS: N=6, 46% and VHS/CABG: N=4, 
31%; P=0.500). 
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The lower panel of Figure 3 illustrates the outcomes for 80 patients with a history of AF 
who underwent either CABG (N=15, 19%), VHS (N=43, 54%), VHS/CABG (N=17, 
21%) or CHD surgery (N=5, 6%) with concomitant sPVI. AF prior to CS was either 
paroxysmal (N=33, 41%), persistent (N=32, 40%) or long-standing persistent (N=15, 
19%).  
EPoAF occurred in 35 (44%) patients (CABG: N=7, 20%, VHS: N=19, 54%, VHS/
CABG: N=6, 17% and CHD: N=3, 9%; P=0.781). The first episode of PoAF manifested 
mainly on postoperative day 2 (N=8, 23%) and 3 (N=8, 23%) compared to the other 
days (day 1: N=3, 8%, day 4: N=4, 11%, day 5: N=7, 20%, day 6: N=2, 6%, day 7: 
N=1, 3% and day 8: N=2, 6%; P=0.012). 
Prior to AF induction, AF was present in 27 (34%) patients without EPoAF and 24 
(30%) patients with EPoAF. In two patients, AF was not induced due to technical 
issues. In the lower panel of Figure 3, the results of intra-operative induction of AF 
are presented for the remaining 26 patients with (N=9) and without (N=17) recurrent 
EPoAF. AF was not inducible in 1 (6%) patient with and 1 without EPoAF. In the other 
Figure 3. Left panels: results of intra-operative inducibility of AF. Middle panels: the relative frequency distribution 
of the type of AF prior to cardiothoracic surgery, Right panels: the relative frequency distribution of the number of 
patients with EPoAF, AF at discharge and LPoAF in patients with AF prior to cardiothoracic surgery without (upper 
panel) and with (lower panel) a sPVI. See text for detailed explanation. AF = atrial fibrillation, AFL = atrial flutter, NS 
= non-sustained, Sus = sustained, PAF= paroxysmal AF, Pers = persistent AF, LPers = long-standing persistent AF, Perm 
=permanent AF, EPoAF = early post-operative AF, LPoAF = late post-operative AF, CABG = coronary artery bypass 
grafting, CHD = congenital heart disease, VHS =valvular heart surgery.
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patients, induction resulted in nsAF (N=2, EPoAF: N=0), nsAFL (N=1, EPoAF: N=0) 
or susAF (N=21, EPoAF: N=8, 89%). 
Therapy of EPoAF consisted of electrical cardioversion without (N=4) or with 
concomitant anti-arrhythmic drug therapy (N=3). Twenty-two patients were treated with 
anti-arrhythmic drug therapy (class II: N=15; class III: N=5; digoxin: N=8). At hospital 
discharge, 19 (54%) patients were still in AF. LPoAF developed in 9 of 35 patients 
with EPoAF (CABG: N=2, 22%, VHS: N=6, 67%, CHD: N=1, 11%; P=0.292). Two 
patients without EPoAF did developed LPoAF (VHS: N=2, 3%). Hence, LPoAF after 
sPVI developed in only 14% (N=11) of the patients, which is a significantly a smaller 
amount compared to patients without sPVI (29% (N=13); P=0.039).
In all patients with a history of AF, susAF was inducible in 72%. As expected, the 
frequency of EPoAF was observed more frequently in patients with AF prior to CS and 
without sPVI compared to patients without AF prior to surgery and subjects with AF 
and concomitant sPVI (84% versus 37% and 44%; P<0.001). Similar observations were 
also made for the frequency of LPoAF (29% versus 0.3% and 14%; P<0.001).
Progressiveness of AF
Progression of AF after CS is shown in Figure 4. Of the 25 patients with LPoAF, AF 
progression was observed in 14 patients. Only one patient without AF prior to CS, 
in whom sustained AF was induced, developed both EPoAF and persistent LPoAF. All 
patients with a history of AF prior to CS and AF progression, arrived in AF at the 
operation room. In 7 patients with a history of AF without sPVI, AF progressed from 
persistent to long-standing persistent AF (N=1) or permanent AF (N=3) and from long-
standing persistent to permanent AF (N=2). One of them did not develop EPoAF, but 
progressed from persistent to permanent AF after VHS/CABG . EPoAF developed in 6 
patients with AF prior to CS and sPVI in whom AF progressed from either persistent to 
long-standing persistent AF (VHS: N=2), persistent to permanent AF (VHS: N=1) or 
long-standing persistent to permanent AF (CABG: N=2 and CHD: N=1).
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Interrelationship between Intra-Operative Inducibility of AF, EPoAF and LPoAF 
In patients without AF, induction of AF and AFL has a sensitivity, specificity, positive 
predictive value, negative predictive value of respectively 79% (95% CI 0.7 – 0.9), 
22% (95% CI 0.2 – 0.3), 37%  and 65% for the prediction of development of PoAF. 
However, there was no relation between induction of AF or AFL and EPoAF (χ2=0.75).
In patients with AF, the sensitivity, specificity, positive and negative predictive value 
for prediction of PoAF was respectively 82% (95% CI 0.6 – 0.9), 9% (95% CI 0.02 – 
0.31), 47% and 33%. Hence, in this group there was also no relation between AF or 
AFL induction and EPoAF (χ2=0.38). In both groups, AFL or AF induction was not 
associated with LPoAF (patients without AF: χ2=0.59; patients with AF: χ2=0.13).
Independent risk factors for prediction of EPoAF were age ≥65 years (OR 3.8, 95% CI 
1.1 – 12.7; P=0.03), diabetes mellitus (OR 4.4, 95% CI 1.2 – 15.5; P=0.02) corrected 
for gender, BMI>30, hypertension, hypercholesterolemia, poor left ventricular function, 
left atrium dilatation (>45 mm), type of surgery and presence of AF prior to CS. Patients 
who have had sPVI have a 6.0 lower risk for development of EPoAF (P=0.001). 
Compared to patients without EPoAF, patients with EPoAF had a 17 times higher risk 
of developing LPoAF (95% CI 4 – 74; P<0.001). Prediction of LPoAF was analyzed in 
a multivariate model including age ≥65 years, gender, BMI ≥30 kg/m2, hypertension, 
Figure 4. Histogram depicting AF progression in patients with de novo EPoAF and recurrent EPoAF. The latter group 
is divided in patients without and with sPVI; most patients progressed to permanent AF. CABG = coronary artery 
bypass grafting, CHD = congenital heart disease, LS = longstanding, NA = not applicable (spontaneous AF), sPVI = 
surgical pulmonary vein isolation, VHS = valvular heart surgery.
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diabetes mellitus, hypercholesterolemia, left atrial dilatation (>45mm), the presence of 
AF prior to CS, type of surgery and EPoAF. Independent predictors of LPoAF were male 
gender (OR 4.2, 95% CI 1.2 – 15.3; P=0.030), presence of AF prior to CS (OR 82.5, 
95% CI 9.3 – 744; P<0.001) and EPoAF (OR 14.0, 95% CI 2.8 – 74.8; P=0.002). 
After introduction of sPVI in the multivariate model, male gender (OR 4.1, 95% CI 1.1 
– 15.5; P=0.037) and EPoAF (OR 10, 95% CI 1.9 – 53.3; P=0.007) were independent 
predictors for LPoAF. 
Discussion
Key Findings
SusAF was inducible in the majority of the patients (79%) undergoing cardiac surgery, 
yet it did not predict development of EPoAF or LPoAF. EPoAF developed in 43% 
of the patients and LPoAF in only 5%. The incidence of EPoAF after sPVI was high 
(36%), whereas the incidence of LPoAF was only 14%. Of the patients with LPoAF, AF 
progression was observed in 71%; 40% progressed to permanent AF within a median 
follow-up period of only one year after CS.
Induction of AF
Intra-operative inducibility of AF in our study was not accomplished in all patients. The 
susceptibility of AF induction might by influenced by drugs used for general anesthesia. 
However, data regarding the effects of general anesthetics on atrial electrophysiology 
are scarce. In the mice model, general anesthetics combined with open chest surgery 
prolonged the atrio-ventricular conduction time, sinus rhythm cycle length and the 
sinus node recovery time, but increased the ventricular effective refractory period.17 
This resulted in a significantly decreased susceptibility of induction of ventricular 
tachyarrhythmia.17 Susceptibility to development of AF could not be investigated in 
this mice model as AF could not be induced during general anesthesia, not even in 
mice with connexin40 deficiency.18 Mountantokanis et al.19 demonstrated in patients 
with paroxysmal AF undergoing pulmonary vein isolation that general anesthesia did 
not affect the susceptibility to induce AF. This is also supported by the observation of 
Gelissen et al20, who showed that the dosage propofol during general anesthesia has little 
negative inotropic effect. There are no reports on the impact of general anesthesia on AF 
inducibility in patients without spontaneous AF. In the present study, AF is inducible 
in the majority of patients without a history of AF (78%). In patients with AF, AF was 
inducible in 86% of the patients. Hence, general anesthesia does not seem to affect AF 
inducibility. Only one other study examined the relation between AF inducibility and 
EPoAF. Lowe et al.7 induced AF in 72% of only 50 patients without a history of AF 
during CABG and found a sensitivity and specificity of AF inducibility for predicting 
EPoAF of respectively 94% and 41%. Yet, in our study we were not able to confirm the 
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relation between intra-operative AFL/AF inducibility and EPoAF. In addition, AF was 
not inducible in all patients which may be explained by a less extensive arrhythmogenic 
substrate.13
Early Post-operative Atrial Fibrillation
EPoAF is an interplay of multiple pre-, peri- and post-operative clinical characteristics 
(e.g. aging, duration of cardioplegic arrest, post-operative inflammation). However, the 
exact underlying mechanism is still unknown.
Similar to other studies, 43% of our cohort developed EPoAF, which mainly occurred 
on the second and third post-operative day.2, 6, 9, 10, 21, 22 As expected, the frequency of 
EPoAF was highest in patients with a history of AF and without concomitant sPVI 
(84%). 
 
Late Post-Operative AF
In our cohort, LPoAF developed in only one patient who did not have AF prior to CS. 
Hence, the incidence of recurrent LPoAF is lower than incidences reported in previous 
studies. Lee et al.10 investigated the relation between de novo EPoAF and LPoAF in 
488 patients who underwent CABG during a follow-up period of 41 months; LPoAF 
developed in 14%. De novo EPoAF was an independent predictor of LPoAF. In another 
cohort, consisting of 571 CABG patients, EPoAF developed in 28.9% of the patients.6 
During a median follow-up period of 3 years, they demonstrated by questionnaires, 
intermittent ECGs or reports of hospitalization by patients that EPoAF was associated 
with a 8 times higher risk to develop LPoAF.6 Ambrosetti et al.9 were the first to describe 
the frequency of both de novo EPoAF and LPoAF in patients after not only CABG, but 
also VHS and VHS/CABG. Independent risk factors for LPoAF were EPoAF, VHS and 
post-operative ventricular arrhythmia. Similar to these studies we also determined the 
incidence of PoAF using surface ECGs and 24-hour Holter monitoring. The differences 
in incidences of AF between aforementioned studies and the current study could be 
explained  by the shorter follow-up period.
All studies described above, excluded patients with a history of AF prior to CS. So far, 
to our knowledge, the time-course of LPoAF in patients with a history of AF is not 
reported. In this study, in patients with a history of AF, LPoAF recurrences after CS 
were observed in almost one out of five patients (no sPVI: 29% and sPVI: 14%). Hence, 
the success rate of sPVI after a median follow-up of one year was 86%. Previous studies 
reported success rates ranging between 66 and 69% one year after Maze procedures 
concomitant with other surgical procedures.23, 24 Differences in these success rates might 
be due to variations in the surgical techniques, patient characteristics and follow-up 
duration.
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Progression of AF
To our knowledge, we are the first to examine post-operative progressiveness of AF in 
patients with a history of AF prior to CS in addition to the time-course of de novo 
EPoAF in a large cohort after CABG, VHS and VHS/CABG. Furthermore, we also 
described the progressiveness of AF after sPVI. 
It is generally accepted that AF progresses over time from a trigger-driven to a substrate 
mediated tachyarrhythmia. Wijffels et al. demonstrated that AF begets AF.25 Several 
studies have reported on progression of AF. In 1,219 patients (age: 64±13years) with 
paroxysmal AF, progression to susAF was observed in 15% of the patients after only 
one year follow-up. This was associated with major cardiovascular events requiring 
hospitalization and ischemic cerebrovascular events. Increasing age and underlying heart 
disease were independent predictors of AF progression.26 The Canadian Registry of Atrial 
Fibrillation (CARAF) study, demonstrated progression of paroxysmal to permanent 
AF in 8.6% of patients with various underlying (heart) diseases within only one year. 
During the next 5 years, progression was observed in 24.7%.27 During a mean follow-up 
period of 25 years, 93% of the patients (age: 44±12years) with lone AF progressed from 
paroxysmal or persistent AF to permanent AF. Again, progression was associated with 
increased morbidity and mortality.28 In our study, only one patient with de novo PoAF 
(0.3%) progressed to persistent AF during a median follow-up period of one year. AF 
progressed in 10% of the patients with AF prior to CS. Progression of AF occurred mainly 
from persistent or long-standing persistent to permanent in 72% (without sPVI: 43%, 
with sPVI: 29%) of the patients. The inter-individual variation in progressiveness of AF 
can be explained by differences in extensiveness of the arrhythmogenic substrate which 
may be caused by differences in the degree of electrical and/or structural remodeling.
Study Limitations
LPoAF was only determined on ECGs and Holter-monitoring and asymptomatic, 
paroxysmal AF could therefore have been missed. The entire duration of the induced 
AF episodes could not be determined as patients went immediately on cardiopulmonary 
bypass after mapping and the moment of spontaneous termination of these AF episodes 
is therefore not known.  
Conclusion
Sustained AF is inducible in the majority of patients undergoing cardiac surgery. Yet, 
intra-operative inducibility of AF/AFL is not a predictor of development of either 
EPoAF or LPoAF. The occurrence of EPoAF is an independent predictor of LPoAF. The 
incidence of LPoAF was low and was mainly observed in patients with a history of AF 
prior to CS. Progression of LPoAF occurred frequently (56%), irrespective of a sPVI, 
which is most likely due to progressive atrial remodeling.
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Abstract  
Aims: Atrial fibrillation (AF) is increasingly observed in patients with congenital heart 
defects (CHD) who survive nowadays into adulthood. Yet, predictors of AF are scarce 
in this high risk population. This study therefore examined the predictive ability of atrial 
extrasystole (AES) for development of AF in CHD patients.
Methods and Results: Adult CHD patients who had a 24-hour Holter registration 
were followed to determine who developed AF. A total of 573 patients (49% male, 
mean age 35±12 years) were included; they had a simple/complete repaired CHD 
(N=279), complex repaired CHD (N=251) or univentricular heart (UVH, N=43). 
Aging (p<0.0001), female gender (p=0.028), UVH (p=0.0010) and left atrial dilatation 
(p=0.0025) were associated with the number of AES. During a median follow-up 
of 51.6 months (IQR 22.8–85.7), 29 patients (5%) developed de novo AF. An one-
point increase in the number of logtotal-AES was associated with a 2-fold higher risk 
of AF development (HR 1.95; 95%CI 1.21–3.13; p=0.016). C-statistic for left atrial 
dilatation, complexity and age had a good discriminative ability for the incidence of AF 
with a C-statistic of 84.5%. Addition of the total number of AES/24 hour to this model 
increased C-statistic to 88.4%. 
Conclusion: AES occur relatively frequent in adult CHD patients compared to patients 
with other cardiac diseases. This is the first study that showed an association between an 
increased AES frequency and a higher risk of AF development in CHD patients. 
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Introduction
Congenital heart defect (CHD) is a common anomaly which affects approximately 8 
per 1,000 live births[1]. Improved treatment over the past decades has resulted in a 
growing number of grown-up CHD (GUCH) patients. Similar to patients without 
CHD, the prevalence of atrial fibrillation (AF) rises with age and is associated with 
multiple severe complications such as stroke and death[2-6].
Episodes of paroxysmal AF are initiated by atrial extrasystole (AES) that most commonly 
originate from the myocardial sleeves within the pulmonary veins[7], although other 
mechanisms have also been described which are associated with GUCH patients such 
as extensive fibrosis or oxidative stress[8]. Several factors are associated with a higher 
frequency of AES including older age and the presence of cardiovascular diseases[9]. 
However, AES are also observed in the majority of healthy individuals of varying ages 
and are therefore usually considered to be benign[10, 11]. As AES may initiate AF, the 
occurrence of frequent AES has been shown to be a predictor for development of AF 
episodes in patients without CHD[12-14]. It was observed that frequent AES (defined 
as either ≥30 AES/hour or >100 AES/day) in a healthy study population was associated 
with development of AF. However, it is unknown whether these cut-off values are also 
applicable to GUCH patients.
In the past years, several predictors for development of AF in patients with a variety 
of cardiac disease have been described[4, 15], but predictors for development of AF 
in GUCH patients are scarce[3]. The aims of this study were therefore 1) to examine 
characteristics of GUCH patients associated with AES, 2) to correlate AES frequency 
with development of AF in GUCH patients and 3) to define the predictive value of AES 
for new-onset AF.
Methods 
This retrospective multicenter cohort study was designed as part of the “DysrhythmiAs 
in patieNts with congenitAlheaRt diseAse” (DANARA) project (MEC-2012-482), 
which was approved by the local Medical Ethics Committee in the Erasmus University 
Medical Center Rotterdam. Informed consent was not obliged. 
Study Population 
All GUCH patients of 18 years of age or older who presented at (tertiary) outpatient 
clinics between January 2013 and December 2015 were evaluated. The original 
DANARA database consisted of 1248 GUCH patients. Patients who had undergone a 
24-hour Holter registration between April 2003 and January 2015 were included in this 
study; 675 patients had no Holter registration. The number of AES of the initial Holter 
registration was used for further analysis. The follow-up period was defined as the time 
between the Holter registration and the last follow-up visit until December 2015.
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Data on demographics and clinical characteristics such as type of CHD, cardiac surgery, 
prescribed anti-arrhythmic drugs and echocardiographic reports were retrieved from 
electronic patient medical records[16]. 
Conform our previous study about AF development in GUCH patients, patients 
were grouped according to simple/complete repaired CHD (aortic valve disease, atrial 
septal defect, atrioventricular septal defect, cor triatrium, mitral valve insuficiency/
stenosis, patent ductus arteriosus, patent foramen ovale, pulmonary stenosis, tricuspid 
insufficiency and ventricular septal defect); complex CHD (coarctation of the aorta, 
Ebstein anomaly, pulmonary atresia with ventricular septal defect, situs inversus, tetralogy 
of Fallot, transposition of the great arteries, congenitally corrected transposition of the 
great arteries and truncus arteriosis); and patients with a univentricular heart (UVH)[5]. 
Analysis of Rhythm Registrations 
Electrocardiograms and 24-hour Holter registrations were used to determine 
incidences of AES and presence of AF episodes. All registrations were 
independently examined by two investigators. AES were quantified in Holter 
registrations as the number of AES per 24 hours including single AES, AES 
couplets and non-sustained runs of AES. Patients in the top quartile of number 
of AES per day were defined as having frequent AES. 
Statistical Analysis 
The association of potential clinical determinants with the total number of AES were 
studied using multivariable ordinary least squares regression models. Assumptions were 
checked utilizing restricted cubic splines (with 3 knots), plotting of the residuals and 
interpretation of the R2 and adjusted R2 during the different steps of model building. For 
model fit and distribution of residuals (when dependent) and/or clinical interpretation of 
graphical depictions (when independent) the number of AES variable was transformed 
by the natural logarithm (x and y-axes are back transformed numbers).
The association of potential clinical determinants with incidences of AF was performed 
using 1) univariate Cox proportional hazard models in order to select potential 
confounders in the association of interest (i.e. association of total number of AES with 
incidence AF) and to overcome potential overfitting given the low number of events 
(incidence AF); and 2) multivariable Cox proportional hazard models including relevant 
variables based on univariate analyses outcomes. The association of AES with the risk of 
death or surgery during follow-up was assessed using multivariate Cox proportion hazards 
model correcting for determinants of AES. Non-linearity and potential threshold effects 
were assessed utilizing restricted cubic splines (with 3 knots) and scaled Schoenfeld 
residuals were used to check the proportional hazards assumption. Graphical depictions 
of cumulative survival were generated by Kaplan-Meier plots stratified per quartile of 
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AES frequency. In addition, based on previous data showing that AES are predictive of 
subsequent AF in the general population, we also investigated the predictive ability of 
AES frequency for incidence of AF by first calculating the univariate C-statistic for AES 
and other potential predictors. Based on the multivariate Cox model, we investigated 
also the addition of AES to the predictive ability of combined, available and well-known 
risk factors for AF by comparing C-statistics with and without addition of AES. For 
future reference and clinical interpretation, the AES cut-off sensitivity and specificity 
were extracted from the 10-year predictive ROC curves.
For covariates with missing data (missing predominantly due to non-recording in 10.5% 
for BMI, 18.6% for MV, 18.5% for AoV and 31.6% for LA dilatation; 0% for all other 
variables) we used multiple imputation according to the Markov Chain Monte Carlo 
method. Five imputed databases were created and pooled for analyses; covariates did 
not differ between the original and/or imputed databases and showed similar results 
in comparison with full-case analysis. R statistical software v 3.2.2 (package Hmisc, 
rms, survivalROC, survival) and Statistical Package of Social Sciences version 21.0 for 
Windows (SPSS Inc. Chicago, IL, USA) were used.
Results 
Study Population
Baseline patient characteristics at the time of the first Holter registration are 
summarized in Table 1. The study population comprised 573 patients (49% 
male) with a mean age was 35±12 years. Patients had a median number of 1 
(range 1 – 12) Holter registrations. However, the majority of patients had yearly 
an ECG (N=417; 73%), whereas the remaining group had an ECG every 2-3 
years (N=77; 13%) or every ≥5 years (N=79; 14%). Patients with simple/complete 
repair (38±12 years) and complex repair (32±11 years) were significantly older 
than patients with UVH (26±8 years, p<0.01). The group of simple/complete repair 
CHD (N=279) consisted of patients with atrial septal defect (N=82), aortic valve 
disease (N=72), pulmonary stenosis (N=58), ventricular septal defect (N=33), 
patent foramen ovale (N=13), mitral valve disease (N=9), atrioventricular septal 
defect (N=5), atrial septal defect and ventricular septal defect (N=4), patent 
ductus arteriosus (N=1), cor triatrium (N=1) and tricuspid insufficiency (N=1). 
In the complex group of 252 patients, the type of CHD was either tetralogy of 
Fallot (N=105), transposition of the great arteries (N=62), coarctation of the 
aorta (N=40), pulmonary atresia with ventricular septal defect (N=20), Ebstein 
anomaly (N=13), congenitally corrected transposition of the great arteries 
(N=10) or truncus arteriosus (N=1). Surgery, either corrective or palliative, 
was performed in 505 patients (88%); nearly all patients with complex CHD 
(94%) and UVH (98%) underwent surgery at young age. In addition, a total 
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of 83 (15%) patients underwent a (re)operation during follow-up including 37 
simple/complete CHD, 40 complex CHD and 6 UVH. Interventions included 
mainly valve repair/replacement (N=60), closure of septal defects (N=9) or 
patent foramen ovale (N=8). A total of 34 (6%) patients had a history of AF. 
The initial Holter registration was routinely performed and additionally in case 
Table 1. Patient characteristicsTable 1. Patient characteristics 
 
Total 
N=573 
Complete 
N=279 
Complex 
N=251 
UVH 
N=43 
Age (yrs), mean±SD 35±12 38±12 32±11 26±8 
Male gender(%) 283(49) 124(44) 136(54) 23(54) 
BMI, mean±SD 24±4 25±4 24±4 22±4 
Surgery(%) 521(91) 242(87) 237(94) 42(98) 
AAD(%) 81(14) 38(14) 41(16) 2(5) 
Symptoms        Palpitations(%) 209(37) 116(42) 78(31) 15(35) 
   Dizziness(%) 52(9) 23(8) 26(10) 3(7) 
   Syncope(%) 27(5) 10(4) 17(7) 0 
LVF*        Normal function(%) 359(70) 198(78) 143(65) 18(47) 
   Mild dysfunction(%) 121(24) 43(17) 62(28) 16(42) 
   Moderate dysfunction(%) 29(6) 10(4) 15(7) 4(11) 
   Severe dysfunction(%) 4(1) 2(1) 1(1) 0 
Dilated LA(%)* 58(15) 34(17) 20(12) 4(17) 
Dilated RA(%)* 113(48) 40(44) 59(48) 14(64) 
Moderate AoV Dysfunction(%) 30(6) 20(8) 6(3) 4(12) 
Moderate MV Dysfunction(%) 24(5) 15(6) 5(3) 4(12) 
History of  AF(%) 34(6) 21(8) 7(3) 6(14) 
AAD=anti-arrhythmic drugs; AF=atrial fibrillation; AoV=aortic valve; BMI=Body Mass Index; 
LA=left atrium; LVF=left ventricular function; MV=mitral valve; RA=right atrium  
*missing data 
 
of symptoms suggestive for arrhythmias including palpitations (N=209; 37%), 
dizziness (N=52; 9%) and/or syncope (N=27, 5%). Patients without (N=272, 
50%) and with (N=20, 59%) a history of AF both had complaints of symptoms 
(p=0.38).
Clinical Determinants of Atrial Extrasystolic Beats 
As demonstrated in Table 2, the average number of AES was 578 (95% range: 0 – 3583) 
per day and the median number of AES was 22/day (interquartile range 5 – 116). 
Patients with simple/complete repaired CHD, complex CHD and UVH had a median 
number of AES per day of respectively 25, 15 and 81. 
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There was a positive association of the number of AES/day with age (p<0.001), female 
gender (p=0.028) and UVH defect (p=0.001; Figure 1). Furthermore, individuals with 
left atrial dilation had a higher number of AES per day (p<0.001) (Figure 1).
During follow-up, a total of 17 patients died due to heart failure (N=4), cerebrovascular 
event (N=2), out-of-hospital cardiac arrest (N=2), postoperative pneumonia (N=1), 
after ICD defibrillator threshold testing (N=1), septic shock (N=1) and unknown cause 
(N=6). 
Atrial Extrasystolic Beats and De Novo Development of Atrial Fibrillation
Thirty-four GUCH patients had a history of AF prior to the Holter registration, while 
another 29 patients developed de novo AF during a median follow-up of 51.6 months 
(IQR 22.8 – 85.7). At the end of follow-up, patients had either paroxysmal AF (N=38, 
Table 2. Atrial ectopy per congenital heart defect (CHD)
Table 2. Atrial ectopy per congenital heart defect (CHD) 
 
Total 
N=573 
Complete 
N=279 
Complex 
N=251 
UVH 
N=43 
Total AES, mean±SD 578±2219 427±1754 506±1703 1977±5220 
Total AES, median(IQR) 22(5–116) 25(5–106) 15(3–85) 81(7–788) 
AF 
    
   - pre Holter(%) 34(6) 21(8) 7(3) 6(14) 
   - post Holter(%) 29(5) 9(3) 14(6) 6(14) 
     
No AF, N(%)  510(89) 249(89) 230(92) 31(72) 
Total AES, mean±SD 404±1787 328±1502 377±1465 1218±4292 
Total AES, median(IQR) 17 (4–81) 21 (5–88) 12 (3–68) 38(3–219) 
     
AF pre, N (%) N=34 (6) 21 (8) 7 (3) 6 (14) 
Total AES, mean±SD 1672±3349 1645±3597 1307±2803 2194±3512 
Total AES, median(IQR) 173(39–1186) 83(35–1349) 240(3–952) 613(123–4268) 
     
AF de novo, N(%) 29(5) 9(3) 14(6) 6(14) 
Total AES, mean±SD 2349±4903 326±613 2220±3241 5687±9269 
Total AES, median(IQR) 127(34–2247) 120(34–306) 195(19–4543) 461(94–13438) 
AES=atrial extrasystole; AF=atrial fibrillation; Complete=simple/complete repaired CHD; 
Complex=complex repaired CHD; interquart=interquartile; post=after Holter registration; 
pre=prior to Holter registration; UVH=univentricular heart 
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60%) or (long-standing) persistent AF (N=25, 40%). The overall incidence of AF in this 
study population was 10.8/1000 person-years. For potential determinants of AF – both 
with a history of AF as well as de novo AF – in this study population, univariate analyses 
Figure 1. Clinical determinants of total number of atrial extrasystole The plots illustrate the association between 
clinical determinants and occurrence of atrial ectopy in grown-up congenital heart disease (GUCH) patients. Scales 
for y-axis are in natural logarithm. Aortic and mitral valve function are classified as normal (0), mild dysfunction (1), 
moderate dysfunction (2) and severe dysfunction (3). BMI=Body Mass Index; Com=complex repaired congenital heart 
defect; F=female; LA=left atrium; M=males; Sim=simple/complete repaired congenital heart defect; UVH=univentricu-
lar heart;
are shown in Table 3. Left atrium dilatation, the total number of AES per day, UVH, the 
presence of moderate to severe mitral valve disease and older age were associated with a 
higher risk of AF (Table 3). 
The relation between the number of AES and de novo AF is depicted in Figure 2A. A 
one-point increase in the number of logtotal AES was associated with a 2.2-fold higher 
risk of AF development (HR 1.95; 95% CI 1.21–3.13, p=0.016; Figure 2 and Table 3). 
There was no evidence for non-linearity in the association of daily AES with the risk of 
AF (data not shown). Patients with frequent AES (top-quartile: ≥115 AES/day, Figure 
2B red line) were at higher risk to develop AF and developed AF earlier during follow-
up as compared to patients with non-frequent AES (log rank test, p<0.001). Symptoms 
(e.g. palpitations and syncope) were present in both patients with (N=83, 58%) and 
without (N=209, 49%) frequent AES (p=0.07).
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The overall discriminative ability (represented by C-statistics) of each variable for AF is 
shown in Table 3. The discriminative ability for the 10-year risk of de novo AF by the 
Table 3. Discriminative ability of determinants for the incidence of AF
Table 3. Discriminative ability of determinants for the incidence of AF 
Variable Hazard ratio (95%CI) C-statistic 
  univariate multivariate   
Left Atrium Dilatation 20.5(8.13-52.7) 12.6(4.70-34.3) 0.792 
Total AES 3.00(1.97-4.56) 1.95(1.21-3.13) 0.775 
Univentricular Heart 3.70(1.50-9.17) 4.58(1.62-12.9) 0.578 
Age 2.44(1.54-3.85) 1.66(0.95-2.89) 0.665 
Moderate/Severe AoV disease 2.27(0.97-5.31)   0.601 
Moderate/Severe MV disease 2.21(0.91-5.36)   0.553 
Female Gender 1.53(0.72-3.25)   0.540 
BMI 0.92(0.57-1.50)   0.520 
Operation 1.35(0.32-5.72)   0.512 
Addition of the number of AES for optimal set of AF prediction 
Age  
Univentricular Heart 
Left Atrium Dilatation 
    0.845 
        
After addition of total AES     0.884 (+3.9%) 
AES=atrial extrasystole; AF=atrial fibrillation; AoV=aortic valve; BMI=Body Mass Index; 
MV=mitral valve 
 
total number of AES/24hour was 79.3% with cut-offs for high sensitivity and specificity 
(>90%) at respectively a total number of 12 and 441 AES per day (Figure 3). 
In summary, the combination of left atrial dilatation, UVH and age had a good overall 
discriminative ability for incidence of AF with a C-statistic of 84.5%. Addition of total 
number of AES to this model increased the C-statistics with 3.9% to 88.4% (Table 3).
Although a higher incidence of AES was associated with a higher risk of death, this 
analysis did not reach statistical significance (HR 1.93 (0.96-3.89); P=0.069). AES were 
not associated with the risk of surgery during follow-up (HR 0.97 (0.69-1.35); P=0.81). 
Additional adjustment for AF in the model for death or surgery during follow-up did 
not change the results (data not shown).
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Figure 2. Association of the number of AES and AF development. The left panel demonstrates the association between 
increase of atrial ectopy and development of atrial fibrillation. The right panel illustrates the risk of development of 
atrial fibrillation for every quartile.
Discussion 
The key findings of this study are that GUCH patients have frequent AES at 
a relatively young age and that aging, female gender, UVH, lower body mass 
index, valvular dysfunction and left atrial dilatation are all determinants of the 
total number of AES. Furthermore, the results show that a higher number of 
AES is associated with a 2-fold higher risk for development of AF. In addition, 
ROC analysis suggests that the total number of AES contribute in the prediction 
of AF in this specific population.
Mechanism of AES
The proposed mechanisms underlying AES are (micro)re-entry and ectopic 
activity, including enhanced automaticity and triggered activity. Increased stress 
levels, both mechanical (e.g. wall stress) and neuroendocrine and hormonal 
(e.g. catecholamines), favour enhanced automaticity and triggered activity. 
The ongoing mechanical stress due to e.g. volume and/or pressure overload 
may increase accumulation of fibroblasts and deposition of extracellular matrix 
proteins that lead to the formation of fibrosis[17, 18]. The fibroblast itself may 
induce ectopic activity[19]. Furthermore, fibrogenesis (scarring) leads to loss of 
cell-to-cell connections that result in conduction disorders (conduction block) 
which favour development of re-entry. Previous invasive studies showed that 
these areas of scarring and conduction disorders are often extensively present in 
GUCH patients as a result of ongoing volume and/or pressure overload as well 
as the (multiple) surgical interventions[20, 21]. 
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Figure 3. Predictive value of the number of AES for development of de novo AF. The upper panel illustrates a ROC 
curve for total number of AES and development of AF. The lower panel shows different cut-off values of the number of 
AES for development of AF. AUC=area under the curve
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Frequency of AES in Patients with Congenital Heart Defects
Conen et al examined risk factors for the presence and frequency of AES in the general 
population[9]. Comparable to their findings, in our population of GUCH patients we 
observed a positive association between age and the total number of AES/day. Chong 
et al observed a median number of 12 beats per day in patients at the mean age of 
67 years who were referred to the hospital with palpitations, dizziness or syncope[12]. 
Although the number of AES is associated with a higher age, we observed a median 
number of 22 AES per day in our study population of only 35 years old. Suzuki et 
al later found a relation between left atrial dilatation/size and the number of AES per 
day[13]. In line with these results, we also observed an increased number of AES in 
patients with LA dilatation. Furthermore, the incidence of AF in our relative young 
population was 10.8/1000 person-years, which is according to The Rotterdam Study 
nearly comparable to the incidence of AF in the general population between 70 – 75 
years old[24]. Although there might be confounding by indication due to the obligatory 
presence of a Holter registration, the incidence of AF is high at a relative young age in 
GUCH patients. However, the incidence may be even higher than described as episodes 
of undiagnosed or asymptomatic AF might have been missed which is also the case 
in the general population[25]. A longer follow-up period could reveal more patients 
with AF. In addition, implantable loop recorders could give further insight in the ‘true’ 
incidence of AF. 
The Role of AES and Development of AF
Initiation of AF is initially caused by triggers and is maintained over time by an 
arrhythmogenic substrate. Several studies focused on the origin and role of AES beats 
as triggers of these AF episodes. Haissaguere et al. observed that the majority of AF 
episodes was initiated by AES originating from the pulmonary veins[7]. Isolation of the 
pulmonary veins resulted in a decrease of AES and thereby a decrease of AF episodes. 
Subsequent studies confirmed these findings, which ensured pulmonary vein isolation 
is the choice of therapy in the prevention of recurrence of AF episodes, especially in 
patients with paroxysmal AF[26]. The role of pulmonary vein isolation in patients 
with CHD has less been examined. Philip et al showed in a group of patients with 
varying types of CHD that endovasvular pulmonary vein isolation might be successful, 
although success rates were lower compared to patients without CHD[27]. These lower 
success rates of endovascular pulmonary vein isolation in patients with CHD indicate 
that either the procedure is more challenging due to the different anatomy or that the 
AES initiating AF episodes originate from other atrial sites than the pulmonary veins. 
The atria in GUCH patients are affected by the extensive presence of e.g. surgical scar 
or prosthetic materials in addition to the altered anatomy. The atria are therefore more 
prone to development of AF. Furthermore, a previous report suggested that other atrial 
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sites are capable of initiating ectopic activity in hearts with ongoing overload/heart 
failure as a result of a different mechanism such as calcium overload leading to delayed 
afterdepolarization[28]. The high success rates of the comprehensive surgical Maze 
procedure suggest that AES in CHD patients originating from the pulmonary veins still 
play an important role in initiation of AF, thereby preventing recurrence of AF. Deal et 
al observed no AF recurrence in patients who underwent a Fontan procedure after 3 
years of follow-up[29]. 
Frequent AES may Predict AF
The burden of AES increases the risk of AF development[12-14, 30]. Wallmann et 
al investigated the role of AES as a marker for development of AF in patients with 
an ischemic stroke[30]. More recent studies observed comparable results including a 
50% higher risk of admission for AF in healthy subjects with every 10 AES per hour 
increase[12-14]. In our study population of GUCH patients, AES frequency is also 
associated with development of AF. ROC curve cut-offs for the 10-year predictive value 
of AF showing high sensitivity for ≤12 AES per day and high specificity for ≥441 AES 
per day. AES might be more common in CHD patients with progressive heart failure 
which may subsequently result in the formation of an arrhythmogenic substrate. We 
hypothesize that in these patients, observational prospective studies could give further 
insight into whether a reduction of the number of AES with pharmacological therapy 
could lower the chance for new-onset AF. 
Next to AES, aging and LA dilatation were both associated with development of AF 
in our GUCH population; this relation is also observed in patients without CHD. 
However, the role of other risk factors for AF such as hypertension and diabetes, which 
are frequently seen in the aging population without CHD, remains uncertain due to the 
low prevalence in our study population.
Limitations
The main limitation of this study is that data was obtained retrospectively, which may 
increase the risk of information bias given that data-availability could be different for 
specific subgroups. However, this was coped with by using multiple imputation for 
missing data of covariates, also accounting for non-random missing data. Another 
limitation is that the study was performed in patients with various CHD types presenting 
at our outpatient clinics, although we did account for these differences in our statistical 
models, this may affect the generalizability of the study results. Furthermore, due to 
the low prevalence of known risk factors of AF such as hypertension and diabetes, these 
risk factors were not used for assessment of AF development in this specific patient 
population. Also, heart failure can play a role in development of AF. However, the 
retrospective design limited us to accurately assess the presence of the diagnosis heart 
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failure and this may in future prospective studies be of added value in the prediction of 
AF. This study is limited by the small number of patients who developed AF. In addition, 
we considered new-onset of AF as the first documented episode. Due to asymptomatic 
AF, the number of patients with AF is probably underestimated. Implantable loop 
recorders might improve detection of asymptomatic AF episodes. 
Different cut-off values have been found in several patient populations mainly based 
on top-quartiles. Although we observed a higher risk of AF development in the top-
quartile, a clear cut-off value was lacking according to our data when looking at non-
linearity. However, a total number of ≥441 AES per day showed a high specificity for 
prediction of AF. Future prospective studies amongst patients with congenital heart 
defects are needed to verify our results.
Conclusion 
In GUCH patients, the number of AES is associated with aging, female gender, 
UVH and left atrial dilatation. Furthermore, an increased number of AES 
is associated with a higher risk of AF development in this study population. 
Therefore, close follow-up is justified in GUCH patients with frequent AES who 
are at high risk for new-onset of AF. Patient characteristics and the total number 
of AES per day should be taken into account when treating patients in order to 
reduce the risk of AF development. 
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Abstract
Background: The incidence of atrial fibrillation (AF) is rising in the aging patients 
with congenital heart defects (CHD). However, studies reporting on AF in patients 
with CHD are scarce. The aim of this multicenter study was to examine in a large 
cohort of patients with a variety of CHD: (1) the age of onset and initial treatment of 
AF, coexistence of atrial tachyarrhythmia and (2) progression of paroxysmal to (long-
standing) persistent/permanent AF during long-term follow-up.
Methods and Results: Patients (n=199) with 15 different CHD and documented AF 
episodes were studied. AF developed at 49±17 years. Regular atrial tachycardia (AT) 
coexisting with AF occurred in 65 (33%) patients; 65% initially presented with regular 
AT. At the end of a follow-up period of 5 (0–24) years, the ECG showed AF in 81 
patients (41%). In a subgroup of 114 patients, deterioration from paroxysm of AF to 
(long-standing) persistent/permanent AF was observed in 29 patients (26%) after only 
3 (0–18) years of the first AF episode. Cerebrovascular accidents/transient ischemic 
attacks occurred in 26 patients (13%), although a substantial number (n=16) occurred 
before the first documented AF episode.
Conclusions: Age at development of AF in patients with CHD is relatively young 
compared with the patients without CHD. Coexistence of episodes of AF and regular 
AT occurred in a considerable number of patients; most of them initially presented 
with regular AT. The fast and frequent progression from paroxysmal to (long-standing) 
persistent or permanent AF episodes justifies close follow-up and early, aggressive 
therapy of both AT and AF.  
WHAT IS KNOWN
• Compared to patients with congenital heart defects have improved survival and are now getting 
 older which is associated with an increased incidence of atrial fibrillation.
• Atrial tachyarrhythmias and atrial fibrillation may coexist more commonly in patients with 
 congenital heart defects.
WHAT THE STUDY ADDS
• Compared to patients without congenital heart defects or with simple congenital heart 
 defects, atrial fibrillation develops at a younger age in patients with complex congenital 
 heart defects.
• Episodes of atrial fibrillation and atrial tachycardia frequently coexist in patients with 
 congenital heart defects.
• Progression from paroxysmal to longstanding persistent/permanent atrial fibrillation 
 occurs frequently and relatively fast after the initial episode of atrial fibrillation.
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Introduction
A trial fibrillation (AF) and regular atrial tachycardia (AT), such as typical atrial flutter 
and intra-atrial reentry tachycardia, occur frequently in patients with congenital heart 
defects (CHD).1,2 The reported incidence of AF in adult CHD patients reaches >10%.3–
5 Kirsh et al6 examined characteristics of CHD patients (n=149) who were scheduled 
for electric cardioversion of regular AT (n=102, 68%), AF (n=30, 20%), or both (n=17, 
11%) and found that compared with intra-atrial reentry tachycardia patients, those with 
AF were older (24 versus 21 years) and the arrhythmia developed later after surgery (13 
versus 11 years), although these differences were not statistically significant. Furthermore, 
AF was more frequently observed in patients with residual left-sided obstructive lesions 
or unrepaired heart defects.
Knowledge of the time course of AF in CHD patients is limited but is essential as AF is 
associated with severe complications, such as cerebrovascular events or heart failure.6–8
The aim of this multicenter study was (1) to examine the age of onset of AF, coexistence 
of atrial tachyarrhythmia, and initial treatment of AF in a large cohort of subjects with 
a variety of CHD and (2) to study the progressive nature of AF after the first episode 
during long-term follow-up.
Methods
This retrospective longitudinal multicenter study was designed as part of the Dysrhythmias 
in Patients With Congenital Heart Disease (DaNaRA) project (MEC-2012–482), 
which was approved by the local ethics committee in the Erasmus University Medical 
Center, Rotterdam. Informed consent was not obliged.
Study Population
Patients with CHD and at least 1 documented episode of AF observed during routine 
control at the outpatient clinic, hospitalization, or at the emergency room were derived 
from medical databases of the participating hospitals in the Netherlands, including 
Erasmus University Medical Center, Rotterdam; Amphia Hospital, Breda; Medisch 
Spectrum Twente, Enschede; VU Medical Center, Amsterdam; Haga Hospital, The 
Hague; Catharina Hospital, Eindhoven; and Center Hospitalier Universitaire Vaudois, 
Lausanne, Switzerland.
Data on demographics and clinical characteristics, including type of CHD, 
echocardiograms, cardiac surgery, prescribed antiarrhythmic drugs (AAD), outcome of 
cardioversion, and ablative therapy, such as endovascular catheter ablation for pulmonary 
vein isolation (ePVI), surgical pulmonary vein isolation (surPVI), transient ischemic 
attack (TIA), cerebrovascular accidents, and death, were retrieved from the patient 
medical records. PVI, either endovascular or surgical, was considered successful when 
isolation of all pulmonary veins was achieved. Regarding the type of CHD, we grouped 
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the patients according to complete repair (aortic valve disease [AVD], atrial septal defect 
[ASD], atrioventricular septal defect, ventricular septal defect [VSD], patent ductus 
arteriosus, pulmonary stenosis, and cor triatrium), complex repair (coarctation of the 
aorta, Ebstein anomaly, pulmonary atresia with VSD, situs inversus, tetralogy of Fallot, 
transposition of the great arteries [TGA], congenitally corrected TGA [ccTGA]), and 
patients with a univentricular heart (UVH). Patients were followed until June 2014.
Analysis of the Rhythm Registrations
ECG and 24-hour Holter registrations were reviewed for episodes of AF or regular AT; 
all registrations were independently examined by 2 investigators. AF was defined as an 
irregular rhythm combined with a clear beat-to-beat variation in the morphology of 
atrial waves. We did not differentiate between a typical (counter) clockwise atrial flutter,
intra-atrial reentry tachycardia, or ectopic atrial tachycardia, as differentiation between 
these types of AT cannot always be made based on the surface ECG only.9 The time 
frame of progression from paroxysmal AF to (longstanding) persistent/permanent AF 
was defined as the moment of the initial AF episode until the moment of the persistent 
AF episode.
Statistical Analysis
Continuous variables were expressed as mean±SD or median and interquartile range 
(25% and 75%). Student’s t test or ANOVA test was used to compare patient groups. 
Categorical data were denoted by percentages and compared with the McNemar test, 
χ2 test, or Fisher exact test. Factors associated with the age of development of AF were 
estimated with the use of linear regression models. Kaplan–Meier curves were made to 
illustrate the risk of progression from paroxys-mal to longstanding persistent/permanent 
AF.
A P value of <0.05 was considered statistically significant. Statistical analysis was 
performed with SPSS, version 21 (IBM, Armonk, NY).
Results
Study Population
A total of 199 CHD patients with documented AF episodes are outlined in Figure 1. The 
study population consisted of 15 different CHD, including ASD (n=58), AVD (n=34), 
tetral-ogy of Fallot (n=21), TGA (n=17), UVH (n=16), VSD (n=12), coarctation of the 
aorta (n=9), patent ductus arteriosus (n=7), pulmonary stenosis (n=7), atrioventricular 
septal defect (n=4), ccTGA (n=4), Ebstein anomaly (n=4), pulmonary atresia with VSD 
(n=4), cor triatrium (n=1), and situs inversus (n=1). Corrective or palliative cardiac 
surgery was performed in 150 patients (75%) at a median age of 12 (3–37) years; the 
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median number of surgical procedures performed was 1 (0–6). Eighteen of them had 
the first documented AF episode 1 (0–3) year before the initial surgical procedure.
First Episode of Atrial Fibrillation
In the entire study population, the first episode of AF was documented at a mean age 
of 49±17 years. As demonstrated in Figure 1, the age of AF onset was widespread in 
most of the various CHD groups. Yet, patients with more complex defects, such as 
TGA (35±7 years) and UVH (29±11 years), mainly developed AF before the age of 40 
years which is significantly younger than patients with ASD (57±6 years, P<0.01), AVD 
(53±15 years, P<0.01), or VSD (54±18 years, P<0.01).
Echocardiographic findings <1 year before the first episode of AF were obtained in 
94 patients (47%). Thirtynine patients (41%) were known with a septal defect (ASD, 
n=9; VSD, n=9), severe valvular dysfunction (aortic, n=4; mitral, n=4; pulmonary, 
n=8; tricuspid, n=8), and severe ventricular dysfunction (n=5). In addition, 29 patients 
(31%) had at most a moderate dysfunction of a valve (aortic, n=5; pulmonary, n=5; 
mitral, n=7; tricuspid, n=7) and ventricle (n=14). Among the patients without an 
echocardiographic report, 14 patients (13%) underwent a surgical procedure in the 
year of the first AF episode ≤3 years later for either an ASD (n=5) or valve repair (mitral 
valve, n=1; tricuspid, n=4; and aortic, n=8).
Coexistence of Atrial Tachyarrhythmia
Figure 2 shows examples of ECGs demonstrating a regular AT preceding development 
of AF observed in an ASD patient (upper panel) and a regular AT observed in a patient 
with PS who initially presented with AF and was treated with class II AAD (lower 
panel). AF coexisted with regular AT in 65 patients (33%) with 11 different types of 
CHD (Figure 3, upper panel). As illustrated in the lower panel of Figure 3, regular AT 
was documented 3 (0–7) years before AF in 42 patients (65%); in the remaining 23 
patients (35%), regular AT was observed only 4 (1–7) years after the initial episode of 
AF. Patients with AF after a documented episode of regular AT (n=42; 44±14 years) 
tended to develop AF at a younger age compared with patients with only AF (n=157; 
50±17 years, P=0.05), also partially because of a relatively high number of patients with 
complex CHD (eg, TGA) and UVH with coexistence (P=0.09).
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Initial Treatment of Atrial Fibrillation
Therapy of AF at the moment of the first presentation is summarized in Figures 4 
and 5 for 199 patients with complete repair, complex repair, and UVH. At the initial 
presentation with AF, cardioversion was performed in 73 (37%) patients, and AAD were 
started in 79 (40%) patients. Initial therapy could not be retrieved in 7 patients. During 
the follow-up period, ePVI (n=7) and surPVI (n=8) were performed in 14 patients, 
mainly with complete repair. surPVI was performed concurrent with other surgical 
procedures except for 1 patient. All ePVI and surPVI (n=14, 7%) were successful during 
procedure although 1 patient with ePVI underwent an additional surPVI 1 year after 
the initial procedure. Six patients underwent a pacemaker implantation followed by a 
His bundle ablation because of recurrent drug refractory AF episodes. Despite ablative 
therapy, episodes of AF were still found after a period of 5 (0–13) years in 5 of them 
(36%) and 1 patient developed a regular AT after surPVI.
Rhythm was evaluated in 197 patients after a follow-up period of 5 (2–11) years; 2 
patients were lost to follow-up. At the end of the follow-up period, 21 patients (11%) 
had died at the age of 61±18 years (ASD: n=7, tetralogy of Fallot: n=6, AVD: n=3, 
Figure 1. 
Age at the time of first presentation with atrial fibrillation (AF) per type of congenital heart disease (CHD), with the 
mean age denoted by a bar. ASD indicates atrial septal defect; AVD, aortic valve defect; AVSD, atrioventricular septal 
defect; ccTGA, congenitally corrected transposition of the great arteries; CoA, coarctation of the aorta; CorT, cor 
triatrium; Ebs, Ebstein anomaly; PA+VSD, pulmonary valve atresia with ventricular septal defect; PDA, patent ductus 
arteriosus; PS, pulmonary valve stenosis; SI, situs inversus; TGA, transposition of the great arteries; ToF, tetralogy of 
Fallot; UVH, univentricular heart; and VSD, ventricular septal defect.
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Figure 2. 
Coexistence of regular atrial tachycardia with atrial fibrillation: ECGs obtained from a patient with an atrial septal 
defect (top) and pulmonary stenosis (bottom).
TGA: n=2, ccTGA: n=1, cor triatrium: n=1, and UVH: n=1); only 7 (33%) of them 
were treated with AAD, ePVI, and surPVI. Causes of death were heart failure (n=11), 
(postoperative) infection (n=3), ventricular fibrillation (n=2), respiratory insufficiency 
(n=1), ventricular fibrillation after defibrillator threshold-testing during implantable 
cardioverter defibrillator implantation (n=1), or unknown (n=3). Twelve patients had 
AF before death. In the remaining 176 patients, the last ECG demonstrated AF in 69 
patients (39%); the other patients had sinus rhythm (n=72, 41%), atrial ectopic rhythm 
(n=11, 6%), AT (n=1, 1%), or paced rhythm (n=24, 14%). AF was most often found in 
the patients with ASD (n=26; 51%), whereas AF was only observed in 1 UVH patient 
(7%).
Progression of Atrial Fibrillation
Progression of AF from paroxysmal to (longstanding) persistent/permanent AF over 
time was studied in a subgroup of 112 patients of whom at least a yearly ECG was 
available. As illustrated in Figure 6, progression was observed in 29 patients (26%). 
Four patients were already known with persistent AF when presenting for the first time. 
AF progressed from paroxysmal to (longstanding) persistent/permanent AF after only 3 
(1–7) years in 29 patients, despite therapy aimed at rhythm control after the initial AF 
episode (AAD: n=20, 69%; surPVI: n=3, 12%). In the 79 patients without progression 
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Figure 3. 
Top, Coexistence of atrial tachycardia (AT) and atrial fibrillation (AF) for every congenital heart disease (CHD) group 
separately. Bottom, Coexistence classification according to either first AT or first AF per type of CHD. ASD indicates 
atrial septal defect; AVD, aortic valve defect; ccTGA, congenitally corrected transposition of the great arteries; CT, 
cor triatrium; PA+VSD, pulmonary valve atresia with ventricular septal defect; PDA, patent ductus arteriosus; PS, 
pulmonary valve stenosis; TGA, transposition of the great arteries; ToF, tetralogy of Fallot; UVH, univentricular heart; 
and VSD, ventricular septal defect.
to (longstanding) persistent/permanent AF, 77 (97%) were treated with AAD. Five 
patients (6%) also underwent an ePVI/surPVI.
Thromboembolic Complications of Atrial Fibrillation
Sixteen patients (8%) experienced a cerebrovascular event 14 (2–33) years before the 
initial AF episode (TIA, n=5 and stroke, n=11). In addition, AF was discovered in 3 
patients when presenting with a stroke. Two of them were already using anticoagulant 
drugs including 1 patient who had a hemorrhagic stroke.
Furthermore, 9 patients (5%) had a cerebrovascular event 2 (1–6) years after the 
initial documented AF episode, including 6 TIA and 3 stroke. Five of them were 
using anticoagulant drugs; data regarding prescribed drugs were missing in 3 patients. 
Altogether, 26 patients experienced a cerebrovascular event including 2 patients who 
had a TIA and stroke.
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Figure 4. 
Flowchart showing the initial atrial fibrillation (AF) therapy and longterm outcome in patients with complete repair: 
aortic valve disease, atrial septal defect, cor triatrium, pulmonary stenosis, atrioventricular septal defect, and ventricular 
septal defect. See text for detailed explanation. AAD indicates antiarrhythmic drugs; CV, cardioversion; HBA, His 
bundle ablation; ePVI, endovascular pulmonary vein isolation; and surPVI, surgical pulmonary vein isolation.
Figure 5. 
Left, Flowchart demonstrating the initial atrial fibrillation (AF) therapy and long-term outcome in patients with 
complex repair (coarctation of the aorta, congenitally corrected transposition of the great arteries, Ebstein anomaly, 
pulmonary atresia with ventricular septal defect, situs inversus, tetralogy of Fallot, and transposition of the great 
arteries). See text for detailed explanation. Right, Flowchart illustrating AF therapy and long-term outcome in patients 
with univentricular heart defects. AAD indicates antiarrhythmic drugs; CV, car-dioversion; HBA, His bundle ablation; 
and surPVI, surgical pulmonary vein isolation.
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Figure 6
Top, Progression of paroxysmal atrial fibrillation (AF) to (long-standing) persistent/permanent AF in 29 patients with 
a diverse congenital heart disease. See text for detailed explanation. Bottom, Kaplan–Meier curve with the cumulative 
risk of progression from paroxysmal to (longstanding) persistent/permanent AF. ASD indicates atrial septal defect; 
AVD, aortic valve disease; CoA, coarctation of aorta; Ebs, Ebstein anomaly; ToF, tetralogy of Fallot; and VSD, ventri-
cular septal defect.
Discussion
To our knowledge, this is the first study examining development of AF over time in 
a large cohort of patients with CHD. Onset of AF occurred at a relatively young age, 
particularly in patients with complex CHD (TGA and UVH). Coexistence of episodes 
of AF and regular AT occurred in a considerable number of patients (33%). Most of 
them initially presenting with regular AT; this occurred more frequently in patients 
with complex defects, such as TGA and UVH. Progression from paroxysmal to (long-
standing) persistent AF was observed in patients with a variety of CHD, especially ASD, 
and occurred only 3 years after the initial documented AF episode.
Development of (Postoperative) AF
Areas of intra-atrial conduction delay or dispersion in refractoriness perpetuate AF.10–13 
Previous electrophysiological studies have demonstrated that multiple zones of intra-
atrial conduction delay and increased dispersion in refractoriness are indeed present in 
patients with surgically corrected CHD.14 Multiple or complex surgical procedures give 
rise to scarring with interposition of fibrotic tissue hampering intra-atrial conduction. 
Conduction abnormalities may be further aggravated by dilatation of the atria because 
of persisting pressure/volume overload after cardiac surgery15 or because of (long-
standing) residual septal defects, valvular, or ventricular dysfunction as observed in our 
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study population. Dilatation of the atria also promotes triggered activity, giving rise to 
premature beats.16,17 Thus, a high number of premature beats combined with large areas 
of conduction delay and local dispersion in refractoriness increase the likelihood for AF 
to occur in this patient group.
To date, observations on the mechanism underlying AF in CHD patients are rare. 
Mapping studies in patients without CHD have demonstrated that the mechanism 
underlying AF may be either focal activity giving rise to fibrillatory conduction or 
multiple, narrow, independently propagated fibrillatory waves.18 Ectopic activity giving 
rise to fibrillatory conduction and hence AF on the surface ECG has been described in 
a patient with Fontan circulation and a TGA patient who had undergone an arterial 
switch procedure.19 The origin of ectopic activity was found in respectively the right 
atrial septum and right atrial free wall, and AF was eliminated by encircling the area of 
focal activity in both patients.19
Aging and Atrial Fibrillation
Patients in our study with ASD, AVD, and VSD developed AF between the fifth and 
sixth decade. As demonstrated in the Rotterdam and Framingham Study, the incidence 
of AF in the general population starts to increase in the fifth decade.20,21 Thus, CHD 
patients with these defects developed AF in the same decade as subjects in the general 
population. However, patients with other defects, in particular UVH and TGA, fre-
quently developed AF already in the third or fourth decade. It is therefore likely that 
development of AF in CHD patients is not only a result of aging.
Coexistence of AT and AF
Coexistence of AF with regular AT was found in 33% of our population. Kirsh et al6 
examined the relation between intra-atrial reentry tachycardia and AF in patients with 
CHD who underwent electric cardioversion. They found that only 17 of 149 subjects 
had both atrial flutter and AF; there was no evidence for progression from atrial flutter 
to AF in these patients or vice versa.6 Ghai et al22 observed in a cohort of Fontan patients 
that development of atrial arrhythmias, including AF and regular AT, was related to a 
higher number of surgical procedures. Cardiac surgery results in atrial incisions and 
insertion of prosthetic materials and the postoperative (persisting) pressure/volume 
overload may further give rise to extensive atrial scarring.23–25 These alterations facilitate 
development of macro reentrant tachycardia as the reentry wavelet can circulate around 
surgically inserted prosthetic materials, suture lines, and areas of scar tissue. Focal 
AT also frequently arise in patients with CHD as low voltage areas result in dimin-
ishing electric coupling thereby facilitating ectopic activity. Regular AT cause electric 
remodeling, consisting of shortening of atrial refractoriness and inverse rate adaptation, 
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thereby facilitating development of AF.26,27 This may explain why regular AT preceded 
development of AF in a large proportion of our population. These findings suggest that 
catheter ablation of regular AT, which is nowadays an accepted treatment modality with 
a reported successful outcome of at least 70% in patients with CHD, could prevent or 
delay the development of AF in some CHD patients.19,28,29
In some patients, episodes of regular AT were documented only after development of 
AF. It could simply be that episodes of AF and AT alternate in CHD patients, due to, for 
example, formation of a functional line of conduction block between the caval veins30,31 
and that the first AF or first regular AT episode is just a matter of which tachycardia is 
by chance documented. Recurring episodes of AF may also play an important role in 
the progression of paroxysmal to persisting AF. Twenty-six percent of our population 
showed deterioration from paroxysms of AF to (longstanding) persistent/permanent AF. 
Progression to persistent or permanent AF has been reported up to 18% and 25% in 
patients without CHD after a follow-up period of 4 and 5 years, respectively.32,33
In patients without CHD, electric and structural remodeling both contribute to the 
persistence of AF,34 which might be aggravated by chronic atrial stretch because of 
persistent pressure/volume overload.35 However, at present, there are no data available 
on the relation between remodeling and progression from paroxysmal to (longstanding) 
persistent/permanent AF in CHD patients. Older age at the moment of first AF 
presentation may influence progression to (longstanding) persistent/permanent AF as 
patients with progression in the European Heart Survey tended to be older than those 
who did not.36 In our study population, progression of paroxysmal to (longstanding) 
persistent/permanent AF was relatively often observed in patients with ASD; a group 
that presents with AF at a relative old age compared with the other groups.
Role of the Pulmonary Vein Area
Deal et al37 reported on surgical treatment of atrial arrhythmias in patients with a 
Fontan correction. After palliative surgery combined with a Cox-Maze III procedure 
in 76 patients with AF, there were no recurrences observed. ePVI has been reported as 
well.38 Likewise our study, ePVI was especially performed in patients with complete 
repaired defects, such as ASD and VSD. After a follow-up period of 4 years, 27% was 
successfully treated, which was comparable with patients without CHD (36%; P=0.46). 
In a study by Kirsh et al,6 patients who underwent palliative surgery or with residual 
left ventricular valvular lesions intended to develop AF more frequently. A substantial 
part of our study population was uncorrected at the time of presentation or needed a 
reoperation for valvular regurgitation/stenosis or residual shunting. These data suggest 
that the posterior left atrial wall also plays a role in the development of AF in CHD 
patients, possibly because of remodeling after long-term volume and pressure overload.
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Cerebrovascular Complications of Atrial Fibrillation
The total incidence of TIA/stroke in our population was 13%. However, a considerable 
number of cerebrovascular events occurred before the initial documented AF episode. 
We cannot exclude that these patients had asymptomatic AF episodes. In patients 
with lone AF without concomitant heart disease, there is a lower incidence of TIA/
stroke compared with our study population.39 Six percent had a TIA/stroke during a 
long-term follow-up period of 15 years. Hoffmann et al also demonstrated a higher 
risk of cerebrovascular accidents in CHD patients. A 10- to 100-fold higher risk to 
develop cerebrovascular accidents was found in the relative young CHD population, 
with and without atrial arrhythmias, compared with patients of the same age.40 A higher 
cerebrovascular accident rate was associated with the absence of sinus rhythm and 
cyanotic heart disease. Therefore, other risk stratifications might be necessary to prevent 
cerebrovascular events not only in CHD patients with AF but also in CHD patients 
without AF.
Study Limitations
Because of the retrospective design of this multicenter study, data on exact surgical details 
or prescribed antiarrhythmic/anticoagulant drugs during the entire follow-up period 
were insufficient for some patients. Onset of AF was defined as the first documentation 
of an AF episode using available ECG or 24-hour Holter monitoring. Asymptomatic 
paroxysms of AF could therefore have been missed. In addition, differentiation between 
(longstanding) persistent or permanent AF could not always be made. Furthermore, 
because of the selection of patients with a yearly ECG to assess to progression of 
paroxysmal to longstanding persistent/permanent AF, the relative number of patients 
with progression might have been overestimated compared with patients encountered in 
daily practice. Patients in this study underwent the first surgical procedure at a relatively 
older age compared with newborn CHD patients nowadays.
Conclusions
Patients with CHD develop AF at a young age, particularly in patients with complex 
defects, and progress frequently from paroxysmal AF to (longstanding) persistent/
permanent AF. Coexistence of episodes of AF and regular AT occurred in a considerable 
number of patients; most of them initially presented with regular AT. The findings of our 
study suggest that aggressive therapy and close follow-up of CHD patients with atrial 
tachyarrhythmias are justified. Early (ablative) therapy for regular AT could theoretically 
prevent development of AF and hence also reduce long-term complications, such as 
stroke.
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Pharmacological Therapy of Tachyarrhythmias 
During Pregnancy
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Abstract
Tachyarrhythmias are the most frequently observed cardiac complications during 
pregnancy. The majority of these maternal and foetal arrhythmias are supraventricular 
tachyarrhythmias; ventricular tachyarrhythmias are rare. The use of anti-arrhythmic 
drugs (AADs) during pregnancy is challenging due to potential foetal teratogenic 
effects. Maintaining stable and effective therapeutic maternal drug levels is difficult 
due to haemodynamic and metabolic alterations. Pharmacological treatment of 
tachyarrhythmias is indicated in case of maternal haemodynamic instability or hydrops 
fetalis. Evidence regarding the efficacy and safety of AAD therapy during pregnancy is 
scarce and the choice of AAD should be based on individual risk assessments for both 
mother and foetus. This review outlines the current knowledge on the development 
of tachyarrhythmias during pregnancy, the indications for and considerations of 
pharmacological treatment and its potential side-effects.
Clinical Perspective
• Initiation of anti-arrhythmic drug therapy requires careful consideration of the 
 potential risks and benefits to the individual patient.
• Pharmacological therapy of a pregnant woman is required in cases of 
 haemodynamic instability and/or diminished placento-uterine blood flow.
• However, the use of AADs during pregnancy should be avoided whenever 
 possible.
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Cardiac arrhythmias during pregnancy pose a serious threat to the health of both 
mother and foetus. Women with established tachyarrhythmias, congenital heart defects 
or channelopathies have the highest risk for development of arrhythmias.1,2 They also 
develop de novo or occur in women without apparent heart diseases. Tachyarrhythmias, 
including both supraventricular and ventricular tachycardias, are the most common 
cardiac complications observed during pregnancy. Not only the mother, but also 
the foetus may develop tachyarrhythmias.3 The exact mechanisms underlying the 
development of cardiac arrhythmias during pregnancy are unknown, and selection of 
the appropriate treatment modality is hampered by the lack of randomised studies in 
pregnant women.1,4,5 This review outlines the current knowledge on the development 
of tachyarrhythmias during pregnancy, the indications for and considerations of 
pharmacological treatment and its potential side-effects.
Incidences of Cardiac Arrhythmia During Pregnancy
Maternal Arrhythmias
(Supra)ventricular premature beats are the most frequently observed arrhythmias during 
pregnancy followed by paroxysmal supraventricular tachycardias (SVT); incidences 
are 33 and 24 per 100,000 pregnancies respectively.6 Atrioventricular nodal reentrant 
tachycardia (AVNRT) and atrioventricular reentry tachycardia (AVRT) are the most 
common supraventricular tachycardias both in pregnant and non-pregnant women with 
structurally normal hearts and usually do not cause haemodynamic deterioration.7,8 
Studies investigating the risk of first onset paroxysmal SVT have shown inconsistent 
results.7,9–12 Tawam et al.9 described development of de novo paroxysmal SVTs during 
pregnancy in 13 out of 38 women (34 %). This is in contrast to a study by Lee et al.7 
who reported development of de novo paroxysmal SVT in only 3.9 % of the pregnancies. 
Recurrences were observed in 55 out of 65 (85 %) pregnant women with a history of 
paroxysmal SVT.7 In women with congenital heart disease (CHD) arrhythmias, mainly 
SVT, occurred in 4.5 % and were associated with multiple factors, including the presence 
of cyanotic heart disease (corrected/uncorrected) and usage of cardiac medication prior 
to gestation.1,13 Focal atrial tachycardia (FAT) occurs rarely during pregnancy and 
has mainly been described in case reports.14–19 Atrial fibrillation (AF) or atrial flutter 
(AFL) develop infrequently during pregnancy; a combined incidence of 2 per 100,000 
pregnancies has been reported.6 In patients with known AF/AFL, a recurrence rate of 52 
% has been described.20
The overall incidence of ventricular tachyarrhythmias (VT) or fibrillation (VF) in 
pregnant women is also very low (2 per 100,000 pregnancies).6 In women with 
structurally normal hearts monomorphic VT may develop during pregnancy, for 
example as a result of coronary artery disease or left ventricular dysfunction.21,22 VTs 
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occur more often in patients with underlying acquired (coronary artery disease, valvular 
heart disease, peripartum cardiomyopathy) or inherited (CHD or channelopathies) 
heart disease. VT recurrences have been described in 27 % of women with heart disease 
and VT episodes prior to pregnancy.20
Foetal Arrhythmias
Foetal tachyarrhythmias occur in approximately 2 % of pregnancies. Most arrhythmias 
are paroxysmal SVT (73 %) or AFL (26 %).23,24 VTs have been described in a review by 
Krapp et al.23 in 3 out of 485 cases (0.6 %) and may be associated with myocarditis, total 
atrioventricular block or congenital long QT syndrome.25
Haemodynamic Alterations During Pregnancy
During pregnancy, the cardiovascular system is faced with significant changes which 
can precipitate the occurrence of arrhythmias. First, the blood volume increases by 
35–40 % and is accompanied by an increase in heart rate and simultaneous decrease 
in vascular resistance. This leads to an increase in cardiac output of 30–50 %, already 
starting within the first weeks of pregnancy and with the largest increase occuring in 
the first 16 weeks.26–30 The increased blood volume has a physiological structural impact 
on the heart. The ventricles and atria dilate and the left ventricular mass increases 
during pregnancy.27,31 These effects are even greater in twin/multiple pregnancies.27,32 
Mechanical stretch can facilitate arrhythmias by depolarisation of the membrane 
potential, premature depolarisations and dispersion in refractoriness.33,34 Furthermore, 
the increase in heart rate during pregnancy may act as a trigger in susceptible patients.35 
There are also indications that oestrogen and progesterone may contribute to altered 
cardiac repolarisation facilitating arrhythmias.36
Besides the hyperdynamic state and altered hormonal status possibly predisposing 
pregnant women to arrhythmias, the high incidence of arrhythmias in patients with 
pre-existent heart disease or previous arrhythmic episodes indicates that this is probably 
the most important risk factor for arrhythmias in pregnancy.20
Indications and Considerations for Anti-arrhythmic 
Drug Therapy during Pregnancy
The goal of anti-arrhythmic drug (AAD) therapy in general is to reduce ectopic activity 
or to modify critically impaired conduction. The ideal AAD has a greater effect on 
the arrhythmogenic substrate than on normal depolarising tissues, decreases mortality 
and has no side-effects. However, many of the currently available AADs have pro-
arrhythmogenic effects and could even increase mortality.4
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Pharmacological therapy of a pregnant woman is imperative in case of haemodynamic 
instability and/or diminished placento-uterine blood flow. The main issue of 
pharmacological treatment of tachyarrhythmias during gestation is the potential 
teratogenic effect on the foetus as most AADs cross the placental barrier. Maintenance 
of adequate therapeutic drug levels in pregnant women is challenged by an increased 
intravascular volume, reduction of plasma proteins concentrations, increased renal blood 
flow and hepatic metabolism. Gastrointestinal absorption is also altered by changes in 
gastric secretion and intestinal motility.37,38 Foetal tachyarrhythmias should be treated 
when there is a risk of developing foetal heart failure. Subsequently, hydrops fetalis may 
develop and premature delivery or foetal death may occur.39,40
Effects and Safety of Anti-arrhythmic Drugs
There are very limited data available for the effects and safety of AAD therapy in 
pregnancy. The US Food and Drug Administration (FDA) has classified drugs into 
five categories (A–D and X) to indicate the supposed effects and level of evidence. In 
categories A and B studies did not show any foetal toxic effects, where in category B 
the evidence is only from animal studies. In category C there have been adverse foetal 
effects demonstrated in animal studies, and in category D adverse foetal effects have 
been reported in human studies. However, for all these categories potential benefits may 
outweigh the risks and the drug may therefore be administrated if the situation requires 
it. Only in category X is the drug clearly contraindicated due to substantial evidence for 
adverse foetal effects. Here the risks do not outweigh the possible benefits. However, it 
is important to keep in mind that this system is a simplified classification and detailed 
drug information should be used when determining the potential safety in individual 
patients. Table 1 demonstrates that for most AADs some negative foetal effects have 
been reported in animal studies (category C), the most safe AADs appear to be lidocaine 
and sotalol and most adverse foetal effects during pregnancy have been reported with 
amiodarone and atenolol. The negative foetal effects of AADs that have been reported 
are also summarised in Table 1.4,41–44 The American Academy of Pediatrics (AAP) has 
classified most AADs as compatible with breastfeeding; only atenolol and amiodarone 
are possibly less favourable to use during the lactation period.45 AADs during pregnancy 
have been more extensively investigated for the treatment of foetal arrhythmias. The 
AADs recommended for foetal arrhythmias include sotalol and digoxin.46
Ventricular Tachycardia
Acute treatment of ventricular tachycardia (VT) is indicated in all patients and can be 
achieved by electrical (first choice) or pharmacological cardioversion.4 Amiodarone IV 
should only be used if VT persists, or when the VT is refractory to electrical cardioversion, 
drug resistant and haemodynamically comprising. Patients with structurally normal 
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hearts or congenital long QT syndrome should be treated with b-blockers as a 
prophylaxis for development of VT recurrences. Verapamil could also be considered in 
patients without structural heart disease.3,4
Drug Therapy
Supraventricular Tachycardia
If immediate conversion of AVNRT or AVRT is required and the vagal manoeuvre 
is unsuccessful, administration of adenosine IV is recommended.3,4 This terminates 
approximately 90 % of the AV(N) RTs;47 an alternative is IV metoprolol.3 If long-
term treatment for AVNRT is required, digitalis or metoprolol are the first-line drugs.3 
Electrical or pharmacological cardioversion for FAT, although often successful, is 
discouraged due to the relatively high risk of recurrences and is only indicated in case of 
haemodynamic instability. Administration of adenosine may successfully terminate FAT 
in 30 %.4 Rate control in FAT is indicated for the prevention of tachycardiomyopathy 
and can be achieved with the use of digitalis or metoprolol.3,4 Flecainide or propafenone 
could be considered for rhythm control therapy. Use of the lowest effective dose of 
amiodarone should only be considered when the FAT results in haemodynamic 
instability, it is refractory to all other AADs and conversion to sinus rhythm is required.4
In case of AF or AFL requiring conversion to sinus rhythm, the use of ibutilide or 
flecainide is effective and recommended for non-pregnant patients,48,49 however 
experience of these drugs during pregnancy is limited.3,4 In pregnant women with an 
AF or AFL episode with a duration longer than 48 hours that requires direct current 
cardioversion, the use of oral anticoagulants at least three weeks before cardioversion 
is necessary.4 Atrial stunning after cardioversion increases the risk of thromboembolic 
events, and it is therefore recommended that oral anticoagulants are continued for at least 
four weeks.4 Oral anticoagulants should be replaced by low molecular weight heparin in 
the first and third trimester of pregnancy because of the potential negative effects on the 
foetus. Metoprolol is the drug of first choice to control ventricular heart rate. Verapamil 
is the drug of second choice since the blood levels of digoxin during pregnancy are 
unreliable. Propafenone or flecainide in conjunction with AV nodal blocking agents or 
sotalol can be used when other rate control strategies fail.3,4,48,49
Foetal Arrhythmias
As mentioned above, persistence of foetal arrhythmias predisposes for development 
of hydrops fetalis, ventricular dysfunction or eventually death.4 Hence, treatment 
of persistent foetal arrhythmias is indicated. Pharmacological treatment of primary 
foetal arrhythmias includes digoxin as the first choice.46 If unsuccessful, sotalol and 
verapamil, procainamide or quinidine can be administered. Sodium and potassium 
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channel blockers have been safely applied during foetal ventricular arrhythmias.50,51 If 
maternal, transplacental treatment is not successful, umbilical or intraperitoneal52 drug 
administration or direct foetal intramuscular injection53 of anti-arrhythmic agents have 
been described. However, this approach has not (yet) been incorporated in the European 
or American Guidelines.
Conclusion
Prescription of anti-arrhythmic drug therapy in pregnant women is challenging due to 
the potential severe side-effects in both the mother and foetus. In addition, there are no 
major studies guiding selection of the safest and most effective anti-arrhythmic drug. 
Hence, initiation of anti-arrhythmic drug therapy requires careful consideration of the 
potential risks and benefits to the individual patient.
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General Discussion 
In daily clinical practice, atrial fibrillation (AF) is the most frequently encountered cardiac 
dysrhythmia.1-5 It is associated with significant morbidity and mortality due to e.g. 
embolic stroke (4–5-fold greater risk than in subjects without AF) or precipitating heart 
failure and results in more hospital admissions than any other cardiac dysrhythmia.2, 6-9 
Present available therapies are only moderately effective due to incomplete comprehension 
of the mechanism underlying AF. Patients with AF represent a group of subjects with 
distinctive cardiovascular diseases and arrhythmia episodes increasing in number and 
duration over time.1, 4, 5, 10 This progressiveness is rooted in electropathology, defined as 
abnormalities in electrical conduction caused by damage of the atrial structure. Areas of 
electropathology can be identified by quantifying electrophysiological parameters at a 
high resolution scale.11-13 
Value of Sinus Rhythm Mapping
Mapping during cardiac surgery offers the opportunity to examine epicardial structures, 
which cannot be reached via an endovascular approach, such as BB.14 We demonstrated 
that conduction disorders at BB, particularly long lines of longitudinal conduction 
block, are more pronounced in patients with AF episodes. However, some patients with 
(post)operative AF had no areas of conduction block, indicating that areas of conduction 
block elsewhere in the atria may also be involved in development of AF. In patients with 
coronary artery disease, mapping during sinus rhythm indeed showed that conduction 
abnormalities were diffusely present throughout the atria, though they mainly occurred 
at the high right atrium. 
Both the spatial distribution and severity of conduction disorders varied considerably 
from patient to patient but the amount of conduction abnormalities was, on average, 
small. These observations suggest that different parts of the atria are affected by a variable 
degree of structural remodeling. Remodeling of the atrial myocardium is caused by 
e.g. interstitial fibrosis and the presence of insulating collagenous septa between atrial 
muscle bundles.15-17 These alterations give rise to non-uniform anisotropic conduction 
resulting in slowing of conduction, unidirectional conduction block and initiation of 
reentry.10, 18-22 The likelihood of conduction abnormalities occurring is increased by e.g. 
ageing, atrial dilatation or the presence of structural heart diseases.10, 19 Yet, the degree 
of conduction disorders during sinus rhythm did not correlate with the occurrence of 
post-operative AF (PoAF). 
In patients with congenital heart disease and right atrial volume overload, conduction 
disorders were mainly found at the right atrium and BB. Long CB lines (≥16 mm) were 
mainly observed at RA and BB in patients with AF. Hence, it is likely that the length of 
lines of conduction block is associated with the electropathological substrate underlying 
AF.
Severer conduction abnormalities may be unraveled at higher rates or when the direction 
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of activation changes, as occurs during AF. The next step would therefore be to examine 
differences in extensiveness of electropathology, in patients with different types of AF, 
ranging from induced, paroxysmal, (longstanding) persistent or permanent AF in order 
to further elucidate the role of areas of electropathology in persistence of AF. 
Value of Simultaneous Endocardial and Epicardial Mapping of the Atrial 
Wall
Previous epicardial mapping studies demonstrated that the incidence of focal fibrillation 
waves was considerably higher in patients with longstanding persistent AF compared to 
patients with acutely induced AF. Focal fibrillation waves during AF can be explained by 
asynchronous activation of the atrial endocardial and epicardial layer and transmurally 
propagating fibrillation waves.11, 12 By performing simultaneous high-resolution mapping 
of the right atrial endocardial and epicardial wall during AF in humans, we provided 
the first evidence for asynchronous activation of the endo-epicardial wall during AF in 
humans. The next step to fully comprehend the role of endo-epicardial asynchrony in 
persistence of AF would be to perform endo-epicardial mapping of the left atrium as 
well. In the near future, determination of endo-epicardial asynchrony could be used 
to select patients who would benefit from ablative AF therapy. For example, when the 
endocardial and epicardial layers of the atria have become fully electrically dissociated, 
extensive ablative therapy is most likely to be ineffective and palliative therapy would 
therefore be a more suitable choice. The discovery of this new mechanism underlying 
AF heralds a new era of AF therapy. 
Post-Operative Atrial Fibrillation
AF after open chest surgery is still an important problem despite improved surgical 
techniques and clinical care.23-28 Development of PoAF is determined by numerous 
variables including patient characteristics, per-operative and post-operative variables, 
yet the exact mechanism underlying PoAF is still unknown.11, 12, 24, 29, 30 Besides surgery-
related triggers, the pre-existence of electropathology can facilitate development of AF 
after cardiac surgery. 
Continuous rhythm monitoring after cardiac surgery offers the opportunity to 
accurately detect cardiac dysrhythmias. Analysis of rhythm recordings as presented 
in this thesis demonstrated that frequent supraventricular ectopy was correlated with 
PoAF. In addition, specific cut-off values could be used to identify patients at risk of 
developing PoAF. However, continuous rhythm recordings obtained from bedside 
monitors still have to be analyzed manually, which is an extremely time-consuming task. 
When the proposed cut-off values can be displayed on bedside monitors in real-time, 
their prospective value and consequences of interventions on cardiac ectopy, e.g. drug 
therapy, can be evaluated. 
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Atrial Fibrillation: To Map or not To Map? 
As demonstrated in this thesis, characteristics of both triggers and arrhythmogenic 
substrates associated with development of AF vary considerably between patients despite 
similar clinical characteristics. Hence, the electrical profile of every patient is unique. 
Our observations clearly indicate the necessity of having a mapping tool available which 
can diagnose the stage of development of the substrate of AF in order to select the 
appropriate treatment modality for the individual patient. Thus, performing mapping 
studies in patients with AF is an essential step in guiding AF therapy.
Electrophysiological parameters obtained during sinus rhythm are not suitable for 
recognizing patients at risk of AF. Nevertheless, data obtained in this thesis provides 
an extensive reference database for electrophysiological properties of electrically non-
remodeled atria for future studies on the arrhythmogenic substrate underlying AF. 
Future Research
Over time, AF tends to progress from trigger dependent paroxysmal AF to a more 
substrate mediated (longstanding) persistent or permanent AF.31 A pulmonary vein 
isolation procedure may be successful in patients with paroxysmal AF32 but it will be an 
ineffective therapy for patients with more advanced types of AF. These patients are more 
likely to benefit from a substrate modification. However, even substrate modification is 
associated with frequent AF recurrences.33
Failure of therapy is caused by an insufficient understanding of the progressive nature 
of recurrent AF episodes. By simultaneous mapping of the endocardial and epicardial 
layer, we discovered a new mechanism, namely endo-epicardial asynchrony, for the 
perpetuation of AF. The role of endo-epicardial asynchrony will be further explored in 
patients with various heart diseases and stages of AF. 
Prior studies demonstrated that the key players of the protein quality control system 
of the cardiomyocyte such as heat shock proteins protect against AF progression by 
attenuation of electropathology, defined as electrophysiological alterations caused 
by structural remodeling of atrial cardiomyocytes.38-43 The correlation between 
electropathology, as identified by endocardial or epicardial mapping or (heat shock) 
protein levels and development of AF recurrences following cardiothoracic surgery, 
pulmonary vein isolation or electrical cardioversion will be investigated. All these 
projects will further increase our knowledge of the mechanism underlying AF. For as 
long as the electropathological substrate remains poorly understood and the stage of 
electropathology cannot be determined, it is challenging to define the optimal approach 
evaluated in the individual AF patient.
Thus, the quest for the arrhythmogenic substrate underlying AF will be continued…
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Summary 
The outline of this thesis is provided in chapter 1. In summary, the aims of this thesis 
were to examine 1) the clinical applicability of a novel, intra-operative high resolution, 
multi-site epicardial mapping approach of the entire atria as a routine procedure during 
cardiac surgery, 2) whether there are preferential sites of electropathology during sinus 
rhythm in patients with various underlying heart diseases, 3) the relevance of conduction 
abnormalities during sinus rhythm at Bachmann’s Bundle, 4) the role of endo-epicardial 
asynchrony in persistence of AF, 5) characteristics of post-operative atrial ectopy and 
AF, 6) the relation between electrical parameters assessed with high resolution mapping, 
atrial ectopy and post-operative AF.
Chapter 2 discusses the possible anti-arrhythmic effects of pulmonary vein isolation. 
Isolation of the pulmonary veins may be an effective treatment modality for eliminating 
AF episodes but unfortunately not for all patients. The effect of RF-ablation on 
persistent AF can be attributed to various mechanisms, including elimination of the 
trigger, modification of the arrhythmogenic substrate, interruption of crucial pathways 
of conduction, atrial debulking or atrial denervation. In patients in whom ablative 
therapy fails, it is assumed that AF has progressed from a trigger-driven to a substrate-
mediated arrhythmia. Cardiac mapping is therefore required in order to comprehend 
the mechanism of AF in the individual patient, to determine extensiveness of the 
arrhythmogenic substrate and subsequently to select the optimal treatment modality.
Bachmann’s Bundle (BB) may play a role in the pathophysiology of AF. BB, also known 
as the interatrial bundle, is well-recognized as a muscular bundle comprising of parallel 
aligned myocardial strands connecting the right and left atrial walls and is considered 
to be the main pathway of interatrial conduction. In chapter 3, the current knowledge 
of the relation between anatomical and electrophysiological properties of BB and its 
possible role in initiation and perpetuation of AF is outlined. BB is the preferential 
pathway of interatrial conduction due to its electro-anatomical properties. Disruption 
of the bundle’s structure causes interatrial conduction block, which is associated with 
development of various atrial tachyarrhythmias and with electromechanical dysfunction 
of the left atrium. Data obtained from clinical studies suggests a relationship between 
electro-pathological alterations of BB and development of AF. Further studies are still 
needed to examine the exact role of BB in initiation and perpetuation of AF and to 
determine whether BB is a potential therapeutic target to prevent the development of 
AF.
In chapter 4, we introduce the QUest for the Arrhythmogenic Substrate of Atrial 
FibRillation (QUASAR) project which is aimed at unraveling the arrhythmogenic 
substrate AF in patients with various heart diseases and different types of AF. It is the 
first study investigating electrophysiological properties on a high-resolution scale of the 
whole atrial surface in patients undergoing cardiac surgery using an innovative, epicardial 
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mapping approach. Patients are divided into groups according to their underlying heart 
disease(s) and presence of prior episodes of AF. Electrophysiological data are acquired 
during sinus rhythm and AF by high-resolution epicardial mapping (inter-electrode 
distance of 2 mm) during cardiac surgery. After surgery, continuous cardiac rhythm 
registrations are analyzed for the incidence of early postoperative AF and patients are 
followed for five years to document the incidence of late postoperative AF. This project 
is the first step towards an individualized treatment strategy for patients with AF.
The clinical applicability of our novel, intra-operative epicardial mapping approach is 
evaluated in chapter 5. The mapping procedure was performed in patients undergoing 
open chest cardiac surgery, just prior to commencement of extracorporeal circulation. 
A floppy 128 or 192-unipolar mapping array is shifted over the entire epicardial surface 
of the right and left atrium and Bachmann’s Bundle, following a predefined mapping 
scheme. Mapping is performed during sinus rhythm and AF. If AF is not the presenting 
rhythm, it is induced by fixed rate atrial pacing. Mean duration of the mapping procedure 
was 9±2 minutes and mapping related complications were not observed. In chapter 6, 
we characterized the presence of conduction disorders in BB during sinus rhythm and 
studied their relation with AF. BB can be activated via multiple directions, but the 
predominant route of conduction is from right-to-left. There is no superfast conduction 
across BB, indicating that there are no specialized conduction cells. Conduction is 
blocked in both longitudinal and transverse direction in the majority of the patients. 
Conduction disorders, particularly long lines of longitudinal conduction block, are 
more pronounced in patients with AF episodes.
The value of intra-operative, high-resolution mapping of the entire epicardial surface for 
detection of the arrhythmogenic substrate underlying AF in 209 patients undergoing 
coronary artery bypass grafting is described in chapter 7. Unipolar electrograms were 
recorded during sinus rhythm at the left and right atrium and Bachmann’s Bundle, 
resulting in 390,379 recording sites (1868±285 sites/patient). Areas of conduction 
delay and conduction block occurred in respectively 1.4% and 1.3% of the total atrial 
epicardial surface. Despite a similar underlying clinical profile, considerate inter-
individual differences were observed. The area underneath the 192-unipolar mapping 
array was subdivided into quadrants of 1cm2. In all patients, the majority of these 
quadrants did not contain any conduction disorders. However, in the remainder of 
the quadrants the amount of conduction block varied from 0.1-34%/cm2. Areas with 
conduction disorders were scattered throughout the atria in all patients. Despite these 
inter-individual and intra-individual variations in conduction disorders, a predilection 
site for both conduction delay and conduction block was present at the superior, 
intercaval right atrium. Conduction disorders during sinus rhythm were not correlated 
with development of early post-operative AF. Hence, mapping during sinus rhythm is 
not a viable approach to identify the arrhythmogenic substrate underlying AF.
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In chapter 8, we tested the hypothesis that conduction disorders occur preferably 
at the right atrium in patients with a right atrial overload due to a congenital heart 
defect. We therefore performed the aforementioned intra-operative high-resolution 
epicardial mapping procedure in twelve patients undergoing first time surgery for a 
congenital heart defect. The right atrium was dilated in all patients. Electrograms were 
recorded from 25,197 recording sites (1,9138±327 /patient), covering 452 quadrants. 
Conduction delay and block was present in respectively 1.6% and 1.5% of the entire 
epicardial surface. Similar to our reference cohort of patients undergoing CABG surgery, 
considerable intra-individual and inter-individual differences in the spatial distribution 
of conduction disorders were observed. Conduction delay and block occurred most 
frequently at Bachmann’s bundle (respectively 50% and 38%) and the right atrium 
(respectively: 38% and 25%). Lines of conduction block longer than 16 mm at these 
sites occurred in all patients with AF.
In chapter 9, the degree of simultaneous activation of the endocardial and epicardial 
myocardium of the right atrial free wall was investigated in 14 patients with induced, 
persistent or longstanding persistent AF. A clamp made of two rectangular 8x16 
electrode arrays (inter-electrode distance 2 mm) was inserted into an incision in the 
right atrial appendage. Recordings of 10 seconds of AF were analyzed to determine 
the incidence of asynchronous endo-epicardial activation times (≥15 ms) of opposite 
electrodes. In these patients, the degree of endo-epicardial asynchrony in activation 
during ten seconds of AF varied between 0.9-55.9% with a mean of 15%. Focal waves 
appeared equally frequent at endocardium and epicardium (11% versus 13%, p=0.18). 
Using strict criteria for breakthrough (presence of an opposite wave within 4mm and 
≤14ms before the origin of the focal wave), the majority (65%) of all focal fibrillation 
waves could be attributed to endo-epicardial excitation. Hence, we provided the first 
evidence for asynchronous activation of the endo-epicardial wall during AF in humans. 
Endo-epicardial asynchrony may play a major role in the pathophysiology of AF and 
may offer an explanation why in some patients therapy fails.
Continuous rhythm recordings after cardiac surgery were used to examine characteristics 
of post-operative atrial dysrhythmias. Knowledge of the mechanism underlying post-
operative atrial fibrillation (PoAF) is essential for the development of preventive 
measures. In the general population, frequent supraventricular premature beats (SVPBs) 
are associated with AF. Whether SVPBs also play a role in development of PoAF is 
unknown. The incidence, characteristics and time course of PoAF, SVPBs triggering 
PoAF, their interrelationship and alterations over time were examined in patients 
undergoing CABG in the first five post-operative days. The outcome is summarized in 
chapter 10. PoAF episodes were mainly repetitive though transient in nature. There was a 
considerable inter-individual variation in characteristics of both AF and supraventricular 
ectopy, despite comparable clinical profiles. The burden of supraventricular premature 
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beats was higher in patients with PoAF and the mode of onset was characterized by short 
coupled supraventricular premature beats. Determination of individual post-operative 
dysrhythmia profiles enables recognition of patients at risk for developing PoAF. In 
chapter 11, we examined early, new-onset PoAF after coronary artery bypass grafting. 
The frequency and burden of post-operative atrial dysrhythmia in patients with coronary 
artery disease and their relation to PoAF was examined. Atrial dysrhythmia occurred in 
all patients after coronary artery bypass surgery whereas PoAF developed in 28% of 
the patients. Independent risk factors for development of PoAF were the frequency 
and burden of supraventricular premature beats and SV-runs. Also, a supraventricular 
premature beat prematurity index ≤59% is a risk factor for PoAF prediction. Hence, 
these parameters could be used to identify patients at risk for developing PoAF and 
allows preventive measures to be taken. In chapter 12, we examined the predictive 
value of intra-operative inducibility of AF for (de novo) early PoAF and late PoAF, and 
the progressiveness of both de novo and recurrent PoAF. Sustained AF was inducible in 
most patients undergoing cardiac surgery. However, intra-operative inducibility of AF 
was not a predictor of development of either early PoAF or late PoAF. The occurrence of 
early PoAF is an independent predictor of late PoAF. Yet the incidence of LPoAF was low 
and was mainly observed in patients with a history of AF prior to cardiothoracic surgery. 
Progression of LPoAF occurred frequently (56%), irrespective of a surgical pulmonary 
vein isolation, which is most likely due to progressive atrial remodeling.
The incidence of AF also rises in ageing patients with congenital heart disease (CHD). 
However, studies reporting on AF in CHD patients are scarce.
In chapter 13, the predictive ability of atrial extrasystole (AES) on development of AF 
was examined in a large cohort of patients with CHD. AES occurred relatively frequently 
in the adult CHD population compared to patients with other cardiac diseases and an 
increased AES frequency is associated with a higher risk of AF development in CHD 
patients. In chapter 14, we performed a multicenter study to examine in a large cohort 
of patients with a variety of CHD 1) the development of AF over time and 2) the 
progression of paroxysmal to long-standing persistent/permanent AF during long-term 
follow-up. Age at AF onset in CHD patients is relatively young compared to patients 
without CHD. Co-existence of episodes of AF and regular AT occurred in a considerable 
number of patients; most of them initially presented with regular AT. The fast and 
frequent progression from paroxysmal to (long)standing persistent or permanent AF 
episodes justifies close follow-up and early, aggressive therapy for both AT and AF. 
Chapter 15 outlines the current knowledge of the development of tachyarrhythmias 
during pregnancy, the indications for and considerations of pharmacological treatment 
and its potential side effects. Tachyarrhythmias are the most frequently observed cardiac 
complications during pregnancy. The majority of these maternal and fetal arrhythmias 
are supraventricular tachyarrhythmias; ventricular tachyarrhythmia is rare. The use of 
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anti-arrhythmic drugs (AAD) during pregnancy is challenging due to potential fetal 
teratogenic effects. Maintaining stable and effective therapeutic maternal drug levels is 
difficult due to hemodynamic and metabolic alterations. Pharmacological treatment of 
tachyarrhythmias is indicated in case of maternal hemodynamic instability or hydrops 
fetalis. Evidence regarding the efficacy and safety of AAD therapy during pregnancy is 
scarce and the choice of AAD should be based on individual risk assessments for both 
mother and fetus. 
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Nederlandse Samenvatting
Atriumfibrilleren (AF) is de meest voorkomende hartritmestoornis in de 
dagelijkse klinische praktijk. Het is geassocieerd met ernstige morbiditeiten zoals 
bijvoorbeeld een herseninfarct (4–5-maal hoger risico dan patiënten zonder AF) 
en hartfalen, en ook een verhoogde mortaliteit. 
Tevens resulteert AF in een hoger aantal ziekenhuisopnames vergeleken met 
elke andere hartritmestoornis. De huidige behandeling van AF is slechts matig 
effectief, omdat het onderliggend mechanisme van AF nog niet volledig begrepen 
wordt. Patiënten met AF vertegenwoordigen een groep mensen met verschillende 
hartziekten. Daarnaast is er na verloop van tijd een toename in het aantal en 
de duur van de hartritmestoornis. Deze progressie wordt veroorzaakt door 
elektropathologie, gedefinieerd als abnormale elektrische geleiding veroorzaakt 
door schade aan het hartspierweefsel. Gebieden van elektropathologie kunnen 
worden geïdentificeerd door het kwantificeren van elektrofysiologische 
parameters op een hoge resolutie. 
De opbouw van dit proefschrift is beschreven in hoofdstuk 1. Samengevat waren 
de doelen van dit proefschrift het onderzoeken van 1) de klinische toepasbaarheid 
van een nieuwe, intra-operatieve hoge resolutie, epicardiale mapping techniek 
van de gehele atria als een routine procedure tijdens cardiale chirurgie, 2) 
preferentiële locaties van elektropathologie tijdens sinusritme in patiënten met 
verschillende onderliggende hartziekten, 3) de relevantie van geleidingsstoornissen 
tijdens sinusritme op Bachmann’s bundel (BB), 4) de rol van endo-epicardiale 
asynchronie in het persisteren van AF, 5) de karakteristieken van postoperatieve 
atriale ectopie en AF, en 6) de relatie tussen elektrische parameters verkregen met 
hoge resolutie mapping, atriale ectopie en postoperatief AF (PoAF). 
In hoofdstuk 2 worden de mogelijke anti-aritmogene effecten van een longader-
isolatie besproken. Het isoleren van de vena pulmonalis kan een effectieve 
therapie zijn voor eliminatie van AF episodes, maar helaas geldt dit niet voor alle 
patiënten. Het effect van radiofrequentie-ablatie op persistent AF kan worden 
toegeschreven aan verschillende mechanismen, waaronder eliminatie van de 
trigger, modificatie van het aritmogene substraat, onderbreking van belangrijke 
geleidingspaden, atriale debulking of atriale denervatie. In patiënten bij wie deze 
ablatie niet succesvol is, wordt aangenomen dat het atriumfibrilleren is verergerd 
van een trigger-afhankelijke naar een substraat-gemedieerde ritmestoornis. 
Cardiale mapping is daarom vereist om de mechanismen van AF in de individuele 
patiënt te begrijpen, de uitgebreidheid van het aritmogeen substraat te bepalen 
en om vervolgens de optimale therapie te selecteren.
BB speelt waarschijnlijk een rol in de pathofysiologie van AF. BB, ook wel bekend 
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als de interatriale bundel, bestaat uit parallel georiënteerde spierbundels die van 
het rechter naar het linker atrium lopen. Deze verbinding wordt verondersteld 
de belangrijkste route voor interatriale geleiding te zijn. In hoofdstuk 3 is de 
huidige kennis over de relatie tussen de anatomische en elektrofysiologische 
eigenschappen van BB en diens mogelijk rol in de initiatie en persistentie van AF 
beschreven. BB is dankzij de elektro-anatomische eigenschappen de preferentiële 
route van interatriale geleiding. Onderbreking van de structuur van deze bundel 
veroorzaakt geleidingsblok tussen het rechter en linker atrium wat geassocieerd 
is met de ontwikkeling van verschillende atriale tachyaritmieën en met 
elektromechanische dysfunctie van het linker atrium. Data uit klinische studies 
suggereren een relatie tussen elektropathologische veranderingen van BB en de 
ontwikkeling van AF. Er is meer onderzoek nodig om de exacte rol van BB in de 
initiatie en de persistentie van AF te onderzoeken en om te bepalen of BB een 
potentieel therapeutisch doelwit is om de ontwikkeling van AF te voorkomen. 
In hoofdstuk 4 introduceren we het QUest for the Arrhythmogenic Substrate 
of Atrial FibRillation (QUASAR) project, dat als doel heeft het aritmogene 
substraat van AF te ontrafelen in patiënten met diverse onderliggende cardiale 
aandoeningen en verschillende types AF. Het is de eerste studie waarin op hoge 
resolutie de elektrofysiologische eigenschappen van het gehele oppervlakte van de 
atria wordt onderzocht, gebruikmakend van een innovatieve epicardiale mapping 
procedure, bij patiënten die een openhartoperatie ondergaan. Patiënten zijn 
onderverdeeld in groepen naar de onderliggende hartziekte en de aanwezigheid 
van AF episodes voor de hart operatie. Elektrofysiologische data wordt verzameld 
tijdens sinusritme en AF door hoge resolutie epicardiale mapping (inter-electrode 
afstand van 2 mm) tijdens de open hart operatie. Postoperatief worden continue 
registraties van hartritme geanalyseerd om de incidentie van vroeg postoperatief 
AF (PoAF) vast te stellen en na ontslag worden patiënten tot 5 jaar na de operatie 
vervolgd op de polikliniek voor identificatie van laat PoAF. Dit project is de eerste 
stap naar een geïndividualiseerde behandelingsstrategie voor patiënten met AF. 
De klinische toepasbaarheid van onze nieuwe, intra-operatieve mapping techniek 
is geëvalueerd in hoofdstuk 5. De mapping procedure werd verricht in patiënten 
die een openhartoperatie ondergaan, net voor het aansluiten van de extracorporale 
circulatie. Een flexibele 128 of 192-polige mapping array wordt volgens een vast 
schema over het gehele epicardiale oppervlak van het rechter en linker atrium 
en BB geschoven. De mapping procedure is uitgevoerd tijdens zowel sinusritme 
en AF. Als AF niet het initiële ritme was, werd dit geïnduceerd door middel van 
hoog frequent atriale pacing. De gemiddelde duur van de mapping procedure 
was 9±2 minuten en er zijn geen mapping gerelateerde complicaties opgetreden.
In hoofdstuk 6 wordt de aanwezigheid van geleidingsstoornissen op BB tijdens 
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sinusritme beschreven en de relatie met AF onderzocht. BB kan vanuit meerdere 
richtingen geactiveerd worden, maar de preferentiële geleidingsroute is van 
rechts naar links. Er is geen supersnelle geleiding over BB, dit impliceert dat 
er geen specialiseerde geleidingscellen aanwezig zijn. In de meeste patiënten 
wordt de geleiding zowel in de longitudinale als in de transversale richting 
geblokkeerd. Geleidingsstoornissen, voornamelijk lange lijnen van longitudinaal 
geleidingsblok, zijn nadrukkelijker aanwezig in patiënten met AF. 
In hoofdstuk 7 wordt de waarde van de intra-operatieve, hoge resolutie mapping 
van het gehele epicardiale oppervlak voor de detectie van het aritmogene 
substraat van AF geëvalueerd in 209 patiënten die een coronaire bypass 
operatie (CABG) ondergaan. Unipolaire electrogrammen werden opgenomen 
tijdens sinusritme van het linker en rechter atrium en BB, resulterend in 
390.379 opnameplaatsen (1868±285 plaatsen/patiënt). Gebieden met 
geleidingsvertraging en geleidingsblok traden op in respectievelijk 1,4% en 
1,3% van het totaal bestudeerde atriale epicardiale oppervlak. Ondanks een 
vergelijkbaar onderliggend klinisch profiel werden aanzienlijke interindividuele 
verschillen gevonden. Het gebied onder de 192-unipolaire mapping array was 
onderverdeeld in kwadranten van 1 cm2. In alle patiënten bevatte de meerderheid 
van deze kwadranten geen geleidingsstoornissen. Echter, de hoeveelheid 
geleidingsblok in de overige kwadranten varieerde van 0,1–34%/cm2. Gebieden 
met geleidingsstoornissen traden op verspreid door de gehele atria. Ondanks 
deze inter- en intra-individuele verschillen in geleidingsstoornissen was er een 
predilectie voor zowel geleidingsvertraging als geleidingsblok aanwezig op het 
superior intercavale deel van het rechter atrium. Geleidingsstoornissen tijdens 
sinusritme waren niet gecorreleerd met de ontwikkeling van vroeg postoperatief 
AF. Mapping tijdens sinusritme is dus niet de aangewezen methode om het 
aritmogene substraat van AF te identificeren. 
In hoofdstuk 8 testten we de hypothese dat geleidingsstoornissen voornamelijk 
voorkomen op het rechter atrium in patiënten met een rechter atrium 
overbelasting ten gevolge van een congenitaal hart defect. Hiervoor hebben we de 
eerdergenoemde intra-operatieve, hoge resolutie, epicardiale mapping procedure 
uitgevoerd in twaalf patiënten die een eerste operatie ondergingen voor een 
congenitaal hart defect. Het rechter atrium was gedilateerd in alle patiënten. 
Electrogrammen werden opgenomen op 25.197 locaties (1914 locaties/patiënt), 
verspreid over 452 kwadranten. Geleidingsvertraging en geleidingsblok waren 
beiden aanwezig in respectievelijk 1,6% en 1,5% van het totale epicardiale 
oppervlak. Vergelijkbaar met ons referentie cohort van patiënten die een CABG 
ondergingen, werden ook in deze populatie aanzienlijke intra- en interindividuele 
verschillen in de spatiele distributie van geleidingsstoornissen geobserveerd. 
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Prevalenties van geleidingsvertraging en geleidingsblok waren beiden het hoogste 
op BB (respectievelijk 50% en 38%) en RA (respectievelijk 38% en 25%). De 
hoeveelheid van deze geleidingsstoornissen was het hoogste op BB in vergelijking 
met het linker atrium en het pulmonaal venen gebied, maar niet ten opzichte 
van het rechter atrium. Indien aanwezig op het rechter atrium kwamen de 
geleidingsstoornissen vaker voor op het superieure dan op het inferieure deel van 
het rechter atrium. Daarnaast kwamen lijnen van geleidingsblok langer dan 16mm 
op BB en RA voor in alle patiënten met AF. Concluderend, geleidingsstoornissen 
in patiënten met een congenitaal hart defect en rechter atrium overbelasting zijn 
niet enkel aanwezig op het rechter atrium, maar ook op BB.
In hoofdstuk 9 is de activatie van het endocardiale en epicardiale myocard van 
de rechterboezemwand onderzocht in 14 patiënten met geïnduceerd, persistent 
en langdurig persistent atriumfibrilleren. Een klem bestaande uit 2 rechthoekige 
8x16 electrode oppervlakte (inter-electrode afstand 2 mm) werd het rechter 
atrium ingebracht. In deze patiënten varieerde de mate van endo-epicardiale 
asynchronie in activatie tijdens 10 seconden atriumfibrilleren tussen de 0,9-
55,9% met een gemiddelde van 15%. Focale golven, atriumfibrillatie golven die 
ontstaan op een focaal punt in het opnamegebied, ontstaan even vaak aan beide 
kanten van de boezemwand (11% versus 13%, p=0,18). Met behulp van strikte 
criteria voor epicardiale doorbraak (de aanwezigheid van een tegenovergestelde 
golf binnen 4 mm en ≤14ms voor de origine van de focale golf ), werd vastgesteld 
dat de meerderheid van deze focale golven (65%) kunnen worden verklaard 
door transmurale geleiding van golven die aan de andere zijde lopen. Derhalve 
toonden wij als eerste aan dat er sprake is van asynchrone activatie van de endo- 
en epicardiale rechter atriumwand tijdens AF in mensen. Endo-epicardiale 
asynchronie speelt een rol in de pathofysiologie van AF en biedt een verklaring 
voor het falen van de huidige AF therapie in sommige patiënten. 
Continue ritmeregistraties na openhartoperaties werden gebruikt om de 
karakteristieken van postoperatieve atriale ritmestoornissen, zoals PoAF te 
onderzoeken. Kennis van het mechanisme onderliggend aan PoAF is essentieel 
voor het ontwikkelen van preventieve therapieën. In de algemene populatie 
zijn frequente supraventriculaire premature slagen geassocieerd met AF. Of 
supraventriculaire premature slagen ook een rol spelen in de ontwikkeling van 
PoAF is onbekend. De incidentie, karakteristieken en het tijdsbeloop van PoAF 
en van supraventriculaire premature slagen die AF triggeren, hun onderlinge 
relatie en veranderingen over de tijd zijn onderzocht in patiënten die een CABG 
ondergingen gedurende de eerste vijf postoperatieve dagen. De resultaten hiervan 
zijn samengevat in hoofdstuk 10. PoAF episodes waren meestal repetitief maar 
voorbijgaand van aard. Er was een aanzienlijke interindividuele variatie in 
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karakteristieken van zowel AF als van supraventriculaire ectopie, ondanks het 
vergelijkbare klinische profiel. De burden van supraventriculaire premature 
slagen was hoger in patiënten met PoAF, vergeleken met patiënten zonder PoAF 
en de initiatie werd gekarakteriseerd door kort gekoppelde supraventriculaire 
premature slagen. Determinatie van het individuele postoperatieve profiel van 
ritmestoornissen maakt het herkennen van patiënten met een hoog risico op 
PoAF mogelijk. In hoofdstuk 11 onderzochten we de novo vroeg PoAF na 
CABG. De frequentie en burden van postoperatieve atriale ritmestoornissen in 
patiënten met coronair lijden en hun relatie met PoAF werd onderzocht. Atriale 
ritmestoornissen traden op in de meerderheid van de patiënten na CABG, terwijl 
PoAF ontwikkelde in 28% van de patiënten. Onafhankelijke risicofactoren voor 
het ontwikkelen van PoAF waren de frequentie en burden van supraventriculaire 
extra slagen en runnen. Tevens was een supraventriculaire extra slag met een 
prematuriteitsindex van ≤59% een voorspellende risicofactor voor PoAF. Deze 
parameters kunnen dus gebruikt worden voor identificatie van patiënten die een 
hoger risico hebben op het ontwikkelen van PoAF en faciliteert het nemen van 
preventieve maatregelen. In hoofdstuk 12 onderzoeken we de voorspellende 
waarde van intra-operatieve induceerbaarheid van AF voor (de novo) vroeg, laat 
PoAF en progressie van zowel de novo als recidiverend PoAF. Aanhoudend AF 
was induceerbaar in de meeste patiënten tijdens de openhartoperatie. Echter 
deze intra-operatieve induceerbaarheid van AF was geen voorspeller voor het 
optreden van vroeg, danwel laat PoAF. Vroeg PoAF was een onafhankelijke 
voorspeller voor laat PoAF. De incidentie van laat PoAF was laag en trad met 
name op in patiënten die voorafgaand aan de operatie al bekend waren met 
AF. Progressie van AF werd frequent geobserveerd (56%), onafhankelijk van 
een chirurgische longaderisolatie, hetgeen meest waarschijnlijk het gevolg is van 
progressieve atriale remodelering. 
De incidentie van AF neemt ook toe in de steeds ouder wordende patiënten 
met congenitale hart defecten. Er zijn echter maar weinig studies over AF in 
patiënten met een congenitale hart defect (CHD). 
In hoofdstuk 13 is de voorspellende waarde van atriale extra slagen voor de 
ontwikkeling van AF onderzocht in een groot cohort bestaande uit patiënten met 
CHD. Extra slagen vanuit de atria traden relatief frequenter op in de volwassen 
patiënten met CHD vergeleken met patiënten met andere onderliggende 
hartaandoeningen en een toegenomen frequentie van atriale extra slagen was 
geassocieerd met een hogere risico op het ontwikkelen van AF in de CHD 
patiënten. In hoofdstuk 14 voerden we een multicenter onderzoek uit om in 
een groot cohort van patiënten met verschillende types CHD het volgende te 
onderzoeken: 1) ontwikkeling van AF in de tijd en 2) progressie van paroxysmaal 
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naar langdurig persistent/permanent AF tijdens lange termijn follow-up. AF 
treed op relatief jonge leeftijd op in patiënten met CHD in vergelijking met 
patiënten zonder CHD. Co-existentie van AF en regulaire atriale tachycardie 
(AT) episodes trad op in een aanzienlijk aantal patiënten; de meerderheid van 
hen presenteerde zich initieel met een regulaire AT. De snelle en frequente 
progressie van paroxysmaal naar (langdurig) persistent of permanent AF episodes 
rechtvaardigt een frequente follow-up en vroege, agressieve therapie van zowel 
AT en AF. 
Hoofdstuk 15 schetst de huidige kennis over de ontwikkeling van tachyaritmieën 
tijdens de zwangerschap, indicaties en overwegingen voor farmacologische 
behandeling en de potentiele bijwerkingen. Tachyaritmieën zijn de meest frequent 
geobserveerde cardiale complicaties tijdens de zwangerschap. De meerderheid 
van deze maternale en foetale aritmieën zijn supraventriculaire tachycardieën; 
ventriculaire tachyarritmieën komen zelden voor. Het gebruik van antiaritmische 
medicatie (AAD) tijdens de zwangerschap is lastig door de mogelijke teratogene 
effecten op de foetus. Het handhaven van stabiele en effectieve medicatie 
spiegels in de moeder wordt bemoeilijkt door hemodynamische en metabole 
veranderingen. Farmacologische behandeling van tachyarritmieën is geïndiceerd 
bij maternale hemodynamische instabiliteit of hydrops foetalis. Er is weinig 
wetenschappelijk bewijs voor de werkzaamheid en veiligheid van AAD-gebruik 
tijdens de zwangerschap en de keuze van AAD moet gebaseerd zijn op een 
individuele risico inschatting voor zowel moeder als foetus.
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Da kwoord
Promotie is een lange weg met veel obstakels. Het is niet één rechte, uniforme weg. De 
reis gaat over bergen en dalen, net als het hartspierweefsel. Die van mij was er een waar 
een lange adem voor nodig was. Gelukkig zijn er mensen om je heen die je steunen en 
kom je gaandeweg veel nieuwe mensen tegen.
Na een lange dag werken op de afdeling elektrofysiologie kwam Natasja de Groot 
bij mij langs om de patiënten door te nemen. We raakten in gesprek en van het een 
kwam al gauw het ander en hadden we het over een promotieplek als haar promovenda 
bij de elektrofysiologie, die ik maar al te graag wilde. Dat was het begin. Ik kwam 
onverwachts, na mijn oudste-coschappen, weer in aanraking met thoraxchirurgie en had 
een nauwe samenwerking met de chirurgen. De samenwerking met m.n. Charles Kik was 
bijzonder en intensief. We hadden regelmatig contact over de app/sms over de inclusie 
van patiënten, zelfs in het weekend en in de avonduren. Charles zei nooit nee tegen 
een mapping, ook al betekende dit dat hij de gehele operatie van een patiënt van zijn 
collega’s moest overnemen in ruil voor 10 minuten mapping. Ik heb veel steun van hem 
gekregen in het overtuigen van de andere chirurgen om mee te doen met het mappen. In 
de loop van de tijd is dit gelukt en gingen meerdere chirurgen meedoen met de mapping 
en ontstond er een goede samenwerking. Hierbij wil ik alle chirurgen die deelnemen 
aan de mapping bedanken voor hun geduld en samenwerking. Daarnaast wil ik ook alle 
anesthesisten, OK-assistenten en baliemedewerkers bedanken voor de medewerking. Jos 
Pieters werd elke week door mij benaderd voor een overzicht van de patiënten van de 
komende week en bijna dagelijks gebeld of gemaild voor het plaatsen van een melding 
voor deelname op het operatieprogramma achter de naam van de patiënt. Dank voor je 
medewerking Jos. Bij aanvang van mijn promotie kreeg ik een laptop die voldeed aan 
de eisen van het mapping-programma. Dit betrof een grote, zware laptop “Alienware”. 
Hierop moest het programma geïnstalleerd worden en hiermee begon de ellende van de 
technische problemen. Ik kwam met deze grote laptop om hulp vragen bij Mark en Rob, 
ICT’ers van de afdeling cardiologie. Al heel snel werd duidelijk dat deze laptop niet 
geschikt was voor het mapping-programma en zijn we overgestapt op een MacBookpro. 
Maar het contact met Mark en Rob was gelegd en ik werd door hen geassocieerd met de 
“Alienware”. Sindsdien tot aan het eind van mijn promotie liep ik regelmatig binnen bij 
Mark en Rob voor allerlei zaken, zoals harde schijven, computers, netwerkkabels of als ik 
weer eens documenten per ongeluk had verwijderd van het V-schijf. Jullie stonden mij 
altijd te hulp, ondanks jullie drukke schema. Er is zelfs een server voor ons aangemaakt 
voor de opslag van de continue hartritme registraties. Dank! Voor de hartritme registraties 
en analyses heb ik regelmatig hulp gehad van Marcel de Wijs en Maarten van Ettinger. 
Dank voor al jullie hulp. Gaandeweg zijn er vele studenten gekomen die ik heb begeleid 
en die ook een bijdrage hebben geleverd aan diverse analyses. Bij deze wil ik gebruik 
maken van de gelegenheid om alle studenten te bedanken. Na circa een jaar kreeg ik 
er een collega bij, Tanwier Ramdjan. Wij hebben samen een hele leuke, intensieve en 
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zware periode achter de rug. Zowel in de goede dagen als in de moeilijke dagen kon ik 
bij je terecht en omgekeerd. We hadden hele gesprekken en konden daarna weer verder. 
Ik ben klaar met mijn lange weg en jij bent de volgende! Ik heb nachten versleten aan 
manuele ritme-analyse van de postoperatieve ritme registraties. In de loop van de tijd 
werd ik versterkt door Ilse Mouws. Uren hebben we doorgebracht op zoek naar de 
juiste analysemethodes en het runnen van de data. De discussies waren nooit saai. Paul 
Knops is de ingenieur van onze groep. Met alle vragen over mijn artikelen, figuren of 
gewoon voor een praatje kon ik terecht bij Paul. Als ik vroeg om kritisch te kijken naar 
een van de ingewikkelde figuren die ik weer eens had gereproduceerd, kreeg ik altijd 
hele goede feedback. Als laatste vroeg ik om de mapping data voor mijn cover in het 
3D-model te zetten middels een programma. Je bent er de hele week mee bezig geweest, 
met als resultaat een prachtig figuur. Super bedankt Paul! Vlak voor mijn terugkeer 
in de kliniek kwamen er nog meer collega’s bij, Eva Lanters, Christophe Teuwen en 
Lisette van der Does. Eva leerde ik al kennen toen ik pas begon. Zij was toen master-
studente bij Natasja. Tijdens je coschappen kwam je regelmatig langs en hielp je een 
handje mee met de beruchte telemetrie analyse of stonden we in de dameskleedkamer te 
solderen, omdat er een draadje los zat in de mappingkast. Uiteindelijk kwam je terug als 
mede-collega en konden mijn taken worden overgenomen. Ik ben de kliniek ingegaan 
en heb sindsdien zeer veel hulp van jou gehad met zowel de artikelen als persoonlijk 
rondom alle perikelen. Christophe ken ik al eerder als master student en nu als collega-
promovendus. We hebben niet alleen op het werk veel met elkaar te maken gehad, 
maar ook op leuke feestjes met Eva. Lisette, eveneens collega-promovenda, heeft veel 
werkzaamheden overgenomen. Super bedankt voor alle steun, begrip en medewerking 
bij de laatste loodjes! Daarnaast wil ik ook de rest van onze researchgroep bedanken 
voor het luisterende oor of de gezelligheid: Danielle, Charlotte, John, Ahmed en Gustaf. 
Tijdens je promotie heb je veel administratieve zaken. Deze kon ik gelukkig altijd, vaak 
last-minute, bij Thea Sigmond (onze secretaresse) neerleggen en dan kwam het altijd 
goed. Dankjewel Thea!
Tevens wil ik graag prof. Allessie bedanken voor het delen van zijn kennis, de kritische 
blik op de eerste artikelen en de soldeerles.
Prof. Bogers, mijn promotor. U zei vrijwel direct “ja” toen ik vroeg of u mijn promotor 
wilde zijn. Ik heb jaren op uw afdeling gewerkt en promoveer nu jaren later bij u. Tijdens 
mijn promotie kon ik altijd bij u terecht met de mapping perikelen op de operatiekamers. 
Bij het afronden van de artikelen en mijn proefschrift kon ik laagdrempelig bij u 
langskomen. Prof. Hanneke Takkenberg, bij jou heb ik mijn masteronderzoek gedaan 
en nu ben je secretaris van mijn promotiecommissie. Het is lang geleden, maar wel fijn 
dat je nu onderdeel bent van mijn promotiecommissie. Prof. Jordaens, ik ben onder 
uw leiding gestart als promovenda van de elektrofysiologie. Bedankt voor uw steun en 
deelname in mijn promotiecommissie. Prof. Hauer, het is een eer om een intelligente 
elektrofysioloog als u in mijn commissie te hebben. Prof. Brundel, ik zag u voor het 
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eerst tijdens een research seminar van de elektrofysiologie. Sindsdien ontstond er een 
samenwerking met onze groep. Dank voor uw deelname in mijn promotiecommissie. 
Prof. Klautz, bedankt voor het lezen en beoordelen van mijn proefschrift en uw 
bereidheid om zitting te nemen in mijn promotiecommissie. 
Natasja, vanaf het moment dat ik je leerde kennen was er een goede klik. Nadat we 
het hadden gehad over promoveren onder jou heb ik de hele nacht niet meer geslapen 
van blijdschap. Ik wilde heel graag een promotieonderzoek verrichten in een vakgebied 
dat mij interesseerde en onder begeleiding van iemand met wie het goed klikte. Dus 
dit was als een droom die uitkwam. Van het begin af aan heb ik alle vrijheid gehad om 
het onderzoek zelf in te richten en nieuwe onderzoeken op te zetten. Ik heb mogen 
genieten van intensieve begeleiding, zowel in het ziekenhuis als bij jou thuis. Hoe groot 
de fout ook was, jij wist het altijd goed over te brengen en ervoor te zorgen dat het 
gecorrigeerd werd en dat ik mezelf bleef verbeteren. Naast het werk hebben we ook 
hele leuke gesprekken en discussies gehad, onder het genot van sushi in Moshi Moshi. 
Door werkzaamheden in de kliniek werd mijn onderzoek regelmatig achtergesteld en 
was het een vrij zware periode de laatste tijd. Maar jij bent mij blijven steunen en samen 
zijn we tot een prachtig proefschrift gekomen, waar ik zeer trots op ben. Ik heb jou 
regelmatig, ongeacht de dag of het tijdstip, lastiggevallen via de mail of app. Dank 
voor alle steun, zowel werk als privé-gerelateerd. Ik hoop dat we nog een langdurige en 
prettige samenwerking zullen hebben!
De laatste periode heb ik in de kliniek gewerkt in het Hagaziekenhuis. Hier wil ik alle 
collega’s en cardiologen bedanken voor de mogelijkheid die ik tijdens de werkzaamheden 
heb gekregen om mijn promotie af te kunnen ronden. En voor het begrip voor de 
rumoerige periode.
Mijn vrienden zijn chronisch verwaarloosd. Dank voor jullie begrip. Af en toe kreeg 
ik een app van een van mijn beste vriendinnen, Shalinie: “leef je nog?”. Heel af en toe 
gingen we wat drinken of eten en kletsten we weer bij en dan konden we er weer voor 
een lange tijd tegenaan. 
Tijdens mijn promotieonderzoek en de laatste periode in combinatie met de kliniek heb 
ik heel erg veel gevraagd van mijn familie. 
Mijn oom, Harold Mohan, heeft zelfs in zijn vrije tijd meegeholpen met de telemetrie-
analyse. Als we samen de telemetrie doornamen was er altijd een lekkere warme maaltijd 
beschikbaar, bereid door mijn tante Sandra Kalika. De kinderen, Vinay en Anuj, zorgden 
voor de nodige afleiding.
Mijn ouders hebben mij altijd gesteund en mijn moeder stond altijd klaar als ik een 
knuffel nodig had. Mijn schoonouders hebben mij eveneens veel gesteund. Mijn 
schoonmoeder zat nachten bij mij als ik met mijn laptop op schoot aan het werk was. 
Mijn schoonfamilie Vishal, Jeannette, Rijaz, Sangeeta en de kids Aryan en Shanaya 
zorgden altijd voor afleiding, maar steunden mij ook waar nodig. Mijn schoonzusje, 
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Razia, heeft alles van dichtbij meegemaakt en mocht al mijn verhalen aanhoren. Van tijd 
tot gingen we op pad, wat hard nodig was voor de ontspanning. Het meest heeft mijn 
vriend, Faizal, geleden. Ik heb de afgelopen jaren weinig tijd voor je gehad en was bijna 
elke weekend weer in het ziekenhuis voor inclusie van patiënten of diensten. Je hebt mij 
altijd gesteund en er was altijd een heerlijke warme maaltijd als ik thuiskwam, ongeacht 
welke tijdstip van de dag. Dankjewel voor al je steun, begrip en liefde!
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